0001760854-23-000015 | 6-K | XBRL Viewer

Print Document View Excel Document

Trade payables and other current liabilities - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Fixed assets payables	€ 0	€ 228
Increase of accrued expenses	2,500
Increase of other trade payables	4,800
Advisory fees	1,400
Cash management fees	3,100
Decrease in payroll tax and other payroll liabilities	700
Current contract liabilities	16,518	€ 16,518
Nanobiotix S.A.
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Decrease in payroll tax and other payroll liabilities	400
Decrease in accrued bonuses	300
Decrease in accrued paid vacation	100
Nanobiotix Corp.
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Decrease in payroll tax and other payroll liabilities	200
312 study
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Increase of accrued expenses	1,500
Cash management fees	2,400
1100 study
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Increase of accrued expenses	1,000
LianBio, NBTXR3
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Current contract liabilities	€ 16,500

Share Capital - Free Share Plans (Details)	Jun. 27, 2023 shares	Jun. 23, 2022 shares € / shares	Jun. 30, 2023 € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Par value per share (euro per share) \| € / shares			€ 0.03
AGA 2023 -= P1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued (in shares)	427,110
AGA 2023 - P2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued (in shares)	439,210
Executive Board and Employees \| AGA 2023 -= P1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued (in shares)		427,110
Par value per share (euro per share) \| € / shares		€ 0.03
Duration of the holding period	1 year
Vesting requirements, acquisition period	2 years
Maximum term for performance obligations	24 months
Executive Board and Employees \| AGA 2023 - P2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued (in shares)		439,210
Par value per share (euro per share) \| € / shares		€ 0.03
Duration of the holding period	1 year
Vesting requirements, acquisition period	2 years

Property, plant and equipment - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure of detailed information about property, plant and equipment
Impairment loss recognised in profit or loss, property, plant and equipment	€ 0
Disposals, property, plant and equipment	(8,000)
Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment
Disposals, property, plant and equipment	6,000
Right of use – Buildings \| Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment
Disposals, property, plant and equipment	€ 0

Related parties (Tables)

6 Months Ended

Jun. 30, 2023

Summary of Key Management Personnel Compensation

The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Salaries, wages and benefits	704	486
Share-based payments	1,001	1,131
Supervisory Board’s fees	78	95
Total compensation to related parties	1,783	1,712

Property, plant and equipment

6 Months Ended

Jun. 30, 2023

Property, plant and equipment [abstract]

Property, plant and equipment

The change in property, plant and equipment is as follows:


(in thousands of euros)	As of December 31, 2022	Increases	Decreases	Other movements & transfer.	Currency translation	As of June 30, 2023
Fixtures, fittings and installations	3,318	2	—	—	—	3,321
Right of use – Buildings	8,462	—	—	—	—	8,462
Technical equipment	2,128	75	—	300	—	2,503
Office and IT equipment	1,012	18	(6)	—	(1)	1,023
Transport equipment	36	—	—	—	(1)	35
Right of use – Transport equipment	—	—	—	—	—	—
Tangible assets in progress	344	—	—	(300)	—	44
Prepayments on tangible assets	—	—	—	—	—	—
Gross book value of tangible assets	15,299	96	(6)	—	(1)	15,387
Fixtures, fittings and installations	(1,959)	(158)	—	—	—	(2,117)
Right of use – Buildings	(3,496)	(462)	8	—	—	(3,950)
Technical equipment	(1,774)	(93)	—	—	—	(1,867)
Office and IT equipment	(915)	(27)	6	—	—	(935)
Transport equipment	(36)	—	—	—	1	(35)
Right of use – Transport equipment	—	—	—	—	—	—
Accumulated depreciation of tangible assets(1)	(8,180)	(740)	14	—	1	(8,904)
Net book value of tangible assets	7,120	(644)	8	—	—	6,483

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

No impairment losses were recognized in application of IAS 36 - Impairment of Assets in the period presented.

Transfer of fixed assets from ‘tangible assets in progress’ to ‘technical equipment’ for €300 thousand is related to an ‘Irradiator’ operating in the laboratory and amortized since the first quarter of 2023.

Trade receivables and other current assets (Tables)

6 Months Ended

Jun. 30, 2023

Subclassifications of assets, liabilities and equities [abstract]

Disclosure of Break Down of Trade Receivables


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Trade receivables	1,090	101
Trade receivables	1,090	101

Disclosure of Break Down of Other Current Assets

Other current assets break down as follows:


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Research tax credit receivable	5,488	4,091
VAT receivable	1,437	1,055
Prepaid expenses	2,236	2,981
Other receivables	1,747	2,741
Other current assets	10,909	10,868

Disclosure of Changes in Research Tax Credit Receivables

The change in research tax credit receivables breaks down as follows:


(in thousands of euros)
Receivable as of December 31, 2022			4,091
2023 research tax credit – Nanobiotix S.A. (1)			1,504
2023 research tax credit – Curadigm S.A.S (1)			100
Receipt of 2022 research tax credit - Curadigm S.A.S			(207)
Receivable as of June 30, 2023			5,488

(1) See Note 15 Revenue and other income.

Operating expenses

6 Months Ended

Jun. 30, 2023

Analysis of income and expense [abstract]

Operating expenses

16.1 RESEARCH AND DEVELOPMENT EXPENSES


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Purchases, sub-contracting and other expenses	(11,982)	(10,543)
Payroll costs (including share-based payments)	(5,239)	(5,395)
Depreciation, amortization and provision expenses(1)	(583)	(670)
Total research and development expenses	(17,805)	(16,608)

(1)see Note 16.4 Depreciation, amortization and provision expenses

Purchases, sub-contracting and other expenses increased by €1.4 million for the six-month period ended June 30, 2023 as compared to the same period in 2022. This increase reflects the Company's focus on advancing its clinical trial development priorities, specifically the global Phase 3 registrational trial (NANORAY-312).

R&D Payroll costs slightly decreased by €0.2 million, or by 3% for the six-month period ended June 30, 2023 as compared with the same period in 2022, which is mainly due by the changes in the geographic mix and seniority of our employees.

16.2 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Purchases, fees and other expenses	(5,398)	(4,251)
Payroll costs (including share-based payments)	(5,295)	(5,244)
Depreciation, amortization and provision expenses (1)	(172)	(140)
Total SG&A expenses	(10,864)	(9,635)

(1)see Note 16.4 Depreciation, amortization and provision expenses

Purchases, fees and other expenses increased by €1.1 million for the six-month period ended June 30, 2023 as compared to the same period in 2022 and mainly relates to the €1.4 million fees to be paid to a financial adviser, further to an advisory services agreement between the parties which has been subsequently terminated (See Note 23 subsequent event).

SG&A payroll costs slightly increased by €0.1 million, or 1%, for the six-month period ended June 30, 2023 as compared to the same period in 2022, which is mainly due to management of SG&A payroll expenses.

16.3 PAYROLL COSTS


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Wages and salaries	(6,814)	(6,711)
Payroll taxes	(2,338)	(2,531)
Share-based payments	(1,349)	(1,360)
Retirement benefit obligations	(33)	(38)
Total payroll costs	(10,534)	(10,640)
Average headcount	98	99
End-of-period headcount	101	103

As of June 30, 2023, the Company had 101 employees, including 71 in R&D and 30 in selling, general and administrative expenses, compared to 103 as of June 30, 2022.

In the first half of 2023, salaries and payroll taxes remained stable as compared to the first half of 2022.

In accordance with IFRS 2 – Share-based Payment, the share-based payment expense recognized in the statement of consolidated operations reflects the amortization of the fair value of the granted awards over the service period. The share-based payment expenses amounted to €1.3 million for the period ended June 30, 2023, which is stable compared with June 30, 2022 (see Note 17 Share-based payments).

16.4 DEPRECIATION, AMORTIZATION AND PROVISION EXPENSES

Depreciation, amortization and provision expenses by function are detailed as follows:


	For the six month period ended June 30, 2023
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	—	—	—
Amortization expense of tangible assets	(579)	(162)	(740)
Litigations	—	—	—
Provision for charges	(4)	(10)	(14)
Reversal of provision for charges	—	—	—
Total depreciation, amortization and provision expenses	(583)	(172)	(754)


	For the six month period ended June 30, 2022
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(14)	—	(14)
Amortization expense of tangible assets	(579)	(153)	(732)
Litigations	3	1	5
Provision for charges	(80)	—	(80)
Reversal of provision for disputes	—	12	12
Total depreciation, amortization and provision expenses	(670)	(140)	(809)

16.5 OTHER OPERATING INCOME AND EXPENSES


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Contract termination indemnities (PharmaEngine)	—	(963)




Contract termination indemnities	(46)	—
Other non recurring income	52	—
Total other operating income and expenses	6	(963)

As of June 30, 2023, the Company has not recorded any material other operating income and expenses.

As of June 30, 2022, the Company has made the $1 million payment following receipt and validation of certain clinical study reports, in the context of the termination agreement signed with PharmaEngine,

Operating expenses - Disclosure of Depreciation, Amortization and Provision Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Operating Expenses
Amortization expense of intangible assets	€ 0	€ (14)
Amortization expense of tangible assets	(740)	(732)
Litigations	0	5
Provision for charges	(14)	(80)
Reversal of provision for charges	0	12
Total depreciation, amortization and provision expenses	(754)	(809)
R&D
Disclosure Of Operating Expenses
Amortization expense of intangible assets	0	(14)
Amortization expense of tangible assets	(579)	(579)
Litigations	0	3
Provision for charges	(4)	(80)
Reversal of provision for charges	0	0
Total depreciation, amortization and provision expenses	(583)	(670)
SG&A
Disclosure Of Operating Expenses
Amortization expense of intangible assets	0	0
Amortization expense of tangible assets	(162)	(153)
Litigations	0	1
Provision for charges	(10)	0
Reversal of provision for charges	0	12
Total depreciation, amortization and provision expenses	€ (172)	€ (140)

Share Capital - Capital Issued (Details) - EUR (€) € / shares in Units, € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of classes of share capital
Total shareholders’ equity	€ (53,783)	€ (27,045)	€ 1,792	€ 26,790
Par value per share (euro per share)	€ 0.03
Share Capital
Disclosure of classes of share capital
Total shareholders’ equity	€ 1,057	€ 1,046	€ 1,046	€ 1,045
Number of shares outstanding (in shares)	35,230,382	34,875,872	34,875,872	34,825,872

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

Financial liabilities - Additional Information (Details)		1 Months Ended			6 Months Ended		12 Months Ended	36 Months Ended
	Jul. 10, 2020 EUR (€) installment	Mar. 31, 2019 EUR (€)	Oct. 31, 2018 EUR (€)	Jul. 31, 2018 EUR (€) tranche	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)	Dec. 31, 2018 EUR (€)	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Jun. 30, 2020 EUR (€)
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Borrowing, interest rate				21.30%
Interest costs					€ 3,714,000	€ 2,602,000
Repayments of borrowings, classified as financing activities					1,598,000	2,583,000
Increase in loans and conditional advances					150,000	0
Conditional advances and loans from Government and Public Authorities
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Impact of discounting, accretion and catch-up impact					(833,000)
Increase in loans and conditional advances					150,000
EIB loan
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount					38,300,000			€ 38,300,000	€ 35,800,000
Number of tranches \| tranche				3
Financial liabilities, at fair value				€ 34,400,000
Borrowing, interest rate		5.00%	6.00%	21.30%
Increase in outstanding loans					2,600,000
Interest costs					3,600,000	€ 2,600,000
Repayments of borrowings, classified as financing activities					233,000
Impact of discounting, accretion and catch-up impact					€ (800,000)
Market rate estimated percent					19.30%			19.30%
Increase in loans and conditional advances		€ 14,000,000	€ 16,000,000
Borrowings					€ 59,600,000			€ 59,600,000
Milestones payment					€ 20,000,000			20,000,000
Consolidated forecasted sales, period					6 years
EIB loan \| At fair value [member]
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount					€ 41,100,000			41,100,000
EIB loan \| Conditional advances and loans from Government and Public Authorities
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Impact of discounting, accretion and catch-up impact					(809,000)
Increase in loans and conditional advances					0
EIB loan \| Milestone One
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Milestones payment					300,000			300,000
EIB loan \| Milestone Two
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Milestones payment					8,100,000			8,100,000
EIB loan \| Milestone Three
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Milestones payment					11,600,000			11,600,000
EIB loan \| Fixed interest rate
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Total interest payable					14,200,000			14,200,000
Interest payable					5,900,000			5,900,000
EIB loan \| Variable interest rate
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Total interest payable					36,800,000			36,800,000
EIB loan \| Top of range
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount				€ 40,000,000
Conditional required draw amount				€ 10,000,000
Bpifrance “PGE”
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount										€ 5,000,000
Borrowing, interest rate	2.25%
Repayments of borrowings, classified as financing activities								680,000
Increase in loans and conditional advances	€ 5,000,000
Borrowing, maturity	6 years
Percentage of state-guaranteed loan	0.90
Borrowing, guarantee fee	1.61%
Number of quarterly instalments \| installment	20
HSBC “PGE”
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount										€ 5,000,000
Borrowing, interest rate										0.31%
Repayments of borrowings, classified as financing activities								€ 600,000
Bpifrance advance \| Conditional advances and loans from Government and Public Authorities
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Impact of discounting, accretion and catch-up impact					8,000
Increase in loans and conditional advances					€ 0
Banque Publique d’Investissement
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Advances, interest rate							1.56%
Advances received							€ 2,100,000
Bpifrance
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Advances received										€ 350,000
Authorized amount to be advanced										500,000
Advances, outstanding amount to be received										€ 150,000

Financial liabilities

6 Months Ended

Jun. 30, 2023

Disclosure of financial liabilities [abstract]

Financial liabilities

Details of financial liabilities


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Lease liabilities – Short term	1,146	962
Repayable BPI loan advances – Short term	400	500
PGE*	2,622	2,632
EIB loan – Short term	5,804	467
Total current financial liabilities	9,972	4,560
Lease liabilities – Long term	4,107	4,568
Repayable BPI loan advances – Long term	2,152	2,258
PGE*	5,251	6,495
EIB loan – Long term	32,518	35,287
Total non-current financial liabilities	44,029	48,608
Total financial liabilities	54,001	53,169

(*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

Lease Liabilities

Lease liabilities correspond to the discounted amount of the rentals to be paid over the lease terms for all outstanding contracts falling within the scope of IFRS 16. For the period presented, the main contracts relate to the buildings rented in Paris and in Villejuif. Note 12.2 Lease liabilities below presents the lease liability and the related liability increases or decreases recorded during the period.

Repayable BPI loan advances

The Company received repayable advances from Banque Publique d’Investissement (“Bpifrance”, formerly known as “OSEO Innovation”). Some of the advances are interest-free and are fully repayable in the event of technical and/or commercial success.

The other advances bear 1.56% interest. The amount to be reimbursed corresponds to the amount received to date, €2.1 million, increased by the interest amount (see Note 12.1).

In June 2020, Curadigm SAS obtained a €500 thousand conditional advance from Bpifrance, €350 thousand of which was received at the signature date. The remaining €150 thousand were released by Bpifrance after the completion of the project in October 2022, and the funds were received in January 2023.

PGE loan (“Prêts Garantis par l’Etat”)

The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for €5 million each in the form of state-guaranteed loans (“Prêts Garantis par l’Etat”, or “PGE” in France).

This loan is booked at amortized cost using an effective interest rate of 0.31%. Reimbursement of the loan started in September 2022 and will continue through mid-2026.

As of June 30, 2023, €0.6 million was repaid on the HSBC PGE loan.

On July 10, 2020, the Company entered into the second €5 million PGE loan with Bpifrance (the ‘‘Bpifrance PGE Loan’’). The Bpifrance PGE loan has a 6-year term and is 90% guaranteed by the French State. Starting after its first year anniversary, the Bpifrance PGE loan bears an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan is being reimbursed in 20 quarterly installments as from October 31, 2021 through July 26, 2026.

As of June 30, 2023, €0.68 million was repaid on the Bpifrance PGE loan.

EIB loan

In July 2018, the Company obtained a fixed rate and royalties-based loan from the EIB. Initially the loan could reach a maximum amount of €40 million, divided in three tranches. However, the conditions required to draw upon the third tranche of €10 million were not met and the Company is no longer able to request this final tranche.

Pursuant to the Amendment Agreement signed on October 18, 2022 (see description of the agreement in Note 4.3 Financing agreement with the European Investment Bank (“EIB”)), the Company determined that the modifications of the agreement were substantial and is to be accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability in accordance with IFRS 9 as of December 31, 2022.

Accordingly, at the Amendment Agreement date, the Company estimated the fair value of the new debt which required determining the present value of estimated discounted future cash flows using an average interest rate representing the prevailing market conditions at the restructuring date. The estimation involved projecting debt cash outflows indexed on annual sales turnover relating to NBTXR3 through specific Company’s license agreement is included in the Business Plan as determined by the company's Strategy direction.

At inception the fair value of the new liability was €34.4 million based on an average discount interest rate of 21.3%. This financial liability is subsequently measured at amortized cost using an effective interest rate (“EIR”) of 21.3%.

As of June 30, 2023, the Company accounted for the debt at amortized cost using the original EIR and adjusting the estimated debt outflows in accordance with the revised forecasts of annual sales turnover relating to NBTXR3 through specific Company’s license agreement(value and timing),

The debt outflows are subject to adjustments depending on:

•advanced payments (upfront or milestone) that the Company may receive as a result of the signature of a partnership (which can lead to earlier payments of Milestones or earlier/adjusted payments of PIK interests),

•the applicable duration of the loan (which can impact the level of interest),

•the annual sales turnover relating to NBTXR3 through the Company’s license agreement made through license agreement (which drive the level of royalties due to EIB) and

•the commercialization date (which trigger the beginning of the royalty calculation period)

The update of the forecasts of debt outflows resulted in a P&L catch-up impact of €0.8 million for the six months ended June 30, 2023 mostly due to certain cash outflows which are later than determined as of December 2022, in accordance with the license agreement signed with Janssen. (See Note 23 Subsequent events).

The EIB loan amounts to €38.3 million as of June 30, 2023 compared to €35.8 million as of December 31, 2022. The increase of €2.6 million over the six months ended June 30 2023 comprises:

•interest expenses accrual for an amount of €3.6 million;

•the payment of €233 thousand in accordance with the repayment schedule; and

•a finance income of €0.8 million corresponding to a catch-up impact due to debt outflow adjustments.

As of June 30, 2023 the fair value of the debt is estimated at €41.1 million. The Company estimated the fair value of the debt using the same methodology as the one performed at renegotiation date. In doing, so the Company kept the same assumption of CCC credit rating. However, essentially because of a decrease in spreads observed as of June 30, 2023 (compared with October and December 2022), the estimated fair market rate was estimated at 19.3%

12.1 CONDITIONAL ADVANCE, BANK LOAN AND LOANS FROM GOVERNMENT AND PUBLIC

AUTHORITIES

The tables below show the detail of liabilities recognized on the statements of financial position by type of conditional advances and loans from government and public authorities.

Conditional advances, interest-free loans from government and public authorities


(in thousands of euros)	Bpifrance advance	Interest-free Bpifrance loan	Curadigm Bpifrance advance	EIB loan	Total
As of December 31, 2022	2,316	125	317	35,754	38,512
Principal received	—	—	150	—	150
Impact of discounting, accretion and catch-up impact	8	—	(32)	(809)	(833)
Accumulated fixed and variable interest expense accrual	17	—	—	3,611	3,628

Repayment	(225)	(125)	—	(233)	(583)
As of June 30, 2023	2,116	—	435	38,322	40,874

Bank loans


(in thousands of euros)	HSBC “PGE”	Bpifrance “PGE”	Total
As of December 31, 2022	4,409	4,717	9,126
Impact of discounting and accretion	—	(3)	(3)
Accumulated fixed interest accrual	17	49	66
Repayment	(640)	(676)	(1,316)
As of June 30, 2023	3,786	4,087	7,873

12.2 LEASE LIABILITIES

The table below shows the detail of changes in lease liabilities recognized in the statement of consolidated financial position over the six-month period ended June 30, 2023:


(in thousands of euros)			Lease liabilities
As of December 31, 2022			5,530
New lease contracts			8
Impact of discounting of the new lease contracts			—
Fixed interest expense			—
Accumulated variable interest expense accrual			103
Repayment of lease			(389)

As of June 30, 2023			5,253

12.3 DUE DATES OF THE FINANCIAL LIABILITIES

The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interests are as follows:


	As of June 30, 2023
(in thousands of euros)	Less than 1 year	Between 1 and 3 years	Between 3 and 5 years	More than 5 years	Total
Bpifrance	325	1,292	595	—	2,212
Interest-free Bpifrance loan	—	—	—	—	—
Curadigm interest-free Bpifrance advance	75	200	225	—	500
HSBC “PGE” (1)	1,291	2,545	—	—	3,836
Bpifrance “PGE” (1)	1,331	2,577	314	—	4,222
EIB fixed rate loan	6,154	9,050	22,024	22,325	59,553
Lease liabilities	1,146	2,291	1,526	777	5,740
Total	10,322	17,955	24,685	23,102	76,064

(1) The Company plans to reimburse the two “PGE” (“Prêts garantis par l’Etat” or state-guaranteed loans) from HSBC and BPI over 5 years with a deferral of 1 year (last reimbursement being in 2026)..


	As of December 31, 2022
(in thousands of euros)	Less than 1 year	Between 1 and 3 years	Between 3 and 5 years	More than 5 years	Total
Bpifrance	300	1,300	837	—	2,437
Interest-free Bpifrance loan	125	—	—	—	125
Curadigm interest-free Bpifrance advance	75	200	75	—	350
HSBC “PGE” (1)	1,287	2,557	631	—	4,475
Bpifrance “PGE” (1)	1,345	2,605	948	—	4,898
EIB fixed rate loan	467	7,630	30,184	19,869	58,150
Lease liabilities	962	2,292	1,904	971	6,129
Total	4,560	16,584	34,579	20,840	76,563

(1) The Company plans to reimburse the two “PGE” (“Prêts garantis par l’Etat” or state-guaranteed loans) from HSBC and BPI over five years with a deferral of 1 year (last reimbursement being in 2026).

The long-term debt obligations indicated above relate to the due fixed rate interests and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts do not include the discounting impact, but only reflect the committed amounts under those contracts as of June 30, 2023.

The outstanding balance of the EIB loan included in the table above was €59.6 million as of June 30, 2023, including €14.2 million of total fixed rate interest to be paid over the term of the loan, out of which €5.9 million to be paid at short term and €20 million of milestones payable into three instalments (€0.3 million in 2023, €8.1 million in 2025 and €11.6 million in 2026). The balance in the table above does not include €36.8 million of estimated variable rate interest (royalties), based on the consolidated forecasted sales expected to be generated by the Company or its partners, according the EIB finance contract definition, during the six-year period beginning upon NBTXR3 commercialization (see Notes 4.3 Financing agreement with the EIB and 12.1 Conditional advance, bank loan and loans from government and public authorities).

Net financial income (loss) - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of financial instruments by type of interest rate [line items]
Interest income on cash and cash equivalents	€ 500
Foreign exchange gains	370	€ 2,459
Interest costs	3,714	2,602
Debt restructuring valuation impact	809	0
Conditional advances and loans from Government and Public Authorities
Disclosure of financial instruments by type of interest rate [line items]
Accumulated fixed and variable interest expense accrual	3,628
EIB loan
Disclosure of financial instruments by type of interest rate [line items]
Interest costs	3,600	2,600
Debt restructuring valuation impact	800
EIB loan \| Conditional advances and loans from Government and Public Authorities
Disclosure of financial instruments by type of interest rate [line items]
Accumulated fixed and variable interest expense accrual	3,611	800
Accumulated variable interest expense accrual		€ 1,700
EIB loan \| Variable interest rate
Disclosure of financial instruments by type of interest rate [line items]
Interest income (expense)	€ 3,600

Cash and cash equivalents (Tables)

6 Months Ended

Jun. 30, 2023

Subclassifications of assets, liabilities and equities [abstract]

Summary of Cash and Cash Equivalents

Cash and cash equivalent break down as follows:


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Cash and bank accounts	21,629	38,576
Short-term bank deposits	—	2,813
Net Cash and cash equivalents	21,629	41,388

Loss per share - Schedule of Basic and Diluted Loss Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Earnings per share [abstract]
Net loss for the period (in thousands of euros)	€ (28,099)	€ (26,357)
Weighted average number of shares (in shares)	35,037,052,000	34,891,876,000
Basic loss per share (in euro per share)	€ (0.80)	€ (0.76)
Diluted loss per share (in euro per share)	€ (0.80)	€ (0.76)

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Non-current assets
Intangible assets	€ 1	€ 1
Property, plant and equipment	6,483	7,120
Non-current financial assets	294	291
Total non-current assets	6,778	7,412
Current assets
Trade receivables	1,090	101
Other current assets	10,909	10,868
Cash and cash equivalents	21,629	41,388
Total current assets	33,628	52,358
TOTAL ASSETS	40,407	59,769
Shareholders’ equity
Share capital	1,057	1,046
Premiums related to share capital	255,734	255,760
Accumulated other comprehensive income	710	700
Treasury shares	(228)	(228)
Retained earnings	(282,958)	(227,282)
Net loss for the period	(28,099)	(57,041)
Total shareholders’ equity	(53,783)	(27,045)
Non-current liabilities
Non-current provisions	307	270
Non-current financial liabilities	44,029	48,608
Total non-current liabilities	44,336	48,878
Current liabilities
Current provisions	340	327
Current financial liabilities	9,972	4,560
Trade payables and other payables	16,712	9,621
Other current liabilities	6,175	6,855
Deferred income	137	55
Current contract liabilities	16,518	16,518
Total current liabilities	49,854	37,936
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	€ 40,407	€ 59,769

Share Capital - Disclosure of Details of Warrants (BSAs) (Details) € in Thousands		6 Months Ended
	May 18, 2022 EUR (€) uSDollarPerEuro shares	Jun. 30, 2023 shares uSDollarPerEuro
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of warrants (BSAs) outstanding (in shares)		3,974,343
BSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of warrants (BSAs) outstanding (in shares)		151,251
Kepler Cheuvreux subscription agreement \| BSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maximum number of shares to be issued (in shares) \| uSDollarPerEuro	5,200,000	5,200,000
Number of shares issued (in shares) \| uSDollarPerEuro	5,200,000
Number of shares likely to receive the right to grant (in shares)	5,200,000
Aggregate value of warrants \| €	€ 500
Number of ordinary share subscribed (in shares)		0
Number of other equity instruments forfeited (in shares) \| uSDollarPerEuro		0
Number of warrants (BSAs) outstanding (in shares)		5,200,000

Operating expenses - Disclosure Of Other Operating Income (Expenses) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Operating Expenses
Other non recurring income	€ 52	€ 0
Total other operating income and expenses	6	(963)
Pharmaengine
Disclosure Of Operating Expenses
Contract termination indemnities	0	(963)
Jefferies
Disclosure Of Operating Expenses
Contract termination indemnities	€ (46)	€ 0

Share-based payments - Disclosure of Expense from Equity (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Expense for the year	€ 1,349	€ 1,360
BSPCE
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Expense for the year	25	27
BSA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Expense for the year	0	0
OSA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Expense for the year	343	147
AGA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Expense for the year	€ 982	€ 1,186

Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	€ 7,120
Increases	(644)
Decreases	8
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	6,483
Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	15,299
Increases	96
Decreases	(6)
Other movements & transfer.	0
Currency translation	(1)
Property, plant and equipment at end of period	15,387
Gross book value of tangible assets \| Fixtures, fittings and installations
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	3,318
Increases	2
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	3,321
Gross book value of tangible assets \| Right of use – Buildings
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	8,462
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	8,462
Gross book value of tangible assets \| Technical equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	2,128
Increases	75
Decreases	0
Other movements & transfer.	300
Currency translation	0
Property, plant and equipment at end of period	2,503
Gross book value of tangible assets \| Office and IT equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	1,012
Increases	18
Decreases	(6)
Other movements & transfer.	0
Currency translation	(1)
Property, plant and equipment at end of period	1,023
Gross book value of tangible assets \| Transport equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	36
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	(1)
Property, plant and equipment at end of period	35
Gross book value of tangible assets \| Right of use – Transport equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	0
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	0
Gross book value of tangible assets \| Tangible assets in progress
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	344
Increases	0
Decreases	0
Other movements & transfer.	(300)
Currency translation	0
Property, plant and equipment at end of period	44
Gross book value of tangible assets \| Prepayments on tangible assets
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	0
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	0
Accumulated depreciation of tangible assets
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	(8,180)
Increases	(740)
Decreases	14
Other movements & transfer.	0
Currency translation	1
Property, plant and equipment at end of period	(8,904)
Accumulated depreciation of tangible assets \| Fixtures, fittings and installations
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	(1,959)
Increases	(158)
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	(2,117)
Accumulated depreciation of tangible assets \| Right of use – Buildings
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	(3,496)
Increases	(462)
Decreases	8
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	(3,950)
Accumulated depreciation of tangible assets \| Technical equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	(1,774)
Increases	(93)
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	(1,867)
Accumulated depreciation of tangible assets \| Office and IT equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	(915)
Increases	(27)
Decreases	6
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	(935)
Accumulated depreciation of tangible assets \| Transport equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	(36)
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	1
Property, plant and equipment at end of period	(35)
Accumulated depreciation of tangible assets \| Right of use – Transport equipment
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment at beginning of period	0
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	€ 0

Commitments	6 Months Ended
Commitments	Jun. 30, 2023
Capital commitments [abstract]
Commitments	Commitments The off-balance sheet commitments have not changed significantly since December 31, 2022, except for the following: Obligations under the loan agreement with the EIB In the event the EIB loan is repaid early, or in the event of a change of control after repayment of the loan, the amount of royalties due will be equal to the higher of the net present value of the royalties as determined by an independent expert required in order for the Bank to realize an internal rate of return on the loan of 20% or an amount equal to €35.0 million. As part of the Amendment Agreement in respect of the EIB, the Company has agreed to maintain a minimum cash and cash equivalents balance equal to the outstanding principal owed to EIB which is €25.3 million as of June 30, 2023. All other covenants included in the 2018 finance contract remain unchanged, other than aforementioned cash covenant which has been lowered to €10.3 million as of June 30, 2023 pursuant to a temporary waiver that was automatically extended until January 31, 2024 upon the Company’s entry into the Janssen Agreement on July 7, 2023. As of June 30, 2023, Cash and cash equivalents amounts to €21.6 million and no covenant is in breach. In certain circumstances, including any material adverse change, a change of control of the Company or if Dr. Laurent Levy, Chairman of the Executive Board, ceases to hold office, the Company may be required to pay a cancellation fee. If Dr. Laurent Levy ceases to hold a certain number of shares or ceases to be an officer, the EIB may require early repayment of the loan.

Share-based payments - Additional Information (Details) - € / shares		6 Months Ended
	Sep. 16, 2014	Jun. 30, 2023
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of preceding trading days taken into account in the determination of the share price on the grant date		20 days
BSA 2014
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Exercise price (in euros per share)	€ 17.67	€ 17.67

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED INCOME STATEMENT - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenues and other income
Revenues	€ 0	€ 0
Other income	3,293	1,329
Total revenues and other income	3,293	1,329
Research and development expenses	(17,805)	(16,608)
Selling, general and administrative expenses	(10,864)	(9,635)
Other Income	6
Other operating incomes and expenses		(963)
Total operating expenses	(28,663)	(27,206)
Operating income (loss)	(25,370)	(25,877)
Financial income	820	2,465
Financial expenses	(3,545)	(2,940)
Financial income (loss)	(2,725)	(474)
Income tax	(3)	(6)
Net loss for the period	€ (28,099)	€ (26,357)
Basic loss per share (in euro per share)	€ (0.80)	€ (0.76)
Diluted loss per share (in euro per share)	€ (0.80)	€ (0.76)

Share Capital (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]

Disclosure of Details of Share Capital Transactions

Detail of share capital transactions


(in thousands or number of shares)	Nature of transaction	Share Capital	Premiums related to share capital	Number of shares
December 31, 2022		1,046	255,760	34,875,872
April 24, 2023	Capital increase AGA 2021	11	—	354,510
March 31, 2023	Prior period adjustment	—	—	—
June 27, 2023	AGA 2023	—	(26)	—
June 30, 2023		1,057	255,734	35,230,382

Disclosure of Details of Warrants (BSAs)

The main terms and conditions of the BSA Kepler are described in the table below:


			BSA Kepler
Date of the shareholders’ meeting			April 28, 2021
Date of grant by the Executive Board			May 18, 2022
Maximum number of BSAs authorized			5,200,000
Total number of BSAs granted			5,200,000
Number of shares to which the BSA were likely to give right on the date of their grant			5,200,000
Starting date for the exercise of the BSA			(1)
BSA expiry date			(2)
BSA issue price			500 € in the aggregate
Exercise price per new share			(3)
Terms of exercise			(1)(4)
Number of shares subscribed as of the date of the Report			0
Total number of forfeited or cancelled BSAs as of the Report			0
Total number of BSAs outstanding as of the date of the Report			5,200,000
Total number of shares available for subscription as of the date of the Report (considering the conditions of exercise of the BSAs)			5,200,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)			5,200,000

1) Subject to meeting the contractual conditions, Kepler Cheuvreux undertakes to exercise the BSA Kepler within 24 months of their date of issue. These conditions include:

(i) Unless Kepler Cheuvreux and the Company agree differently from time to time, a limit as to the number of new shares to be issued as part of the exercise of stock warrants: the cumulative number of new shares issued upon exercise of the BSA Kepler shall be less than or equal to 25% of the total number of Nanobiotix shares traded on the regulated market of Euronext Paris (excluding block trades) from the date of the implementation of the financing facility, and

(ii) a limit as to the exercise price of the BSA Kepler: such exercise price shall not be lower than, in any case, the price limit set forth by the combined shareholders’ meeting of the Company dated April 28, 2021.

(2) The BSA Kepler may be exercised during a 24-month period as from their issuance date (subject to (i) a prior termination by the Company, at any time, or (ii) an extension for a maximum 6-month period in certain situations), at the end of which the BSA Kepler that are still outstanding shall be purchased by the Company at their issuance price and cancelled.

(3) The exercise price of the BSA Kepler will be based on the lower of the two daily volume-weighted average share prices for the two trading days preceding each issuance, less a maximum discount of 5.0%.

(4) The BSA Kepler may be exercised at any time in whole or in part by Kepler Cheuvreux during their exercise period, subject to a minimum proceeds condition.

Consolidated principles and methods	6 Months Ended
Consolidated principles and methods	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Consolidated principles and methods	Consolidated principles and methods 3.1 BASIS OF CONSOLIDATION Consolidated entities As of June 30, 2023, the consolidation scope is identical to that at December 31, 2022 as Nanobiotix S.A. has five wholly owned subsidiaries: •Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA, •Nanobiotix Germany GmbH, created in October 2017 and located in Germany, •Nanobiotix Spain S.L.U., created in December 2017 and located in Spain, •Curadigm SAS, created on July 3, 2019 and located in France, and •Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Cambridge, Massachusetts. Accordingly, the unaudited interim condensed consolidated financial statements as of June 30, 2023 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation. Foreign currency transactions The unaudited interim condensed consolidated financial statements are presented in thousands of euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate for the statement of financial position, whereas items of the statement of operations, statement of comprehensive loss and statement of cash flow are converted at the average exchange rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar-to-euro exchange rate used in the interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were a closing of $1.0866 as of June 30, 2023 and an average of $1.0811 for the six-month period ended June 30, 2023 compared with $1.0387 and $1.0940 respectively, as of and for the six-month period ended June 30, 2022 (source: Banque de France). The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment. 3.2. USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS The preparation of interim condensed consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are going concern, share-based payments, deferred tax assets, clinical trials accruals and the measurement of financial instruments (fair value and amortized costs). Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Executive and Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., option vesting terms) and market data (e.g., expected share volatility) (See Note 17 Share-based payments). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. Deferred tax assets are also recognized for unused tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow for sufficiently reliable income projections to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position. Clinical trial accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision is recognized accordingly. (See Note 13.1 Trade and other payables for information regarding the clinical trial accruals as of June 30, 2023 and December 31, 2022.) Revenue recognition In order to determine the amount and timing of revenue under the contract with customers, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to customers Determining the distinctiveness of performance obligations — A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services. Allocation of transaction price to performance obligations — A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. To determine the proper revenue recognition method, the Company evaluates whether the contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment. Some of the Company’s contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Variable consideration — Due to the nature of the work required to be performed on many of the Company’s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch‑up basis. Revenue recognized over time and input method — Some of the Company’s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers. See Note 15 for additional detail regarding the Company’s accounting policies for its additional sources of revenue and other income. Measurement of financial assets and liabilities At the renegotiation date in October 2022, the fair value measurement of the EIB loan required the Company to determine: –the discount rate of the new liability executed in October 2022. The discount rate reflects the company’s credit risk at the Amendment Agreement date as well as a premium to reflect uncertainties associated with the timing and the amount of the royalties’ payment. The Company involved external financial instruments valuation specialists to support in determining the average discount rate; –the amount of additional interest (“royalties”, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing upon commercialization. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to annual sales turnover relating to NBTXR3 through specific Company’s license agreement. For the purpose of measuring the fair value of the EIB loan, the Company forecasts expected sales relating to NBTXR3 during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see Notes 4.3 and 12 for details about this loan and the accounting treatment applied). Subsequently to the estimate of the fair value of the EIB loan performed at the renegotiation date, the debt has been measured at amortized cost based on the revised best estimate of the future cash flows related to the debt at each closing date. Accordingly, the Company determines the amount of additional interest as described above. Any subsequent adjustment of flows indexed to turnover has been discounted at the original effective interest rate and the adjustment is recognised in Profit or loss.

Intangible assets (Tables)

6 Months Ended

Jun. 30, 2023

Intangible assets other than goodwill [abstract]

Schedule of Intangible Assets

The change in intangible assets breaks down as follows:


(in thousands of euros)	As of December 31, 2022	Increases	Decreases	Transfer	As of June 30, 2023
Patents	65	—	—	—	65
Software	658	1	—	—	659
Intangible assets in progress	—	—	—	—	—
Gross book value of intangible assets	723	1	—	—	724
Patents	(65)	—	—	—	(65)
Software	(657)	—	(1)	—	(657)
Accumulated depreciation of intangible assets (1)	(722)	—	(1)	—	(722)
Net book value of intangible assets	1	2	(1)	—	1

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

Revenue and other income

6 Months Ended

Jun. 30, 2023

Revenue [abstract]

Revenue and other income

The revenue recognition accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2023 are identical to those used for the year ended December 31, 2022.

Application of IFRS 15 to the license and collaboration agreement and clinical supply agreement with LianBio

In May 2021, the Company executed a license arrangement with LianBio, pursuant to which LianBio received an exclusive right to develop and commercialize NBTXR3 in China and other east Asian countries. the Company remains responsible for the manufacturing of the licensed products. The Company is not required to transfer manufacturing know-how, unless the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's requirements for licensed products in a given calendar year. Pursuant to the agreement, the parties will collaborate on the development of NBTRX3 and LianBio will participate in global Phase 3 registrational studies, for several indications, by enrolling patients in China.

The Company received in June 2021 a non-refundable upfront payment of $20 million. In addition, the Company may receive up to $205 million potential additional payments upon the achievement of certain development and sales milestones, as well as tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The Company is also entitled to receive payments for development and commercial vials ordered by LianBio and supplied by the Company.

The license to commercialize a product candidate, ongoing transfer of unspecified know-how related to development and commercialization and the supply services (for commercial products) are in the scope of IFRS 15, as they are an

output of the Company’s ordinary activities. For IFRS 15 purpose, it was determined that the license is not distinct from the commercial manufacturing services because the customer cannot benefit from the license without the manufacturing services and such services are not available from third party-contract manufacturers. Accordingly, the license and commercial manufacturing services are treated as one single performance obligation which is recognized as manufacturing services are performed. Milestone payments linked to regulatory marketing approvals will be included in the transaction price only when and if the contingency is resolved and will be recognized as revenue when manufacturing services are provided. Sales-based milestone payments will be recognized when the sales thresholds are achieved. Royalties will be recognized when the underlying sales are made by LianBio.

The $20 million upfront payment received in June 2021 has been recognized as a Contract Liability and will be recognized as revenue over the term of the arrangement, as manufacturing services (for commercial products) are provided.

The execution of development efforts leading to the regulatory marketing approvals are treated as a collaboration arrangement outside of the scope of IFRS 15. If any R&D cost incurred is eligible for partial reimbursement by Lianbio, the corresponding recharge is recognized as Other Income, as well as the supply of products necessary to conduct the clinical trials. The related income is recognized respectively when the products will be delivered to Lianbio and when the eligible costs are incurred by LianBio.

On May 9, 2022, the Company signed the clinical supply agreement with LianBio as defined in the license, development, and commercialization agreement This agreement provides for the supply by the Company to LianBio of vials of NBTXR3 and Cetuximab products for clinical trial development activities. For the period ended June 30, 2023, the Company billed the delivery of NBTXR3 and Cetuximab vials to LianBio amounting to €217 thousand, recorded within Other Income as it relates to the non-IFRS 15 components of the agreement (the development collaboration).

As of June 30, 2023, the Company signed a global trial collaboration agreement (or “GTCA”) with LianBio in connection with the License Agreement signed on May 11, 2021. As contemplated by the LianBio License Agreement, LianBio shall participate in the global registrational Phase 3 trial “HNSCC 312” conducted by Nanobiotix, with regards to NANORAY-312 trials conducted within the licensed territories. According to the GTCA, LianBio is responsible for all internal and external costs incurred in connection with the study in the licensee territories as well as all external costs and expenses incurred by or on behalf of the Company for the global study that are generally applicable to both the licensee territories study with respect to the patients enrolled within the enrollment commitment and the portion of the global study conducted outside of the licensee territories. Recharge of related costs to LianBio cumulated since 2021, has started to be invoiced by the Company during the first half of 2023: the recharge invoice billed to LianBio amounting to €1.3 million as of June 30, 2023, has been recorded within Other Income as it relates to the non-IFRS 15 components of the agreement (the development collaboration).

Grants and Subsidies

Since its creation, the Company has received, because of its innovative approach to nanomedicine, certain grants and subsidies from the French State or French public authorities. These grants and subsidies are intended to finance its general or specified activities. Grants are recognized as income as the related expenses are incurred, provided there is reasonable assurance that the Company will comply with the conditions attaching to them and that the grants will be received.

Research tax credit

The research tax credit ("CIR") is granted to companies by the French government to encourage them to conduct technical and scientific research. Companies that can prove that they have incurred expenses that meet the required criteria (research expenses located in France or, since January 1, 2005, in the European Community or in another country that is a party to the Agreement on the European Economic Area and that has entered into a tax treaty with France containing an administrative assistance clause) are entitled to a tax credit which, in principle, can be offset against the corporate income tax due for the fiscal year in which the expenses were incurred and for the three following years. Any unused portion of the tax credit is then reimbursed by the Treasury. In the particular case where the Company qualifies as a small and medium-sized enterprise (SME), the Company may request immediate reimbursement of the balance of the tax credit without application of the three-year period.

The Company has benefited from the research tax credit since its creation. This financing is recorded under "Other income" in the year in which the corresponding expenses were incurred. The portion of the financing related to capitalized expenses is deducted in the balance sheet from the capitalized expenses and in the income statement from the amortization charges of these expenses.

Detail of revenue and other income

The following table summarizes the Company’s revenue and other income per category for the six-month period ended June 30, 2023 and 2022:


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Services	—	—
Other sales	—	—
Total revenue	—	—
Research tax credit	1,604	1,053
Subsidies	202	111
Other Income	1,487	165
Total other income	3,293	1,329
Total revenue and other income	3,293	1,329

Research tax credit

Research tax credit increased from €1,053 thousand in 2022 to €1,604 thousand in 2023 due mainly to an increase of research and development expenses, and to the inclusion of additional eligible expenses from contract research organizations for clinical trials, mainly related to the 312 study.

Subsidies

Besides, “Subsidies” in the other income included €150 thousand recognized as revenue, in connection with the Bpifrance Deep Tech Funding granted to Curadigm SAS for the half-year ended June 30, 2023, as compared to €92 thousand for the half-year ended June 30, 2022.

Other income

At last, Other income includes the recharge of NANORAY-312 trials costs conducted within the territories of LianBio. in connection with the GTCA signed as of June 30, 2023 (see Note 4.1). The Company has started to invoice LianBio during the first half of 2023, amounting to €1.3 million as of June 30, 2023. The Company shall invoice LianBio for shared costs on a quarterly basis.

Other income also includes income for supply services, provided in connection with the clinical supply agreement signed in May 2022 with LianBio (see Note 4.1), amounting to €217 thousand for the half-year ended June 30, 2023, as compared to €160 thousand for the half-year ended June 30, 2022. The Company shall supply LianBio with NBTXR3 product for the purpose of the development of licensed products in LianBio’s territory.

Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Research tax credit receivable	€ 5,488	€ 4,091
VAT receivable	1,437	1,055
Prepaid expenses	2,236	2,981
Other receivables	1,747	2,741
Other current assets	€ 10,909	€ 10,868

Provisions - Disclosure of Changes in Provisions (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure of other provisions
Other provisions at beginning of period	€ 596
Increases	52
Decreases	0
Currency translation adjustments	(1)
Other provisions at end of period	647
Non-current provisions
Disclosure of other provisions
Other provisions at beginning of period	270
Increases	38
Decreases	0
Currency translation adjustments	0
Other provisions at end of period	307
Lump-sum retirement benefits
Disclosure of other provisions
Other provisions at beginning of period	270
Increases	38
Decreases
Currency translation adjustments	0
Other provisions at end of period	307
Current provisions
Disclosure of other provisions
Other provisions at beginning of period	327
Increases	14
Decreases	0
Currency translation adjustments	(1)
Other provisions at end of period	340
Provisions for disputes
Disclosure of other provisions
Other provisions at beginning of period	177
Increases	10
Decreases	0
Currency translation adjustments	(1)
Other provisions at end of period	186
Provisions for charges
Disclosure of other provisions
Other provisions at beginning of period	150
Increases	4
Decreases
Currency translation adjustments	0
Other provisions at end of period	€ 154

Intangible assets - Schedule of Intangible Assets (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	€ 1
Increases	2
Decreases	(1)
Transfer	0
Intangible assets at end of period	1
Gross book value of intangible assets
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	723
Increases	1
Decreases	0
Transfer	0
Intangible assets at end of period	724
Gross book value of intangible assets \| Patents
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	65
Increases	0
Decreases	0
Transfer	0
Intangible assets at end of period	65
Gross book value of intangible assets \| Software
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	658
Increases	1
Decreases	0
Transfer	0
Intangible assets at end of period	659
Gross book value of intangible assets \| Intangible assets in progress
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	0
Increases	0
Decreases	0
Transfer	0
Intangible assets at end of period	0
Accumulated depreciation of intangible assets
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	(722)
Increases	0
Decreases	(1)
Transfer	0
Intangible assets at end of period	(722)
Accumulated depreciation of intangible assets \| Patents
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	(65)
Increases	0
Decreases	0
Transfer	0
Intangible assets at end of period	(65)
Accumulated depreciation of intangible assets \| Software
Disclosure of detailed information about intangible assets
Intangible assets at beginning of period	(657)
Increases	0
Decreases	(1)
Transfer	0
Intangible assets at end of period	€ (657)

Revenue and other income (Tables)

6 Months Ended

Jun. 30, 2023

Revenue [abstract]

Schedule of Revenues and Other Income

The following table summarizes the Company’s revenue and other income per category for the six-month period ended June 30, 2023 and 2022:


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Services	—	—
Other sales	—	—
Total revenue	—	—
Research tax credit	1,604	1,053
Subsidies	202	111
Other Income	1,487	165
Total other income	3,293	1,329
Total revenue and other income	3,293	1,329

Cover page	6 Months Ended
Cover page	Jun. 30, 2023
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	NANOBIOTIX S.A.
Entity Address, Address Line	60 rue de Wattignies
Entity Address, Postal Zip Code	75012
Entity Address, City or Town	Paris
Entity Address, Country	FR
Amendment Flag	false
Entity Central Index Key	0001760854
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2

Subsequent events (Details) € in Thousands, $ in Thousands			1 Months Ended	6 Months Ended
Subsequent events (Details) € in Thousands, $ in Thousands	Sep. 01, 2023 shares	Jul. 10, 2023 EUR (€)	Aug. 31, 2023 EUR (€)	Jun. 30, 2023 EUR (€)	Jul. 19, 2023 USD ($)
Disclosure of non-adjusting events after reporting period
Payment of advisory fees				€ 1,400
Going concern minimum cash balance				€ 25,300
Termination Agreement
Disclosure of non-adjusting events after reporting period
Payment of advisory fees			€ 1,500
Contractual commitments, payment \| $					$ 750
Contractual commitments, milestone payment upon second regulatory approval \| $					$ 750
Janssen Pharmaceutica NV \| Major collaboration agreement
Disclosure of non-adjusting events after reporting period
Collaboration agreement, upfront payment license fee		€ 30,000
Collaboration agreement, success-based payment		1,800,000
Collaboration agreement, shares authorized for issuance (shares) \| shares	959,637
Janssen Pharmaceutica NV \| Major collaboration agreement \| Top of range
Disclosure of non-adjusting events after reporting period
Collaboration agreement, potential development and commercial milestones payments		650,000
Collaboration agreement, equity investment receivable		30,000
Janssen Pharmaceutica NV \| Major collaboration agreement \| Nanobiotix Corp. \| Top of range
Disclosure of non-adjusting events after reporting period
Collaboration agreement, compensation per indication		220,000
Janssen Pharmaceutica NV \| Major collaboration agreement \| Tranche one
Disclosure of non-adjusting events after reporting period
Collaboration agreement, equity investment receivable		5,000
Percentage f total shares outstanding (percent)	2.65%
Janssen Pharmaceutica NV \| Major collaboration agreement \| Tranche two
Disclosure of non-adjusting events after reporting period
Collaboration agreement, equity investment receivable		€ 25,000

Financial liabilities - Summary of Conditional Advances and Interest-Free Loans from Government and Public Authorities (Details) - EUR (€) € in Thousands	1 Months Ended		6 Months Ended
	Mar. 31, 2019	Oct. 31, 2018	Jun. 30, 2023	Jun. 30, 2022
Changes in liabilities arising from financing activities
Principal received			€ 150	€ 0
Conditional advances and loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period			38,512
Changes in liabilities arising from financing activities
Principal received			150
Impact of discounting, accretion and catch-up impact			(833)
Accumulated fixed and variable interest expense accrual			3,628
Repayment			(583)
Liabilities arising from financing activities at end of period			40,874
Bpifrance advance \| Conditional advances and loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period			2,316
Changes in liabilities arising from financing activities
Principal received			0
Impact of discounting, accretion and catch-up impact			8
Accumulated fixed and variable interest expense accrual			17
Repayment			(225)
Liabilities arising from financing activities at end of period			2,116
Interest-free Bpifrance loan \| Conditional advances and loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period			125
Changes in liabilities arising from financing activities
Principal received			0
Impact of discounting, accretion and catch-up impact			0
Accumulated fixed and variable interest expense accrual			0
Repayment			(125)
Liabilities arising from financing activities at end of period			0
Curadigm Bpifrance advance \| Conditional advances and loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period			317
Changes in liabilities arising from financing activities
Principal received			150
Impact of discounting, accretion and catch-up impact			(32)
Accumulated fixed and variable interest expense accrual			0
Repayment			0
Liabilities arising from financing activities at end of period			435
EIB loan
Changes in liabilities arising from financing activities
Principal received	€ 14,000	€ 16,000
Impact of discounting, accretion and catch-up impact			(800)
EIB loan \| Conditional advances and loans from Government and Public Authorities
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period			35,754
Changes in liabilities arising from financing activities
Principal received			0
Impact of discounting, accretion and catch-up impact			(809)
Accumulated fixed and variable interest expense accrual			3,611	800
Accumulated variable interest expense accrual				€ 1,700
Repayment			(233)
Liabilities arising from financing activities at end of period			€ 38,322

Loss per share - Additional Information (Details) - shares		6 Months Ended
	May 18, 2022	Jun. 30, 2023
Earnings per share [abstract]
Potential additional ordinary shares that are considered antidilutive (in shares)		9,174,343,000
Underwriting agreement, maximum number of shares issued (in shares)	5,200,000

Operating expenses - Disclosure of Selling, General and Administrative Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Analysis of income and expense [abstract]
Purchases, fees and other expenses	€ (5,398)	€ (4,251)
Payroll costs (including share-based payments)	(5,295)	(5,244)
Depreciation, amortization and provision expenses	(172)	(140)
Total SG&A expenses	€ (10,864)	€ (9,635)

Trade payables and other current liabilities - Disclosure of Trade And Other Payables (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Fixed assets payables	€ 0	€ 228
Accrued expenses - clinical trials	7,909	5,394
Other trade payables	8,803	3,999
Total trade and other payables	€ 16,712	€ 9,621

Intangible assets

6 Months Ended

Jun. 30, 2023

Intangible assets other than goodwill [abstract]

Intangible assets

The change in intangible assets breaks down as follows:


(in thousands of euros)	As of December 31, 2022	Increases	Decreases	Transfer	As of June 30, 2023
Patents	65	—	—	—	65
Software	658	1	—	—	659
Intangible assets in progress	—	—	—	—	—
Gross book value of intangible assets	723	1	—	—	724
Patents	(65)	—	—	—	(65)
Software	(657)	—	(1)	—	(657)
Accumulated depreciation of intangible assets (1)	(722)	—	(1)	—	(722)
Net book value of intangible assets	1	2	(1)	—	1

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

No impairment losses were recognized in application of IAS 36 - Impairment of Assets in the period presented.

Cash and cash equivalents

6 Months Ended

Jun. 30, 2023

Subclassifications of assets, liabilities and equities [abstract]

Cash and cash equivalents

Cash and cash equivalent break down as follows:


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Cash and bank accounts	21,629	38,576
Short-term bank deposits	—	2,813
Net Cash and cash equivalents	21,629	41,388

As of June 30, 2023, net cash and cash equivalents decreased by €19.8 million as compared with December 31, 2022.

In the framework of the Amendment Agreement with the EIB signed in 2022 and of the waiver letter signed in March 2023, the Company has agreed to maintain a minimum cash and cash equivalents balance equal to the outstanding principal owed to EIB down to €10.3 million as of June 30, 2023 (See Note 4.3 Financing agreement with the European Investment Bank (“EIB”).

Segment reporting	6 Months Ended
Segment reporting	Jun. 30, 2023
Disclosure of operating segments [abstract]
Segment reporting	Segment reportingIn accordance with IFRS 8 – Operating Segments, reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company’s Chairman and the members of the Executive and Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France.

Net financial income (loss)

6 Months Ended

Jun. 30, 2023

Net Financial Income (Loss) [Abstract]

Net financial income (loss)


	For the six month period ended June 30,
(in thousands of euros)	2023	2022
Income from cash and cash equivalents	450	6
Foreign exchange gains	370	2,459
Other financial income	—	—
Total financial income	820	2,465
Interest cost	(3,714)	(2,602)
EIB debt catch-up	809	—
IFRS 16 related interests	(103)	(122)
Foreign exchange losses	(537)	(216)
Total financial expenses	(3,545)	(2,940)
Net financial income (loss)	(2,725)	(474)

For the six month period ended June 30, 2023, the €0.5 million income from cash and cash equivalents was related to short-term deposits. The foreign exchange gains realized by the Company amounted to €0.4 million mainly related to the appreciation of the USD on HSBC bank account denominated in U.S. dollars. As of June 30, 2023, the interest cost amounts to €3.7 million, mainly due to interest costs on the EIB loan (see Note 12.1 Conditional advances, bank loan and loan granted by public authorities) which is an addition of EIB fixed and variable rate interests for €3.6 million.

For the six month period ended June 30, 2022, the foreign exchange gains realized by the Company amounted to €2.5 million mainly related to the HSBC bank account denominated in U.S. dollars.

As of June 30, 2022, the interest cost amounts to €2.6 million, mainly due to interest costs on the EIB loan (see Note 12.1 Conditional advances, bank loan and loan granted by public authorities) which is an addition of EIB fixed and variable rate interests for respectively €0.8 million and €1.7 million.

EIB debt catch-up

The P&L catch up impact of €0.8 million is related to the update of the forecasts of debt outflows mostly due to the consideration of the license agreement signed with Janssen signed on July 7, 2023. (See Note 12 Financial Liabilities).

General information, statement of compliance and basis of presentation- Narrative (Details) shares in Millions, $ in Millions				6 Months Ended
	Sep. 13, 2023 USD ($)	Jun. 30, 2023 EUR (€)	May 18, 2022 shares	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)	Aug. 15, 2023 EUR (€)	Jul. 07, 2023 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Disclosure of changes in accounting estimates
Net loss for the period				€ 28,099,000	€ 26,357,000
Net decrease in cash and cash equivalents				19,759,000	20,900,000
Accumulated deficit		€ 282,958,000		282,958,000				€ 227,282,000
Working capital				(22,953,000)	(21,437,000)
Going concern minimum cash balance		25,300,000		25,300,000
Cash and cash equivalents		21,629,000		21,629,000	€ 63,021,000			€ 41,388,000	€ 83,921,000
Underwriting agreement, maximum number of shares issued (in shares) \| shares			5.2
Going Concern Reuirements
Disclosure of changes in accounting estimates
Going concern minimum cash balance						€ 15,000,000
Major collaboration agreement \| Janssen Pharmaceutica NV
Disclosure of changes in accounting estimates
Upfront fees receivable \| $							$ 30
Proceeds from shares issued \| $	$ 5
Janssen Pharmaceutica NV
Disclosure of changes in accounting estimates
Potential conditional funding		25,000,000		€ 25,000,000
Cumulative Effect, Period of Adoption, Adjusted Balance
Disclosure of changes in accounting estimates
Working capital		€ (22,700,000)

Loss per share

6 Months Ended

Jun. 30, 2023

Earnings per share [abstract]

Loss per share


	For the six month period ended June 30,
	2023	2022
Net loss for the period (in thousands of euros)	(28,099)	(26,357)
Weighted average number of shares	35,037,052	34,891,876
Basic loss per share (in euros)	(0.80)	(0.76)
Diluted loss per share (in euros)	(0.80)	(0.76)

Instruments providing deferred access to the capital (stock options, free shares, founders' warrants, warrants and equity line) are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore,

diluted loss per share is identical to basic loss per share as all equity instruments issued, representing a total of 9,174,343 potential additional ordinary shares, have been considered antidilutive (including 5,200,000 equity line related warrants, please refer to Note 10.3 for more details)

Significant transactions	6 Months Ended
Significant transactions	Jun. 30, 2023
Disclosure of transactions between related parties [abstract]
Significant transactions	Significant transactions 4.1 LIANBIO In May 2021, Nanobiotix announced a partnership with Lian Oncology Limited (LianBio) a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. LianBio has started to collaborate in the development of NBTXR3 in Asia Pacific region in the frame of the study NANORAY-312 and will contribute to patient enrollment in four other future global registrational studies across several tumor types and therapeutic combinations. LianBio will also participate in the global Phase 3 registrational study in head and neck cancer into Greater China and South Korea, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations. As of June 30, 2023, a non-refundable upfront payment of $20 million has been collected by the Company at the signature of the LianBio Agreement. Additionally, the Company is entitled to receive up to an aggregate of $205 million in potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. In May 2022 and according to the license agreement executed in May 2021, the Company entered into a clinical supply agreement and a related quality agreement with LianBio for the purpose of the Company supplying LianBio and LianBio purchasing exclusively from the Company all the required quantities of NBTXR3 for the global clinical study NANORAY-312 and any other studies conducted within the licensed territories. For the period ended June 30, 2023, the Company has collected €320 thousand from LianBio pursuant to this clinical supply agreement. Furthermore, LianBio is required to order and purchase NBTXR3 product from the Company according to quantities specified in binding forecasts prepared by LianBio. As of June 30, 2023, the Company signed a global trial collaboration agreement (or the “GTCA”) with LianBio in connection with the license agreement signed on May 11, 2021. As expressed as part of the License Agreement, LianBio shall participate in the global registrational Phase 3 trial “HNSCC 312” conducted by Nanobiotix, with regards to NANORAY-312 trials conducted within the licensed territories. Invoicing related to the recharge of related costs to LianBio has started as of June 30, 2023 totalling €1.3 million for the first half of 2023. See Note 15 for the accounting analysis of the partnership with LianBio and for impact in ‘Revenue and other Income’ and see Note 8 for impact in ‘Trade Receivables’. 4.2 PHARMAENGINE In August 2012, the Company entered into a license and collaboration agreement with PharmaEngine, which provided for the development and commercialization of NBTXR3 by PharmaEngine throughout the covered Asia-Pacific countries. In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement set-up in August 2012. As of December 31, 2022, the Company had paid a total of $7.5 million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine is entitled to receive an additional payment of $5 million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. As of June 30, 2023, these future payments were not accrued because the triggering events have not occurred. 4.3 FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK (“EIB”) In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to €40 million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria. This financing is divided in three tranches: •a first tranche of €16 million, received in October 2018, subject to a 6% fixed rate and that will be fully repaid in 2023 at the latest; •a second tranche of €14 million, received in March 2019, subject to a 5% fixed rate, with repayments beginning in 2021 and continuing into 2024; and, •a last tranche of €10 million, however the Company did not meet the criteria to request this tranche prior to the contractual deadline for requesting this third tranche. Accordingly the third tranche is no longer available to the Company. In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) royalties to EIB. The amount of royalties payable is calculable based on low single digit royalties indexed on annual sales turnover relating to NBTXR3 through specific Company’s license agreement, which vary according to the number of tranches that have been drawn, and indexed on the Company’s annual sales turnover. On October 18, 2022, the Company and the EIB amended the set of financing and royalties’ agreements (together the “Amendment Agreement to the Finance Contract” or “Amendment Agreement”) relating to the EIB loan to re-align the Company’s outstanding debt obligations with its expected development and commercialization timelines. The main terms and conditions of the Amendment Agreement are as follows: Under the Amendment Agreement, the repayment of the remaining €25.3 million in principal for both tranches is due at the earliest of the third royalty payment (four years after commercialization of NBTXR3) for the first tranche and the second royalty payment (three years following commercialization of NBTXR3) for the second tranche, or on June 30, 2029 irrespective of the commercialization date of NBTXR3. Commercialization date corresponds to the first fiscal year during which annual sales turnover relating to NBTXR3 through specific Company’s license agreement will exceed €5 million. Under these main terms and conditions, an amount of €5.4 million in interest accrued as payment-in-kind (“PIK”) on the first tranche shall be prepaid in October 2024, except in the case of the closing of a collaboration agreement in which case the PIK will be subject to an earlier redemption by October 2023. On July 10, 2023, the Company announced a license agreement with Janssen (see Note 23 Subsequent events), accordingly the Company is subject to payment of the PIK by October 2023 latest. Going forward, principal from the first tranche will accrue interest at the unchanged rate of 6% annually, with such interest being capitalized and due as PIK interest at maturity. Interest on the remaining €9.3 million in principal from the second tranche will continue to accrue at the unchanged 5% fixed rate paid in semi-annual installments through the repayment date. The annual royalty payment remains in the low single digits and indexed on our net sales turnover, and continues to cover a six-year period but was re-aligned as of the first year of NBTXR3 commercialization meaning, when the Company achieves annual net sales in excess of €5.0 million. In addition to the royalty fees, the Amendment Agreement also includes a “milestone” payment of €20 million, which will be due at the latest June 2029. An accelerated redemption schedule for this milestone payment would be triggered calling for the repayment in two equal installments due one year and two years after commercialization, respectively. Further, should the Company secure non-dilutive capital through the execution of any business development deal, such as a co-development and/or commercialization arrangement, an accelerated repayment of the €20 million The amount of the accelerated payment would be subject to, and prorated based upon, the size of any upfront or milestone payments received pursuant to the aforementioned business development deal, not to exceed 10% of any upfront or milestone payment received by the Company. On July 10, 2023, the Company announced a license agreement with Janssen (see Note 23 Subsequent events), and received an upfront cash licensing fee of $30 million in August 2023. Consequently the Company has paid an advance payment of the milestone payment in September 2023 representing a low single digit of the cash licensing fee received. As part of the Amendment Agreement in respect of the EIB, the Company has agreed to maintain a minimum cash and cash equivalents balance equal to the outstanding principal owed to EIB which is €25.3 million as of June 30, 2023. All other covenants included in the 2018 finance contract remain unchanged, other than aforementioned cash covenant which has been lowered to €10.3 million as of June 30, 2023 pursuant to a temporary waiver that was automatically extended until January 31, 2024 upon the Company’s entry into the Janssen Agreement on July 7, 2023. As of June 30, 2023, Cash and cash equivalents amounts to €21.6 million and no covenant is in breach (see Note 9 Cash and cash equivalents and Note 2 General information). See Note 12 for the accounting of this liability and the valuation assumptions to determine the average discount rate and the fair value of the loan. See Note 14 for discussion of the liquidity risk associated with the covenant. 4.4 COLLABORATION AGREEMENT WITH MD ANDERSON On December 21, 2018, the Company entered into a strategic collaboration agreement with MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients, which was amended and restated in January 2020 and subsequently amended in June 2021. Pursuant to the MD Anderson Collaboration Agreement, the Company and MD Anderson established a large-scale, comprehensive NBTXR3 clinical collaboration to improve the efficacy of radiotherapy for certain types of cancer. The collaboration initially is expected to support multiple clinical trials conducted by MD Anderson, as sponsor, with NBTXR3 for use in treating several cancer types (including head and neck, pancreatic, and lung cancers). We expect to inject approximately 312 patients in total across these clinical trials. As part of the collaboration funding, Nanobiotix is committed to pay $10.6 million for those clinical trials during the collaboration, and made an initial $1.0 million payment at the commencement of the collaboration and a second $1.0 million payment on February 3, 2020. Additional payments have been made every six months following patient’s enrollment in the trials, with the balance payable due upon enrollment of the final patient for all studies. During the six months ended June 30, 2023, the Company recognized prepaid expenses for €1.4 million. Besides, expenses are recorded during the course of the collaboration in the statement of consolidated operations, when incurred, based on the patients enrolled during the relevant period. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. This milestone payment will depend on the year when trigger event occurs, with a minimum amount of $2.2 million if occurred in 2020 up to $16.4 million if occurred in 2030. See Note 8.2 for further details on other current assets. 4.5 EQUITY LINE In May 2022, Nanobiotix established an equity line financing with Kepler Cheuvreux. Provided the contractual conditions are met, this equity line of financing will provide financial optionality and near-term flexibility over a maximum timeframe ending in May 2024, if needed, as Nanobiotix continues efforts to reduce operating expenses and to focus on its priority programs. The shares will be issued based on the lower of the two daily volume weighted average share prices for the two trading days preceding each issuance, less a maximum discount of 5.0%. An 2% exercise commission of the exercise price also applies on each exercise date of its warrants by Kepler Cheuvreux. No warrant has been exercised as of June 30, 2023. (See Note 10.3 Equity Line Agreement and Note 21 Commitments)

Loss per share (Tables)

6 Months Ended

Jun. 30, 2023

Earnings per share [abstract]

Schedule of Basic and Diluted Loss Per Share


	For the six month period ended June 30,
	2023	2022
Net loss for the period (in thousands of euros)	(28,099)	(26,357)
Weighted average number of shares	35,037,052	34,891,876
Basic loss per share (in euros)	(0.80)	(0.76)
Diluted loss per share (in euros)	(0.80)	(0.76)

Company information	6 Months Ended
Company information	Jun. 30, 2023
Disclosure Of Information Related To The Company [Abstract]
Company information	COMPANY INFORMATION Nanobiotix, a société anonyme registered with the Paris registry of trade and companies under number 447 521 600 and having its registered office at 60 rue de Wattignies, 75012, Paris (“Nanobiotix” or the “Company” and, with its subsidiaries, the “Group”), is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to the treatment of cancer and other significant unmet medical needs with the express intent of favorably impacting the lives of millions of patients. Nanobiotix believes that the nanotherapeutics it is developing for the treatment of cancer have the potential to significantly enhance patients’ response to radiotherapy and increase the number of patients that may benefit from systemic cancer treatments, including targeted therapeutics and chemotherapy. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The Company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. The Group has been listed on Euronext: Paris under the ticker symbol “NANO” since 2012 (ISIN: FR0011341205, Bloomberg Code: NANO:FP) and on the Nasdaq Global Select Market in the United States under the ticker symbol “NBTX”since December 2020. The Group is the owner of more than 20 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The Company’s resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform.

Trade payables and other current liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Subclassifications of assets, liabilities and equities [abstract]

Disclosure of Trade and Other Payables


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Fixed assets payables	—	228
Accrued expenses - clinical trials	7,909	5,394
Other trade payables	8,803	3,999
Total trade and other payables	16,712	9,621

Disclosure of Other Current Liabilities

OTHER CURRENT LIABILITIES


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Tax liabilities	382	358
Payroll tax and other payroll liabilities	5,517	6,237
Other payables	276	260
Other current liabilities	6,175	6,855

Disclosure of Deferred Income and Contract Liabilities

DEFERRED REVENUES AND CONTRACT LIABILITIES


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Deferred income	137	55
Contract liabilities	16,518	16,518
Deferred income and contract liabilities	16,655	16,573

General information, statement of compliance and basis of presentation	6 Months Ended
	Jun. 30, 2023
General Information, Statement of Compliance and Basis of Presentation [Abstract]
General information, statement of compliance and basis of presentation	General information, statement of compliance and basis of presentation General principles The unaudited interim condensed consolidated financial statements as of June 30, 2023 and for the six-month period ended June 30, 2023 were prepared under the supervision of the management of the Company and were submitted by the Executive Board to the review of the Supervisory Board. All amounts in the unaudited interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the unaudited interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. See Note 3.2 Use of judgement, estimates and assumptions. The unaudited interim consolidated financial statements of the Company have been prepared in compliance with IAS 34 – “Interim Financial Reporting”. As they are unaudited interim condensed financial statements, they do not contain all information required for the consolidated annual financial statements and should therefore be read in conjunction with the consolidated financial statements of the Company for the financial year ended December 31, 2022 as described below. Seasonality of the Company’s activities According to IAS 34 – Interim Financial Reporting, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed financial statements in order to provide a better understanding and comparison of its interim financial statements. As mentioned in Note 15 Revenue and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. Therefore, the following unaudited interim condensed financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34-20. Statement of compliance and basis of presentation The unaudited interim condensed consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of June 30, 2023. The unaudited interim condensed consolidated financial statements are also compliant with IFRS as adopted by the European Union in effect at the date of preparation of these financial statements. The accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2023 are identical to those used for the year ended December 31, 2022 except for the standards listed below that required adoption in 2023. Application of New or Amended Standards and Interpretations The following standards, interpretations and amendments to existing standards applicable for reporting periods beginning on or after January 1, 2023, were applied where necessary to the interim condensed consolidated financial statements for the six months ended June 30, 2023: •Amendments to IAS 8 – Definition of Accounting Estimates •Amendments to IAS 1 and IFRS Practice Statement 2 – Disclosure of Accounting Policies •Amendments to IAS 12 – Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction The application of these standards and these amendments had no impact on the Company’s interim condensed consolidated financial statements. Standards, interpretations and amendments to existing standards available for early adoption in reporting periods beginning on or after January 1, 2023 In first-half 2023, there were no new standards, interpretations or amendments to existing standards applicable to accounting periods starting on or after January 1, 2024 that the Group could have early adopted as from January 1, 2023. Standards, interpretations and amendments to existing standards published but not yet applicable The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable concern: •Amendments to IAS 1 – Classification of Liabilities as Current or Non-current •Amendment to IAS 12 – International Tax Reform – Pillar Two Model Rules The Company is currently evaluating if the adoption of these amendments will have a material impact on our results of operations, financial position, or cash flows. Going Concern The Company experienced net losses of €28.1 million in the six months ended June 30, 2023 and a net decrease in cash and cash equivalents of €19.8 million during the same period. As of June 30, 2023, the Company’s accumulated deficit was €283.0 million with a negative working capital of €22.7 million. the Company expects to continue to incur significant expense related to the development and manufacturing of nanotechnology product candidates such as NBTXR3 and conducting clinical studies. Additionally, the Company may encounter unforeseen difficulties, complications, development delays and other unknown factors that require additional expense. As a result of these expenditures, the company expects to continue to incur significant losses in the near term. Additionally, the Company’s debt instruments contain covenants that require maintenance of minimum cash and cash equivalent balances that limit the availability of cash resources to pursue operational needs: Pursuant to the terms of the finance contract for the EIB loan, for so long as the EIB loan remains outstanding, the Company was required to maintain a minimum cash and cash equivalents balance equal to the outstanding principal owed to EIB which is €25.3 million as of June 30, 2023. The remaining principal of the loan would become payable, together with accrued interest, prepayment fees and other accrued or outstanding amounts, if and when requested by EIB, if the cash balance were to fall below this minimum cash amount requirement. However, in March 2023, the Company has obtained a temporary waiver that reduces the minimum cash balance requirement by €15.0 million: upon the Company’s entry into the global licensing agreement executed with Janssen - condition that has been fulfilled following the “HSR” antitrust clearance announced as of August 15, 2023 - the duration of this temporary waiver was automatically extended until January 31, 2024. Therefore, the Company’s covenant obligations and the ongoing activities entail that the amount of cash and cash equivalents, amounting to €21.6 million as of June 30, 2023 (see section II note 9 cash and cash equivalents) is sufficient to fund its operating expenses into the first quarter of 2024. While the Company has taken and will continue to take actions to obtain additional funding and manage costs, as necessary, the above factors raise substantial doubt about the Company’s ability to continue as a going concern as there is no assurance that the Company will be successful in satisfying its future cash needs. The Executive Board has determined that it is appropriate to prepare its unaudited condensed consolidated financial statements as of and for the period ended June 30, 2023, on a going concern basis, assuming the Company will continue to operate for the foreseeable future, and to address its liquidity challenges by pursuing activities to generate additional cash inflows and by closely monitoring its operating expenditures. As part of the Company’s efforts to address the risk of going concern, management has undertaken the following: •The Company has signed a Global Trial Collaboration Agreement with LianBio which was executed as of June 30, 2023, providing for LianBio to participate in the global registrational Phase 3 trial “HNSCC 312” costs; •On July 7, 2023, the Company entered into the Janssen worldwide co-development and commercialization Agreement, allowing the Company to receive a $30 million upfront payment, which became payable as of August 15, 2023, following the “HSR” antitrust clearance period, and which has been received by the Company from Janssen; •In addition, as of September 13, 2023, the Company has received a gross amount of $5 million in consideration of the initial tranche equity investment by JJDC according to the terms of the JJDC SPA; •Operating Expense Monitoring: the Company continues efforts to control its operating expenses and to focus on its priority programs by enhancing operational efficiencies and optimizing capital allocation for continued investment in priority development pathways. The Company also continuously evaluates additional financing avenues on an opportunistic basis. Such opportunities may include one or more possible new financings from institutional or strategic investors, debt or product financing structures, from the capital markets, business development and licensing, grants or subsidies, or a combination of the above, whether or not in combination with the potential second tranche equity investment of $25.0 million under the JJDC SPA, if the conditions thereto are satisfied. Additionally, the Equity Line (PACEO) executed in May 2022 might provide financing flexibility until its expiration in May 2024. Moreover, the Company is eligible for success-based milestones under its collaboration agreements, including the Janssen Agreement, although the Company cannot guarantee if or when such milestones will be achieved.

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows used in operating activities
Net loss for the period	€ (28,099)	€ (26,357)
Elimination of other non-cash, non-operating income and expenses
Depreciation and amortization	741	746
Provisions	47	113
Expenses related to share-based payments	1,349	1,360
Cost of net debt	1,010	1,028
Impact of deferred income related to financial liabilities discounting effect	1,999	1,668
Other charges with no impact on cash	0	4
Cash flows from (used in) operations, before tax and changes in working capital	(22,953)	(21,437)
(Increase) / Decrease in trade receivables	(989)	(238)
(Increase) / Decrease in Research tax credit receivable	207	215
(Increase) / Decrease in other receivables	(290)	(671)
Increase (Decrease) in trade and other payables	7,321	2,750
Increase / (Decrease) in other current liabilities	(570)	1,861
Increase in deferred revenues and contract liabilities		0
Changes in operating working capital	5,678	3,918
Net cash flows from (used in) operating activities	(17,275)	(17,518)
Cash flows from (used in) investing activities
Acquisitions of intangible assets	(1)	0
Acquisitions of property, plant and equipment	(323)	(79)
(Increase) / Decrease in non-current financial assets	(3)	133
Net cash flows from (used in) investing activities	(327)	53
Cash flows from (used in) financing activities
Warrants subscription	0	0
Transaction costs	0	0
Increase in loans and conditional advances	150	0
Loans repayments	(1,598)	(2,583)
Payment of lease liabilities	(285)	(442)
Interest paid	(301)	(359)
Charges of lease debt interest	(103)	(122)
Net cash flows from (used in) financing activities	(2,138)	(3,506)
Effect of exchange rates changes on cash	(18)	71
Net increase (decrease) in cash and cash equivalents	(19,759)	(20,900)
Net cash and cash equivalents at beginning of period	41,388	83,921
Net cash and cash equivalents at end of period	€ 21,629	€ 63,021

Financial instruments included in the statement of financial position and impact on income (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure of detailed information about financial instruments [abstract]

Schedule of Financial Assets

Detail of financial instruments included in the statements of financial position and impact on income


	As of June 30, 2023
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	294	—	294	294
Trade receivables	1,090	—	1,090	1,090
Cash and cash equivalents	21,629	—	21,629	21,629
Total assets	23,013	—	23,013	23,013
Financial liabilities
Non-current financial liabilities	46,798	—	46,798	49,427
Current financial liabilities	7,203	—	7,203	7,317
Trade payables and other payables	16,712	—	16,712	16,712
Total liabilities	70,713	—	70,713	73,456

(1)The fair value of current and non-current financial liabilities including loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost, was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value.

Schedule of Financial Liabilities

Details of financial liabilities


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Lease liabilities – Short term	1,146	962
Repayable BPI loan advances – Short term	400	500
PGE*	2,622	2,632
EIB loan – Short term	5,804	467
Total current financial liabilities	9,972	4,560
Lease liabilities – Long term	4,107	4,568
Repayable BPI loan advances – Long term	2,152	2,258
PGE*	5,251	6,495
EIB loan – Long term	32,518	35,287
Total non-current financial liabilities	44,029	48,608
Total financial liabilities	54,001	53,169

(*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

Detail of financial instruments included in the statements of financial position and impact on income


	As of June 30, 2023
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	294	—	294	294
Trade receivables	1,090	—	1,090	1,090
Cash and cash equivalents	21,629	—	21,629	21,629
Total assets	23,013	—	23,013	23,013
Financial liabilities
Non-current financial liabilities	46,798	—	46,798	49,427
Current financial liabilities	7,203	—	7,203	7,317
Trade payables and other payables	16,712	—	16,712	16,712
Total liabilities	70,713	—	70,713	73,456

Financial liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure of financial liabilities [abstract]

Summary of Changes in Financial Liabilities

Details of financial liabilities


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Lease liabilities – Short term	1,146	962
Repayable BPI loan advances – Short term	400	500
PGE*	2,622	2,632
EIB loan – Short term	5,804	467
Total current financial liabilities	9,972	4,560
Lease liabilities – Long term	4,107	4,568
Repayable BPI loan advances – Long term	2,152	2,258
PGE*	5,251	6,495
EIB loan – Long term	32,518	35,287
Total non-current financial liabilities	44,029	48,608
Total financial liabilities	54,001	53,169

(*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans

Detail of financial instruments included in the statements of financial position and impact on income


	As of June 30, 2023
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	294	—	294	294
Trade receivables	1,090	—	1,090	1,090
Cash and cash equivalents	21,629	—	21,629	21,629
Total assets	23,013	—	23,013	23,013
Financial liabilities
Non-current financial liabilities	46,798	—	46,798	49,427
Current financial liabilities	7,203	—	7,203	7,317
Trade payables and other payables	16,712	—	16,712	16,712
Total liabilities	70,713	—	70,713	73,456

Summary of Conditional Advances and Interest-Free Loans from Government and Public Authorities and Bank Loans

Conditional advances, interest-free loans from government and public authorities


(in thousands of euros)	Bpifrance advance	Interest-free Bpifrance loan	Curadigm Bpifrance advance	EIB loan	Total
As of December 31, 2022	2,316	125	317	35,754	38,512
Principal received	—	—	150	—	150
Impact of discounting, accretion and catch-up impact	8	—	(32)	(809)	(833)
Accumulated fixed and variable interest expense accrual	17	—	—	3,611	3,628

Repayment	(225)	(125)	—	(233)	(583)
As of June 30, 2023	2,116	—	435	38,322	40,874

Bank loans


(in thousands of euros)	HSBC “PGE”	Bpifrance “PGE”	Total
As of December 31, 2022	4,409	4,717	9,126
Impact of discounting and accretion	—	(3)	(3)
Accumulated fixed interest accrual	17	49	66
Repayment	(640)	(676)	(1,316)
As of June 30, 2023	3,786	4,087	7,873

Summary of Changes in Lease Liabilities

The table below shows the detail of changes in lease liabilities recognized in the statement of consolidated financial position over the six-month period ended June 30, 2023:


(in thousands of euros)			Lease liabilities
As of December 31, 2022			5,530
New lease contracts			8
Impact of discounting of the new lease contracts			—
Fixed interest expense			—
Accumulated variable interest expense accrual			103
Repayment of lease			(389)

As of June 30, 2023			5,253

Summary of Maturity Analysis for Advances Loans and Lease Liabilities

The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interests are as follows:


	As of June 30, 2023
(in thousands of euros)	Less than 1 year	Between 1 and 3 years	Between 3 and 5 years	More than 5 years	Total
Bpifrance	325	1,292	595	—	2,212
Interest-free Bpifrance loan	—	—	—	—	—
Curadigm interest-free Bpifrance advance	75	200	225	—	500
HSBC “PGE” (1)	1,291	2,545	—	—	3,836
Bpifrance “PGE” (1)	1,331	2,577	314	—	4,222
EIB fixed rate loan	6,154	9,050	22,024	22,325	59,553
Lease liabilities	1,146	2,291	1,526	777	5,740
Total	10,322	17,955	24,685	23,102	76,064


	As of December 31, 2022
(in thousands of euros)	Less than 1 year	Between 1 and 3 years	Between 3 and 5 years	More than 5 years	Total
Bpifrance	300	1,300	837	—	2,437
Interest-free Bpifrance loan	125	—	—	—	125
Curadigm interest-free Bpifrance advance	75	200	75	—	350
HSBC “PGE” (1)	1,287	2,557	631	—	4,475
Bpifrance “PGE” (1)	1,345	2,605	948	—	4,898
EIB fixed rate loan	467	7,630	30,184	19,869	58,150
Lease liabilities	962	2,292	1,904	971	6,129
Total	4,560	16,584	34,579	20,840	76,563

Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables	€ 1,090	€ 101

Share Capital - Disclosure of Details of Share Capital Transactions (Details) - EUR (€) € in Thousands				6 Months Ended
	Jun. 27, 2023	Apr. 24, 2023	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2022
Disclosure of classes of share capital
Equity at beginning of period				€ (27,045)	€ 26,790
Capital increase				0	0
Subscription of warrants				0	0
Equity at end of period				(53,783)	1,792
Share Capital
Disclosure of classes of share capital
Equity at beginning of period				1,046	1,045
Capital increase				11	2
Equity at end of period				€ 1,057	€ 1,046
Number of shares outstanding at beginning of period (in shares)				34,875,872	34,825,872
Free shares vested/capital increase (in shares)				354,510	50,000
Number of shares outstanding at end of period (in shares)				35,230,382	34,875,872
Premiums related to share capital
Disclosure of classes of share capital
Equity at beginning of period				€ 255,760	€ 255,767
Capital increase					0
Prior period adjustment			€ 0
Subscription of warrants				(26)	(7)
Equity at end of period				€ 255,734	€ 255,760
AGA 2021 \| Share Capital
Disclosure of classes of share capital
Capital increase		€ 11
Free shares vested/capital increase (in shares)		354,510
AGA 2023 \| Premiums related to share capital
Disclosure of classes of share capital
Subscription of warrants	€ (26)

Commitments (Details) - EUR (€) € in Thousands	6 Months Ended
Commitments (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of contingent liabilities
Guarantee of EIB loan by subsidiaries, minimum threshold	20.00%
Cash and cash equivalents	€ 21,629	€ 41,388	€ 63,021	€ 83,921
EIB loan
Disclosure of contingent liabilities
Cash and cash equivalents	25,300
Minimum cash balance	10,300
Minimum \| EIB loan
Disclosure of contingent liabilities
Estimated financial effect of contingent liabilities	€ 35,000

Operating expenses - Disclosure of Research and Development Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Analysis of income and expense [abstract]
Purchases, sub-contracting and other expenses	€ (11,982)	€ (10,543)
Payroll costs (including share-based payments)	(5,239)	(5,395)
Depreciation, amortization, and provision expenses	(583)	(670)
Total research and development expenses	€ (17,805)	€ (16,608)

Provisions (Tables)

6 Months Ended

Jun. 30, 2023

Provisions [abstract]

Disclosure of Changes in Provisions

Details of provisions


(in thousands of euros)	As of December 31, 2022	Increases	Decreases(1)	Currency translation adjustments	As of June 30, 2023
Lump-sum retirement benefits	270	38		—	307
Non-current provisions	270	38	—	—	307
Provisions for disputes	177	10	—	(1)	186
Provisions for charges	150	4		—	154
Current provisions	327	14	—	(1)	340
Total provisions	596	52	—	(1)	647

(1)See Note 16.4 Depreciation, amortization and provision expenses for the nature of these decreases

Disclosure of Commitments for Retirement Benefits

Commitments for retirement benefits


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Provision as of beginning of period	270	318
Cost of services	33	75
Discounting costs	5	3
Expense for the period	38	78
Actuarial gains or losses recognized in other comprehensive income	—	(126)
Provision as of the end of period	307	270

Disclosure of Assumptions Used to Measure Retirement Benefits

The assumptions used to measure lump-sum retirement benefits are as follows:


Measurement date	June 30, 2023	December 31, 2022
Retirement assumptions	Executive: Age 66 Non-Executive: Age 64	Executive: Age 66 Non-Executive: Age 64
Social security contribution rate	44 %	44 %
Discount rate	3.69 %	3.69 %
Mortality tables	Regulatory table INSEE 2016 - 2018	Regulatory table INSEE 2016 -2018
Salary increase rate (including inflation)	Executive: 3% Non-Executive: 2.5%	Executive: 3% Non-Executive: 2.5%
Staff turnover	Constant average rate of 5.86%	Constant average rate of 5.86%
Duration	20 years	20 years

Operating expenses (Tables)

6 Months Ended

Jun. 30, 2023

Analysis of income and expense [abstract]

Disclosure of Research and Development Expenses

RESEARCH AND DEVELOPMENT EXPENSES


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Purchases, sub-contracting and other expenses	(11,982)	(10,543)
Payroll costs (including share-based payments)	(5,239)	(5,395)
Depreciation, amortization and provision expenses(1)	(583)	(670)
Total research and development expenses	(17,805)	(16,608)

(1)see Note 16.4 Depreciation, amortization and provision expenses

Disclosure of Selling, General and Administrative Expenses

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Purchases, fees and other expenses	(5,398)	(4,251)
Payroll costs (including share-based payments)	(5,295)	(5,244)
Depreciation, amortization and provision expenses (1)	(172)	(140)
Total SG&A expenses	(10,864)	(9,635)

(1)see Note 16.4 Depreciation, amortization and provision expenses

Disclosure of Payroll Costs

PAYROLL COSTS


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Wages and salaries	(6,814)	(6,711)
Payroll taxes	(2,338)	(2,531)
Share-based payments	(1,349)	(1,360)
Retirement benefit obligations	(33)	(38)
Total payroll costs	(10,534)	(10,640)
Average headcount	98	99
End-of-period headcount	101	103

Disclosure of Depreciation, Amortization and Provision Expenses

Depreciation, amortization and provision expenses by function are detailed as follows:


	For the six month period ended June 30, 2023
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	—	—	—
Amortization expense of tangible assets	(579)	(162)	(740)
Litigations	—	—	—
Provision for charges	(4)	(10)	(14)
Reversal of provision for charges	—	—	—
Total depreciation, amortization and provision expenses	(583)	(172)	(754)


	For the six month period ended June 30, 2022
(in thousands of euros)	R&D	SG&A	Total
Amortization expense of intangible assets	(14)	—	(14)
Amortization expense of tangible assets	(579)	(153)	(732)
Litigations	3	1	5
Provision for charges	(80)	—	(80)
Reversal of provision for disputes	—	12	12
Total depreciation, amortization and provision expenses	(670)	(140)	(809)

Disclosure Of Other Operating Income (Expenses)

OTHER OPERATING INCOME AND EXPENSES


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Contract termination indemnities (PharmaEngine)	—	(963)




Contract termination indemnities	(46)	—
Other non recurring income	52	—
Total other operating income and expenses	6	(963)

Related parties

6 Months Ended

Jun. 30, 2023

Related parties

Key management personnel compensation

The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:


	For the six-month period ended June 30,
(in thousands of euros)	2023	2022
Salaries, wages and benefits	704	486
Share-based payments	1,001	1,131
Supervisory Board’s fees	78	95
Total compensation to related parties	1,783	1,712

The methods used to measure share-based payments are presented in Note 17 Share-based payments of the Company’s financial statements as of and for the year ended December 31, 2022.

Revenues and other income - Additional Information (Details) - EUR (€) € in Thousands	1 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers
Research tax credit utilisation period		3 years
Research tax credit		€ 1,604	€ 1,053	€ 1,053
Subsidies		202	111
Bpifrance “PGE”
Disclosure of disaggregation of revenue from contracts with customers
Subsidies		€ 150	92
LianBio, NBTXR3
Disclosure of disaggregation of revenue from contracts with customers
Minimum threshold to provide additional know-how to third party under collaboration agreement		80.00%
Collaboration agreement, upfront payment received	€ 20,000
Collaboration agreement, collected		€ 320
Recharge invoice billed		1,300
Supply Services		217	€ 160
Receivables related to collaboration agreements		1,300
LianBio, NBTXR3 \| Maximum
Disclosure of disaggregation of revenue from contracts with customers
Collaboration agreement, potential development and commercial milestones payments	€ 205,000
LianBio, NBTXR3 And Cetuximab
Disclosure of disaggregation of revenue from contracts with customers
Collaboration agreement, collected		€ 217

Trade receivables and other current assets - Additional Information (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Trade Receivables and Other Current Assets
Prepaid expenses	€ 2,236	€ 2,981
Current advances to suppliers	1,400	€ 2,600
Third party services
Disclosure of Trade Receivables and Other Current Assets
Prepaid expenses	700
Clinical products
Disclosure of Trade Receivables and Other Current Assets
Prepaid expenses	200
MD Anderson Cancer Center, NBTXR3
Disclosure of Trade Receivables and Other Current Assets
Prepaid expenses	1,400		€ 1,500
ICON Plc
Disclosure of Trade Receivables and Other Current Assets
Current advances to suppliers	800
Imaging EndPoints
Disclosure of Trade Receivables and Other Current Assets
Current advances to suppliers	€ 500

Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Deferred income	€ 137	€ 55
Contract liabilities	16,518	16,518
Deferred income and contract liabilities	€ 16,655	€ 16,573

Trade receivables and other current assets

6 Months Ended

Jun. 30, 2023

Subclassifications of assets, liabilities and equities [abstract]

Trade receivables and other current assets

8.1 TRADE RECEIVABLES


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Trade receivables	1,090	101
Trade receivables	1,090	101

As of June 30, 2023, trade receivables balance only relates to the recharge invoice to LianBio of cumulated development costs since 2021, as per the GTCA signed with the Company in June 2023 (see Note 4.1 LianBio for more details).

8.2 OTHER CURRENT ASSETS

Other current assets break down as follows:


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Research tax credit receivable	5,488	4,091
VAT receivable	1,437	1,055
Prepaid expenses	2,236	2,981
Other receivables	1,747	2,741
Other current assets	10,909	10,868

As of June 30, 2023, €2.2 million prepaid expenses mainly relate to research agreements with MD Anderson for €1.4 million as compared to €1.5 million as of December 31, 2022 (see Note 4.4 Collaboration agreement with MD Anderson), €0.7 million related to invoices received for third party services beyond the closing period, mainly related to IT, insurance and other invoices related to annual administrative contracts, and €0.2 million related to purchases of clinical product not yet consumed as of closing date.

Other receivables are mainly comprised of advance payments to suppliers amounting of €1.4 million as of June 30, 2023, as compared to €2.6 million as of December 31, 2022. This amount is mainly related to advance payments to ICON for €0.8 million, and Imaging EndPoints for €0.5 million in connection with the execution of the 312 study. The significant decrease observed during the six months ended June 30 2023 is mainly due to ICON, for which prepayments were offset by recorded services invoices.

Research tax credit

The Company is eligible for the Research Tax Credit - CIR (Crédit d’Impôt Recherche) issued by the French tax authorities.

The change in research tax credit receivables breaks down as follows:


(in thousands of euros)
Receivable as of December 31, 2022			4,091
2023 research tax credit – Nanobiotix S.A. (1)			1,504
2023 research tax credit – Curadigm S.A.S (1)			100
Receipt of 2022 research tax credit - Curadigm S.A.S			(207)
Receivable as of June 30, 2023			5,488

(1) See Note 15 Revenue and other income.

Share-based payments (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Disclosure of Changes in Founders' Warrants, Warrants, and Free Shares

The number of stock options, founders’ warrants, warrants and free shares outstanding on June 30, 2023 and their main characteristics, are detailed below:

Founders’ warrants outstanding as at June 30, 2023


	BSPCE 08-2013	BSPCE 09-2014	BSPCE 2015-1	BSPCE 2015-3
Date of the shareholders' meeting	28-Jun-13	18-Jun-14	18-Jun-14	18-Jun-14
Date of grant by the Executive Board	28-Aug-13	16-Sep-14	10-Feb-15	10-Jun-15
Total number of BSPCEs authorized	500,000	450,000	450,000	450,000
Total number of BSPCEs granted	50,000	97,200	71,650	53,050
Total number of shares to which the BSPCE were likely to give right on the date of their grant	50,000	97,200	71,650	53,050
the number of which that may be subscribed by corporate officers:	—	21,000	24,000	—
the number that can be subscribed by Laurent LEVY	—	21,000	24,000	—
Number of beneficiaries who are not corporate officers	1	30	13	42
Starting date for the exercise of the BSPCE	08/28/13	09/16/15	02/10/2016	06/10/2016
BSPCE expiry date	08/28/23	09/16/24	02/10/2025	06/10/2025
BSPCE exercise price	€5.92	€18.68	€18.57	€20.28
Number of shares subscribed as of June 30, 2023	—	—	—	—
Total number of BSPCEs lapsed or cancelled as of June 30, 2023	—	11,250	3,200	23,050
Total number of BSPCEs outstanding as of June 30, 2023	50,000	85,950	68,450	30,000
Total number of shares available for subscription as of June 30, 2023	50,000	85,950	68,450	30,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met)	50,000	85,950	68,450	30,000


	BSPCE 2016 Ordinary	BSPCE 2016 Performance	BSPCE 2017 Ordinary	BSPCE “2017”
Date of the shareholders' meeting	25-Jun-15	25-Jun-15	23-Jun-16	23-Jun-16
Date of grant by the Executive Board	2-Feb-16	2-Feb-16	7-Jan-17	7-Jan-17
Total number of BSPCEs authorized	450,000	450,000	450,000	450,000
Total number of BSPCEs granted	126,400	129,250	117,650	80,000
Total number of shares to which the BSPCE were likely to give right on the date of their grant	126,400	129,250	117,650	80,000
the number of which that may be subscribed by corporate officers:	23,500	23,500	26,400	32,000
the number of which that may be subscribed by Laurent LEVY	23,500	23,500	26,400	32,000
Number of beneficiaries who are not corporate officers	43	50	42	3
Starting date for the exercise of the BSPCE	02/02/2017	02/02/2016	01/07/2017	01/07/2017
BSPCE expiry date	02/02/2026	02/02/2026	01/07/2027	01/07/2027
BSPCE exercise price	€14.46	€14.46	€15.93	€15.93
Number of shares subscribed as of June 30, 2023	333	—	—	—
Total number of BSPCEs lapsed or cancelled as of June 30, 2023	25,850	29,682	18,850	—
Total number of BSPCEs outstanding as of June 30, 2023	100,217	99,568	98,800	80,000
Total number of shares available for subscription as of June 30, 2023	100,217	99,568	98,800	80,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of said BSPCEs are met)	100,217	99,568	98,800	80,000

Warrants outstanding as at June 30, 2023


	BSA 2013	BSA 2014	BSA 2015-1	BSA 2015-2 (a)
Date of the shareholders’ meeting	4-May-12	18-Jun-14	18-Jun-14	18-Jun-14
Date of grant by the Executive Board	10-Apr-13	16-Sep-14	10-Feb-15	25-Jun-15
Maximum number of BSAs authorized	200,000	100,000	100,000	100,000
Total number of BSAs granted	10,000	14,000	26,000	64,000
Number of shares to which the BSA were likely to give right on the date of their grant	10,000	14,000	26,000	64,000
including the total number of shares that may subscribed by the corporate officers of the Company	—	8,000	15,000	—
Relevant officers:
Anne-Marie GRAFFIN	—	—	5,000	—
Enno SPILLNER	—	—	3,000	—
Alain HERRERA	—	4,000	5,000	—
Gary PHILLIPS	—	—	—	—
Christophe DOUAT (observer)	—	4,000	2,000	—
Number of beneficiaries who are not corporate officers	1	1	2	1
Starting date for the exercise of the BSA	04/30/2014	09/16/2014	02/10/2015	06/25/2015
BSA expiry date (6)	04/10/2023	09/16/2024	02/10/2025	06/25/2025
BSA issue price	€2.50	€4.87	€4.87	€5.00
Exercise price per BSA	€6.37	€17.67	€17.67	€19.54
Number of shares subscribed as of June 30, 2023	—	—	—	—
Total number of forfeited or cancelled BSAs as of June 30, 2023	10,000	4,000	5,000	—
Total number of BSAs outstanding as of June 30, 2023	—	10,000	21,000	64,000
Total number of shares available for subscription as of June 30, 2023 (considering the conditions of exercise of the BSAs)	—	—	—	—
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)	—	10,000	21,000	64,000


	BSA 2018	BSA 2018-1	BSA 2018-2	BSA 2019-1	BSA 2020	BSA 2021 (a)	BSA 2021 (b)
Date of the shareholders’ meeting	14-Jun-17	14-Jun-17	23-May-18	23-May-18	11-Apr-19	30-Nov-20	30-Nov-20
Date of grant by the Executive Board	6-Mar-18	6-Mar-18	27-Jul-18	29-Mar-19	17-Mar-20	20-Apr-21	20-Apr-21
Maximum number of BSAs authorized	116,000	116,000	140,000	140,000	500,000	650,000	650,000
Total number of BSAs granted	18,000	10,000	5,820	18,000	18,000	48,103	30,000
Number of shares to which the BSA were likely to give right on the date of their grant	18,000	10,000	5,820	18,000	18,000	48,103	30,000
including the total number of shares that may subscribed by the corporate officers of the Company	12,700	—	—	12,700	14,024	—	—
Relevant officers:
Anne-Marie GRAFFIN	2,900	—	—	2,900	3,843	—	—
Enno SPILLNER	4,000	—	—	4,000	3,829	—	—
Alain HERRERA	2,900	—	—	2,900	3,195	—	—
Gary PHILLIPS	—	—	—				—
Christophe DOUAT (observer)	2,900	—	—	2,900	3,157	—	—
Number of beneficiaries who are not corporate officers	1	1	1	1	1	1	1
Starting date for the exercise of the BSA	03/06/2018	03/06/2018	07/27/18	03/29/19	03/17/20	04/20/21	04/20/21
BSA expiry date (6)	03/06/2023	03/06/2023	07/27/28	03/29/29	03/17/30	04/20/31	04/20/31
BSA issue price	€1.62	€1.62	€2.36	€1.15	€0.29	€2.95	€0.68
Exercise price per BSA	€13.55	€13.55	€16.10	€11.66	€6.59	€13.47	€13.64
Number of shares subscribed as of June 30, 2023	—	—	—	—	—	—	—
Total number of forfeited or cancelled BSAs as of June 30, 2023	18,000	10,000	—	—	—	33,672	30,000
Total number of BSAs outstanding as of June 30, 2023	—	—	5,820	18,000	18,000	14,431	—
Total number of shares available for subscription as of June 30, 2023 (considering the conditions of exercise of the BSAs)	—	—	—	—	—	—	—
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)	—	—	5,820	18,000	18,000	14,431	—

Free shares outstanding as at June 30, 2023


	AGA 2020	AGA 2021	AGA 2022	AGA 2023 -= P1	AGA 2023 - P2
Date of the shareholders’ meeting	11-Apr-19	30-Nov-20	20-Apr-21	27-Jun-23	27-Jun-23
Date of grant by the Executive Board	11-Mar-20	20-Apr-21	22-Jun-22	27-Jun-23	27-Jun-23
Total number of AGAs authorized	650,000	850,000	850,000	1,200,000	1,200,000
Total number of AGAs granted	50,000	362,515	300,039	427,110	439,210
Total number of shares to which the AGAs were likely to give right on the date of their grant	50,000	362,515	300,039	427,110	439,210
including the number that can be subscribed by corporate officers:	50,000	270,000	245,000	298,860	293,470
the number that can be subscribed by Laurent LEVY	—	180,000	150,000	200,116	200,116
the number that can be subscribed by Anne-Juliette HERMANT	50,000	90,000	35,000	33,354	33,354
the number that can be subscribed by Bart VAN RHIJN	—	—	60,000	65,390	65,390
Number of beneficiaries who are not corporate officers	—	79	79	88	87
Date of acquisition (end of the acquisition period)	03/11/22	04/20/23	06/22/24	06/27/25	06/27/25
Number of shares subscribed as of June 30, 2023	50,000	354,510	—	—	—
Total number of AGAs lapsed or cancelled as of June 30, 2023	—	8,005	1,009	—	—
Total number of AGAs outstanding as of June 30, 2023	—	—	299,030	427,110	439,210
Total number of shares that may be subscribed	—	—	299,030	427,110	439,210
Duration of the holding period	1 year	1 year	1 year	1 year	1 year


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of June 30, 2023	612,985	151,251	2,044,757	1,165,350	3,974,343

Disclosure of Changes in Share Options

Stock options outstanding as at June 30, 2023


	OSA 2016-1 Performance	OSA 2016-2	OSA 2017 Ordinary	OSA 2018	OSA 2019-1	OSA 2019 LLY
Date of the shareholders’ meeting	25-Jun-15	23-Jun-16	23-Jun-16	14-Jun-17	23-May-18	11-Apr-19
Date of grant by the Executive Board	02-Feb-16	03-Nov-16	07-Jan-17	6-Mar-18	29-Mar-19	24-Oct-19
Total number of OSAs authorized	450,000	450,000	450,000	526,800	648,000	500,000
Total number of OSAs granted	6,400	4,000	3,500	62,000	37,500	500,000
Total number of shares to which the OSAs were likely to give right on the date of their grant	6,400	4,000	3,500	62,000	37,500	500,000
including the number that may be subscribed or purchased by corporate officers:	—	—	—	—	—	500,000
the number that can be subscribed by Laurent LEVY	—	—	—	—	—	500,000
the number that can be subscribed by Anne-Juliette HERMANT	—	—	—	—	—	—
the number that can be subscribed by Bart VAN RHIJN	—	—	—	—	—	—
Number of beneficiaries who are not corporate officers	2	1	2	5	12	—
Starting date for the exercise of the OSA	02/02/2017	11/03/2017	01/08/2018	03/07/2019	03/30/2021	10/24/2019
OSA expiry date	02/02/2026	11/03/2026	01/07/2027	03/06/2028	03/29/2029	10/24/2029
Exercise price per OSA	€13.05	€14.26	€14.97	€12.87	€11.08	€6.41
Number of shares subscribed as of June 30, 2023	—	—	—	—	—	—
Total number of lapsed or cancelled OSAs as of June 30, 2023	6,000	—	3,000	10,000	11,750	—
Total number of OSAs outstanding as of June 30, 2023	400	4,000	500	52,000	25,750	500,000
Maximum number of shares available for subscription as of June 30, 2023 (given the vesting conditions of the OSAs)	120	4,000	500	52,000	25,750	—
Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)	400	4,000	500	52,000	25,750	500,000


	OSA 2020	OSA 2021-04 Ordinary	OSA 2021-04 Performance	OSA 2021-06 Performance	OSA 2021-06 Ordinary
Date of the shareholders’ meeting	11-Apr-19	30-Nov-20	30-Nov-20	30-Nov-20	28-Apr-21
Date of grant by the Executive Board	11-Mar-20	20-Apr-21	20-Apr-21	21-Jun-21	21-Jun-21
Total number of OSAs authorized	500,000	850,000	1,000,000	1,000,000	850,000
Total number of OSAs granted	407,972	143,200	428,000	60,000	60,000
Total number of shares to which the OSAs were likely to give right on the date of their grant	407,972	143,200	428,000	60,000	60,000
including the number that may be subscribed or purchased by corporate officers:	180,000	—	240,000	60,000	60,000
the number that can be subscribed by Laurent LEVY	120,000	—	180,000	—	—
the number that can be subscribed by Anne-Juliette HERMANT	60,000	—	60,000	—	—
the number that can be subscribed by Bart VAN RHIJN	—	—	—	60,000	60,000
Number of beneficiaries who are not corporate officers	104	13	14	—	—
Starting date for the exercise of the OSA	03/11/2021	04/20/22	04/20/22	06/21/22	06/21/22
OSA expiry date	03/11/2030	04/20/31	04/20/31	06/21/31	06/21/31
Exercise price per OSA	€6.25	€13.74	€13.74	€12.99	€12.99
Number of shares subscribed as of June 30, 2023	—	—	—	—	—
Total number of lapsed or cancelled OSAs as of June 30, 2023	28,065	103,000	60,000	—	—
Total number of OSAs outstanding as of June 30, 2023	379,907	40,200	368,000	60,000	60,000
Maximum number of shares available for subscription as of June 30, 2023 (given the vesting conditions of the OSAs)	379,907	30,128	—	—	40,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)	379,907	40,200	368,000	60,000	60,000


	OSA 2022-001 Performance	OSA 2022-06 Performance	OSA 2022-06 Ordinaire
Date of the shareholders’ meeting	30-Nov-20	30-Nov-20	28-Apr-21
Date of grant by the Executive Board	22-Jun-22	22-Jun-22	22-Jun-22
Total number of OSAs authorized	1,000,000	1,000,000	850,000
Total number of OSAs granted	20,000	170,400	410,500
Total number of shares to which the OSAs were likely to give right on the date of their grant	20,000	170,400	410,500
including the number that may be subscribed or purchased by corporate officers:	—	—	245,000
the number that can be subscribed by Laurent LEVY	—	—	150,000
the number that can be subscribed by Anne-Juliette HERMANT	—	—	35,000
the number that can be subscribed by Bart VAN RHIJN	—	—	60,000
Number of beneficiaries who are not corporate officers	1	83	49
Starting date for the exercise of the OSA	04/14/23	06/22/23	06/22/23
OSA expiry date	04/14/32	06/22/32	06/22/32
Exercise price per OSA	€6.17	€4.16	€4.16
Number of shares subscribed as of June 30, 2023	—	—	—
Total number of lapsed or cancelled OSAs as of June 30, 2023	20,000	14,400	12,500
Total number of OSAs outstanding as of June 30, 2023	—	156,000	398,000
Maximum number of shares available for subscription as of June 30, 2023 (given the vesting conditions of the OSAs)	—	—	139,333
Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)	—	156,000	398,000


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of June 30, 2023	612,985	151,251	2,044,757	1,165,350	3,974,343

Disclosure of Number of Founders' Warrants, Warrants and Free Shares Outstanding and Their Characteristics

As of June 30, 2023, the assumptions related to the probability that the performance conditions of the BSPCE, BSA and OSA will be met have been updated:


BSPCE	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
BSPCE 2012-2	6.65	6.63	44.3% - 47.6%		5 / 7.3	0.84% - 1.22%		0.00	%	288	—	—
BSPCE 08-2013	6.30	5.92	256	%	7	0.90	%	0.00	%	152	—	—
BSPCE 09-2014	18.68	18.68	58	%	5.5/6/6.5	0.64	%	0.00	%	932	—	—
BSPCE 2015-2	18.57	18.57	58% - 62% - 61%		5.5/6/6.5	0.39	%	0.00	%	50	—	—
BSPCE 2015-3	20.28	20.28	61% - 62% - 61%		5.5/6/6.5	0.56	%	0.00	%	483	—	—
BSPCE 2016 Ordinary	14.46	14.46	59% - 62% - 60%		5.5/6/6.5	0.32	%	0.00	%	1,080	2	—
BSPCE 2016 Performance	14.46	14.46	59	%	5	0.19	%	0.00	%	1,212	18	27
BSPCE 2017 Ordinary	15.93	15.93	58% - 61% - 59%		5.5/6/6.5	0.23	%	0.00	%	1,000	1	—
BSPCE 2017	15.93	15.93	59	%	5	0.11	%	0.00	%	627	—	—
Total BSPCE	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	25	27


BSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
BSA 04-2012	6.00	6.00	49	%	10	0.96	%	0.00	%	183	—	—
BSA 2013	6.30	6.30	156	%	6	0.90	%	0.00	%	1	—	—
BSA 2014	18.68	17.67	57	%	5	0.41	%	0.00	%	—	—	—
BSA 2015-1	17.67	17.67	58	%	5	0.26% - 0.27%		0.00	%	63	—	—
BSA 2015-2 (a)	17.67	17.67	58%-58%-57%-58%		5/5.1/ 5.3/5.4	0.39	%	0.00	%	16	—	—
BSA 2017	15.76	15.76	33	%	2.4	—	%	0.00	%	—	—	—
BSA 2018	13.55	13.55	38	%	4.8	0.7% - 0.1%		0.00	%	2	—	—
BSA 2018-1	13.55	13.55	38	%	4.8	0.7% - 0.1%		0.00	%	—	—	—
BSA 2018-2	16.10	16.10	38	%	4.8	0.7% - 0.1%		0.00	%	1	—	—
BSA 2019-1	11.66	11.66	37	%	9.8/9.9	0.16% - 0.50%		0.00	%	24	—	—
BSA 2020	13.03	6.59	38	%	10	/ -0.07%		0.00	%	19	—	—
BSA 2021 (a)	13.47	13.47	39.10	%	10	0.27	%	0.00	%	44	—	—
BSA 2021 (b)	n.a.	13.64	n.a.		10	n.a.		0.00	%	—	—	—
Total BSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	—	—


AGA	Share price (in euros)	Exercise price (in euros)	Volatility	Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
AGA 2018-1	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	4,951	—	—
AGA 2018-2	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	75	—	—
AGA 2019-1	10.90	0.00	n.a.	n.a.	0.19% / 0.141%		0.00	%	4,776	—	—
AGA 2020	5.90	0.00	n.a.	n.a.	-0.74%/ -0.69%		0.00	%	287	—	28
AGA 2021	13.60	0.00	n.a.	n.a.	0.63% / 0.59%		0.00	%	4,869	694	1,146
AGA 2022	3.68	0	n.a.	n.a.	0.95% /1.46%		0.00	%	1,092	271	12
AGA 2023 - P1	4.87	0.00	n.a.	n.a.	3% / 3.2%		0.00	%	2,071	9	n.a.
AGA 2023 - P2	4.87	0	n.a.	n.a.	3% /3.2%		0.00	%	2,130	9	n.a.
Total AGA	n.a.	n.a.	n.a.	n.a.	n.a.		n.a.		n.a.	982	1,186


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended June 30, 2023	25	—	343	982	1,349


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended June 30, 2022	27	—	147	1,186	1,360

Disclosure of Number of Shares Options Outstanding and Their Characteristics


OSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
OSA 2016 Performance	13.05	13.05	59	%	5	0.19	%	0.00	%	69	—	—
OSA 2016-2	14.26	14.26	58% - 62% - 59%		5.5 / 6 /6.5	0.04	%	0.00	%	27	—	—
OSA 2017 Ordinary	15.93	14.97	58% - 61% - 59%		5.5 / 6 /6.5	0.23	%	0.00	%	31	—	—
OSA 2018	12.87	12.87	35	%	5.5 / 6 /6.5	—	%	0.00	%	252	—	—
OSA 2019-1	11.08	11.08	38.1% / 37.4%		6 /6.5	0.103% / 0.149%		0.00	%	140	—	(1)
OSA 2019-2	6.41	6.41	37	%	10	0.40	%	0.00	%	252	—	—
OSA 2020	6.25	6.25	38.30	%	10	0.31	%	0.00	%	939	13	28
OSA 2021-04 O	13.60	13.74	38.9% - 37.8% - 38.3%		5.5 / 6 /6.5	0.38% / 0.33% / 0.28%		0.00	%	684	25	(49)
OSA 2021-04 P	13.60	13.74	39.10	%	10	0.03	%	0.00	%	1,816	86	76
OSA 2021-06 O	12.20	12.99	39.2% - 37.9% - 38.1%		5.5 / 6 /6.5	0.35% / 0.30% / 0.26%		0.00	%	246	33	72
OSA 2021-06 P	12.20	12.99	39.10	%	10	0.13	%	0.00	%	212	12	12
OSA 2022-001 P	6.06	6.17	40.00	%	10	1.29	%	0.00	%	1	—	—
OSA 2022-06 P	3.68	4.16	40.08	%	10	2.28	%	0.00	%	71	4	—
OSA 2022-06 O	3.68	4.16	42.06% - 41.21% - 40.65%		5.5 / 6 /6.5	1.83% / 1.87% / 1.90%		0.00	%	580	170	8
Total OSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	343	147


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended June 30, 2023	25	—	343	982	1,349


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended June 30, 2022	27	—	147	1,186	1,360

Financial instruments included in the statement of financial position and impact on income (Details) € in Thousands	Jun. 30, 2023 EUR (€)
Disclosure of detailed information about financial instruments
Total financial assets	€ 23,013
Total financial assets, at fair value	23,013
Total financial liabilities	70,713
Total financial liabilities, at fair value	73,456
Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments
Total financial liabilities	70,713
Non-current financial liabilities
Disclosure of detailed information about financial instruments
Total financial liabilities	46,798
Total financial liabilities, at fair value	49,427
Non-current financial liabilities \| Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments
Total financial liabilities	46,798
Current financial liabilities
Disclosure of detailed information about financial instruments
Total financial liabilities	7,203
Total financial liabilities, at fair value	7,317
Current financial liabilities \| Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments
Total financial liabilities	7,203
Trade payables and other payables
Disclosure of detailed information about financial instruments
Total financial liabilities	16,712
Total financial liabilities, at fair value	16,712
Trade payables and other payables \| Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments
Total financial liabilities	16,712
Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments
Total financial assets	0
Assets and liabilities carried at amortized cost
Disclosure of detailed information about financial instruments
Total financial assets	23,013
Non-current financial assets
Disclosure of detailed information about financial instruments
Total financial assets	294
Total financial assets, at fair value	294
Non-current financial assets \| Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments
Total financial assets	0
Non-current financial assets \| Assets and liabilities carried at amortized cost
Disclosure of detailed information about financial instruments
Total financial assets	294
Trade receivables
Disclosure of detailed information about financial instruments
Total financial assets	1,090
Total financial assets, at fair value	1,090
Trade receivables \| Assets and liabilities carried at amortized cost
Disclosure of detailed information about financial instruments
Total financial assets	1,090
Cash and cash equivalents
Disclosure of detailed information about financial instruments
Total financial assets	21,629
Total financial assets, at fair value	21,629
Cash and cash equivalents \| Assets and liabilities carried at amortized cost
Disclosure of detailed information about financial instruments
Total financial assets	€ 21,629

Share-based payments - Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments (Details)	Jun. 30, 2023 shares
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	3,974,343
BSPCE
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	612,985
BSA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	151,251
OSA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of share options outstanding (in shares)	2,044,757
AGA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	1,165,350

Cash and cash equivalents (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Cash and bank accounts	€ 21,629	€ 38,576
Short-term bank deposits	0	2,813
Cash and cash equivalents	€ 21,629	€ 41,388	€ 63,021	€ 83,921

Financial instruments included in the statement of financial position and impact on income - Additional Information (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Cash and cash equivalents	€ 21,629	€ 41,388	€ 63,021	€ 83,921
EIB loan
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Cash and cash equivalents	25,300
Minimum cash balance	€ 10,300

Related parties (Details) - EUR (€) € in Thousands	6 Months Ended
Related parties (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Jun. 30, 2022
Related party transactions [abstract]
Salaries, wages and benefits	€ 704	€ 486
Share-based payments	1,001	1,131
Supervisory Board’s fees	78	95
Total compensation to related parties	€ 1,783	€ 1,712

Financial instruments included in the statement of financial position and impact on income

6 Months Ended

Jun. 30, 2023

Disclosure of detailed information about financial instruments [abstract]

Financial instruments included in the statement of financial position and impact on income

Detail of financial instruments included in the statements of financial position and impact on income


	As of June 30, 2023
(in thousands of euros)	Book value on the statement of financial position	Financial assets carried at fair value through profit or loss	Assets and liabilities carried at amortized cost	Fair value (1)
Non-current financial assets
Non-current financial assets	294	—	294	294
Trade receivables	1,090	—	1,090	1,090
Cash and cash equivalents	21,629	—	21,629	21,629
Total assets	23,013	—	23,013	23,013
Financial liabilities
Non-current financial liabilities	46,798	—	46,798	49,427
Current financial liabilities	7,203	—	7,203	7,317
Trade payables and other payables	16,712	—	16,712	16,712
Total liabilities	70,713	—	70,713	73,456

Management of financial risks

The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments.

The principal risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.

Liquidity risk

The Company has incurred operating losses since inception in 2005. As of June 30, 2023, the Company has cash and cash equivalent of €21.6 million and the current level of cash and cash equivalent is not sufficient to meet its projected financial obligations beyond the first quarter of 2024. In order to meet its operating cash flow requirements, the Company plans to pursue new business development partnerships, collaborative or strategic alliances, additional financing through public or private offerings of capital or debt securities, and through the implementation of cash preservation activities to reduce or defer discretionary spending. (See Note 2 General information for more details)

There are no assurances that its efforts to meet our operating cash flow requirements will be successful. If the current cash and cash equivalent as well as the Company’s plans to meet operating cash flow requirements are not sufficient to fund necessary expenditures and meet its obligations as they come due, the liquidity of the Company, its financial condition, and its business prospects will be materially affected.

As part of the Amendment Agreement in respect of the EIB, the Company has agreed to maintain a minimum cash and cash equivalents balance equal to the outstanding principal owed to EIB which is €25.3 million as of June 30, 2023. All other covenants included in the 2018 finance contract remain unchanged, other than aforementioned cash covenant which has been lowered to €10.3 million as of June 30, 2023 pursuant to a temporary waiver that was automatically extended until January 31, 2024 upon the Company’s entry into the Janssen Agreement on July 7, 2023.

As of June 30, 2023, Cash and cash equivalents amounts to €21.6 million and no covenant is in breach (see Note 9 Cash and cash equivalents)

Foreign Currency Exchange Risk

The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is derived almost entirely from intragroup transactions between Nanobiotix S.A. and its U.S. subsidiaries, for which the functional currency is the U.S. dollar, as well as trade payable relations with customers and suppliers outside the euro zone.

However, a significant increase in its business activity could lead to a greater exposure to foreign currency exchange risk.

At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. The Company may implement a suitable hedging policy for these risks if needed.

Credit risk

Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments.

The credit risk related to cash and cash equivalents and to current financial instruments is not material given the rating and size of the relevant financial institutions. Customer credit risk is limited, due in part to low trade receivables as of June 30, 2023 and, on the other hand, the high credit rating of the public authority for other receivables.

Interest rate risk

The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.

As of June 30, 2023, loans issued by the Company are exclusively fixed rate loans and thus our exposure to interest rate and market risk is deemed low.

Variable interests on the EIB loan are royalty-based and are not subject to market rate risks

Fair value

As of June 30, 2023, the carrying value of receivables and current liabilities is assumed to approximate their fair value.

Property, plant and equipment (Tables)

6 Months Ended

Jun. 30, 2023

Property, plant and equipment [abstract]

Schedule of Property, Plant and Equipment

The change in property, plant and equipment is as follows:


(in thousands of euros)	As of December 31, 2022	Increases	Decreases	Other movements & transfer.	Currency translation	As of June 30, 2023
Fixtures, fittings and installations	3,318	2	—	—	—	3,321
Right of use – Buildings	8,462	—	—	—	—	8,462
Technical equipment	2,128	75	—	300	—	2,503
Office and IT equipment	1,012	18	(6)	—	(1)	1,023
Transport equipment	36	—	—	—	(1)	35
Right of use – Transport equipment	—	—	—	—	—	—
Tangible assets in progress	344	—	—	(300)	—	44
Prepayments on tangible assets	—	—	—	—	—	—
Gross book value of tangible assets	15,299	96	(6)	—	(1)	15,387
Fixtures, fittings and installations	(1,959)	(158)	—	—	—	(2,117)
Right of use – Buildings	(3,496)	(462)	8	—	—	(3,950)
Technical equipment	(1,774)	(93)	—	—	—	(1,867)
Office and IT equipment	(915)	(27)	6	—	—	(935)
Transport equipment	(36)	—	—	—	1	(35)
Right of use – Transport equipment	—	—	—	—	—	—
Accumulated depreciation of tangible assets(1)	(8,180)	(740)	14	—	1	(8,904)
Net book value of tangible assets	7,120	(644)	8	—	—	6,483

(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

Financial liabilities - Summary of Bank Loans (Details) - Long-term borrowings € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period	€ 9,126
Changes in liabilities arising from financing activities
Impact of discounting, accretion and catch-up impact	(3)
Accumulated fixed interest accrual	66
Repayment	(1,316)
Liabilities arising from financing activities at end of period	7,873
HSBC “PGE”
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period	4,409
Changes in liabilities arising from financing activities
Impact of discounting, accretion and catch-up impact	0
Accumulated fixed interest accrual	17
Repayment	(640)
Liabilities arising from financing activities at end of period	3,786
Bpifrance “PGE”
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period	4,717
Changes in liabilities arising from financing activities
Impact of discounting, accretion and catch-up impact	(3)
Accumulated fixed interest accrual	49
Repayment	(676)
Liabilities arising from financing activities at end of period	€ 4,087

Operating expenses - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€) employee	Jun. 30, 2022 EUR (€) employee
Disclosure Of Operating Expenses
Payment of advisory fees	€ 1,400
Number of employees \| employee	101	103
Expense from share-based payment transactions with employees	€ 1,349	€ 1,360
Pharmaengine
Disclosure Of Operating Expenses
Contract termination indemnities	0	€ 963
R&D
Disclosure Of Operating Expenses
Increase in purchases, sub-contracting and other expenses	1,400
Increase in employee benefit expense	€ 200
Percentage of increase in employee benefit expense	3.00%
Number of employees \| employee	71
SG&A
Disclosure Of Operating Expenses
Increase in employee benefit expense	€ 100
Percentage of increase in employee benefit expense	1.00%
Increase in purchases, fees, and other expenses	€ 1,100
Number of employees \| employee	30

INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS’ EQUITY - EUR (€) € in Thousands	Total	Share capital Ordinary shares	Premiums related to share capital	Accumulated other comprehensive income (loss)	Treasury shares	Retained earnings	Net loss for the period
Equity at beginning of period at Dec. 31, 2021	€ 26,790	€ 1,045	€ 255,767	€ 643	€ (202)	€ (183,459)	€ (47,003)
Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2021		34,825,872
Net loss for the period	(26,357)						(26,357)
Currency translation adjustments	(71)			(71)
Actuarial gains and losses (IAS 19)	106			106
Total comprehensive loss	(26,322)	€ 0	0	35	0	0	(26,357)
Allocation of prior period loss	0					(47,003)	47,003
Free Shares vested/Capital increase	0	€ 2	0			(2)
Free shares vested/capital increase (in shares)		50,000
Subscription of warrants	0		(7)			7
Share based payment	1,360					1,360
Treasury shares	(37)				(37)
Equity at end of period at Jun. 30, 2022	1,792	€ 1,046	255,760	678	(239)	(229,096)	(26,357)
Number of shares outstanding at end of period (in shares) at Jun. 30, 2022		34,875,872
Equity at beginning of period at Dec. 31, 2022	(27,045)	€ 1,046	255,760	700	(228)	(227,283)	(57,041)
Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2022		34,875,872
Net loss for the period	(28,099)						(28,099)
Currency translation adjustments	10			10
Actuarial gains and losses (IAS 19)	0
Total comprehensive loss	(28,088)			10			(28,099)
Allocation of prior period loss	0					(57,041)	57,041
Free Shares vested/Capital increase	0	€ 11				(11)
Free shares vested/capital increase (in shares)		354,510
Subscription of warrants	0		(26)			26
Share based payment	1,349					1,349
Treasury shares	1				0
Equity at end of period at Jun. 30, 2023	€ (53,783)	€ 1,057	€ 255,734	€ 710	€ (228)	€ (282,958)	€ (28,099)
Number of shares outstanding at end of period (in shares) at Jun. 30, 2023		35,230,382

Net financial income (loss) - Summary of Net Financial Income (Loss) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Net Financial Income (Loss) [Abstract]
Income from cash and cash equivalents	€ 450	€ 6
Foreign exchange gains	370	2,459
Other financial income	0	0
Total financial income	820	2,465
Interest cost	(3,714)	(2,602)
Debt restructuring valuation impact	809	0
IFRS 16 related interests	(103)	(122)
Foreign exchange losses	(537)	(216)
Total financial expenses	(3,545)	(2,940)
Financial income (loss)	€ (2,725)	€ (474)

Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)	Jun. 30, 2023 security
Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]
Number of security types (security)	4

Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure of Trade Receivables and Other Current Assets
Research tax credit receivable at beginning of period	€ 4,091
Refund of research tax credit	(207)
Research tax credit receivable at end of period	5,488
Nanobiotix S.A.
Disclosure of Trade Receivables and Other Current Assets
Research tax credit	1,504
Curadigm SAS
Disclosure of Trade Receivables and Other Current Assets
Research tax credit	€ 100

Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Tax liabilities	€ 382	€ 358
Payroll tax and other payroll liabilities	5,517	6,237
Other payables	276	260
Other current liabilities	€ 6,175	€ 6,855

Financial liabilities - Summary of Maturity Analysis for Advances Loans and Lease Liabilities (Details) € in Thousands		6 Months Ended	12 Months Ended
	Jul. 10, 2020	Jun. 30, 2023 EUR (€) borrowing	Dec. 31, 2022 EUR (€) borrowing
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Lease liabilities		€ 5,740	€ 6,129
Total		€ 76,064	€ 76,563
Borrowing, number of PGE \| borrowing		2	2
Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Lease liabilities		€ 1,146	€ 962
Total		10,322	4,560
Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Lease liabilities		2,291	2,292
Total		17,955	16,584
Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Lease liabilities		1,526	1,904
Total		24,685	34,579
More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Lease liabilities		777	971
Total		23,102	20,840
Bpifrance
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		2,212	2,437
Bpifrance \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		325	300
Bpifrance \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		1,292	1,300
Bpifrance \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		595	837
Bpifrance \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	0
Interest-free Bpifrance loan
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	125
Interest-free Bpifrance loan \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	125
Interest-free Bpifrance loan \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	0
Interest-free Bpifrance loan \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	0
Interest-free Bpifrance loan \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	0
Curadigm interest-free Bpifrance advance
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		500	350
Curadigm interest-free Bpifrance advance \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		75	75
Curadigm interest-free Bpifrance advance \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		200	200
Curadigm interest-free Bpifrance advance \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		225	75
Curadigm interest-free Bpifrance advance \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	0
HSBC "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		3,836	4,475
HSBC "PGE" \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		1,291	1,287
HSBC "PGE" \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		2,545	2,557
HSBC "PGE" \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	631
HSBC "PGE" \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	0
Bpifrance "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		4,222	4,898
Borrowing, maturity	6 years
Bpifrance "PGE" \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		1,331	1,345
Bpifrance "PGE" \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		2,577	2,605
Bpifrance "PGE" \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		314	948
Bpifrance "PGE" \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		0	0
EIB fixed rate loan
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		59,553	58,150
EIB fixed rate loan \| Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		6,154	467
EIB fixed rate loan \| Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		9,050	7,630
EIB fixed rate loan \| Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		22,024	30,184
EIB fixed rate loan \| More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowings		€ 22,325	€ 19,869
HSBC "PGE" and Bpifrance "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities
Borrowing, maturity		5 years	5 years
Borrowing, deferment period		1 year	1 year

Significant transactions (Details) € in Thousands, shares in Millions, $ in Millions						1 Months Ended						6 Months Ended		12 Months Ended
	Jul. 10, 2023 EUR (€)	Oct. 18, 2022 EUR (€) installment	May 18, 2022 shares	Jan. 01, 2021	Feb. 03, 2020 USD ($)	May 31, 2022	Jun. 30, 2021 EUR (€) patient	Mar. 31, 2019 EUR (€)	Jan. 31, 2019 EUR (€)	Oct. 31, 2018 EUR (€)	Aug. 31, 2012 USD ($)	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Jan. 31, 2019 USD ($)	Jul. 31, 2018 EUR (€)
Disclosure of transactions between related parties [line items]
Increase in loans and conditional advances												€ 150	€ 0
Borrowing, interest rate																		21.30%
Cash and cash equivalents												21,629	€ 63,021		€ 41,388	€ 83,921
Prepaid expenses												2,236			2,981
Underwriting agreement, maximum number of shares issued (in shares) \| shares			5.2
Kepler Cheuvreux subscription agreement \| BSA
Disclosure of transactions between related parties [line items]
Underwriting agreement, maximum discount						5.00%
Underwriting agreement, exercise commission percentage						2.00%
Event One \| Maximum
Disclosure of transactions between related parties [line items]
Milestone payment increase														€ 2,200
Event Two \| Maximum
Disclosure of transactions between related parties [line items]
Milestone payment increase														€ 16,400
EIB loan
Disclosure of transactions between related parties [line items]
Royalties agreement, period		6 years		6 years
Notional amount												38,300			35,800
Increase in loans and conditional advances								€ 14,000		€ 16,000
Borrowing, interest rate								5.00%		6.00%								21.30%
Undrawn borrowing facilities																10,000
Borrowings, remaining notional amount		€ 25,300
Borrowings, net sales threshold		5,000
Interest payable, payment-in-kind		5,400
Borrowings, milestone payment		€ 20,000
Borrowings, milestone payment, number of installments \| installment		2
Borrowings, milestone payment, first installment period		1 year
Borrowings, milestone payment, second installment period		2 years
Borrowings, prorated payment, maximum percentage of milestone payment		10.00%
Cash and cash equivalents												25,300
Minimum cash balance												10,300
EIB loan \| Tranche one
Disclosure of transactions between related parties [line items]
Borrowing, interest rate		6.00%
EIB loan \| Tranche two
Disclosure of transactions between related parties [line items]
Borrowing, interest rate		5.00%
EIB loan \| Maximum
Disclosure of transactions between related parties [line items]
Notional amount																		€ 40,000
European Investment Bank Loan Agreement, Tranche Two
Disclosure of transactions between related parties [line items]
Borrowings, remaining notional amount		€ 9,300
LianBio, NBTXR3
Disclosure of transactions between related parties [line items]
Cumulative upfront fees collected												20,000
Collaboration agreement, collected												320
Recharge invoice billed												1,300
LianBio, NBTXR3 \| Maximum
Disclosure of transactions between related parties [line items]
Collaboration agreement, potential development and commercial milestones payments							€ 205,000
LianBio, NBTXR3 \| Maximum
Disclosure of transactions between related parties [line items]
Collaboration agreement, potential development and commercial milestones payments																205,000
Termination of Pharma Engine collaboration agreement, NBTXR3
Disclosure of transactions between related parties [line items]
Cumulative payments															€ 7,500
Contractual commitments, milestone payment upon second regulatory approval \| $											$ 5.0
Royalties agreement, period											10 years
MD Anderson Cancer Center, NBTXR3
Disclosure of transactions between related parties [line items]
Number of patients in clinical trial \| patient							312
Contractual commitments, payment \| $																	$ 10.6
Contractual commitments, payment					$ 1.0				€ 1,000
Milestone payment, deferment period after enrollment									6 months
Prepaid expenses												€ 1,400				€ 1,500
Janssen Pharmaceutica NV \| Major collaboration agreement
Disclosure of transactions between related parties [line items]
Collaboration agreement, upfront payment license fee	€ 30,000

Financial liabilities - Summary of Changes in Financial Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure Of Changes In Financial Liabilities
Current financial liabilities	€ 9,972	€ 4,560
Non-current financial liabilities	44,029	48,608
Total financial liabilities	54,001	53,169
Lease liabilities
Disclosure Of Changes In Financial Liabilities
Current financial liabilities	1,146	962
Non-current financial liabilities	4,107	4,568
Conditional advances
Disclosure Of Changes In Financial Liabilities
Current financial liabilities	400	500
Non-current financial liabilities	2,152	2,258
PGE \| Long-term borrowings
Disclosure Of Changes In Financial Liabilities
Current financial liabilities	2,622	2,632
Non-current financial liabilities	5,251	6,495
EIB loan \| Long-term borrowings
Disclosure Of Changes In Financial Liabilities
Current financial liabilities	5,804	467
Non-current financial liabilities	€ 32,518	€ 35,287

- Definition

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement of comprehensive income [abstract]
Net loss for the period	€ (28,099)	€ (26,357)
Actuarial gains and losses on retirement benefit obligations (IAS 19)	0	106
Tax impact	0	0
Other comprehensive loss that will not be reclassified subsequently to income or loss	0	106
Currency translation adjustment	10	(71)
Tax impact	0	0
Other comprehensive income that may be reclassified subsequently to income or loss	10	(71)
Total comprehensive loss	€ (28,088)	€ (26,322)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2022-03-24
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2022-03-24
-Paragraph 39L
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2022-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard
-URIDate 2022-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2022-03-24
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2022-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2022-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2022-03-24

+ Details

Provisions - Disclosure of Commitments for Retirement Benefits (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Provisions [abstract]
Provision as of beginning of period	€ 270	€ 318
Cost of services	33	75
Discounting costs	5	3
Expense for the period	38	78
Actuarial gains or losses recognized in other comprehensive income	0	(126)
Provision as of the end of period	€ 307	€ 270

Financial liabilities - Summary of Changes in Lease Liabilities (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Summary Of Conditional Advances, Banks Loans And Loans
Fixed interest expense	€ 103	€ 122
Lease liabilities
Summary Of Conditional Advances, Banks Loans And Loans
Liabilities arising from financing activities at beginning of period	5,530
New lease contracts	8
Impact of discounting of the new lease contracts	0
Fixed interest expense	0
Accumulated variable interest expense accrual	103
Repayment of lease	(389)
Liabilities arising from financing activities at end of period	€ 5,253

Trade payables and other current liabilities

6 Months Ended

Jun. 30, 2023

Subclassifications of assets, liabilities and equities [abstract]

Trade payables and other current liabilities

13.1 TRADE AND OTHER PAYABLES


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Fixed assets payables	—	228
Accrued expenses - clinical trials	7,909	5,394
Other trade payables	8,803	3,999
Total trade and other payables	16,712	9,621

Trade payables are not discounted, as none of the amounts has a maturity date above one year.

The €0.2 million of fixed assets payables as of December 31, 2022 was settled during the six months ended June 30, 2023 due to activation of related laboratory purchased equipment (See Note 6 Property, plant and equipment for more details).

The €2.5 million increase of accrued expenses in clinical studies is mainly related to progress of 312 study involving ICON services accrual increase not invoiced yet (€1.5 million) and to additional sites activation on 1100 study (€1.0 million). The €4.8 million increase of other trade payables is mainly driven by a €1.4 million fees to be paid to a financial adviser of the Company - subject to an advisory services agreement between the parties which has been subsequently terminated - and by €3.1 million of cash management impact at the end of June 2023 (mainly ICON €2.4 million), as the Company was able to defer trade payables payments with certain vendors.

13.2 OTHER CURRENT LIABILITIES


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Tax liabilities	382	358
Payroll tax and other payroll liabilities	5,517	6,237
Other payables	276	260
Other current liabilities	6,175	6,855

Payroll tax and other payroll liabilities primarily consist of payroll taxes and social charges, namely the employer withholdings relating to free shares, as well as accrued bonuses, vacation day accruals and related social charges.

Payroll tax and social charges have decreased by €0.7 million during the first half of 2023, of which Nanobiotix S.A. accounts for €0.4 million (of which €0.3 million decrease related to accrued bonuses and €0.1 million decrease related to employer’s social contribution on granted stock-options and free shares) and Nanobiotix Corp. accounts for €0.2 million (mainly accrued bonuses decrease).

13.3 DEFERRED REVENUES AND CONTRACT LIABILITIES


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Deferred income	137	55
Contract liabilities	16,518	16,518
Deferred income and contract liabilities	16,655	16,573

Deferred revenues and contract liabilities as of June 30, 2023, mainly consists of contract liabilities related to the LianBio upfront payment of €16.5 million, accounted for in accordance with IFRS 15 (See Note 15 Revenues and other income). The amount of this upfront has not changed during the six months ended June 30, 2023 and not since it was initially recognized in 2021.

Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure of defined benefit plans
Social security contribution rate	44.00%	44.00%
Discount rate	3.69%	3.69%
Staff turnover	5.86%	5.86%
Duration	20 years	20 years
Executive
Disclosure of defined benefit plans
Retirement assumptions	66 years	66 years
Salary increase rate (including inflation)	3.00%	3.00%
Non-executive
Disclosure of defined benefit plans
Retirement assumptions	64 years	64 years
Salary increase rate (including inflation)	0.025%	0.025%

Consolidated principles and methods (Policies)	6 Months Ended
Consolidated principles and methods (Policies)	Jun. 30, 2023
Significant Accounting Policies [Abstract]
General principles and statement of compliance and basis of presentation	General principles The unaudited interim condensed consolidated financial statements as of June 30, 2023 and for the six-month period ended June 30, 2023 were prepared under the supervision of the management of the Company and were submitted by the Executive Board to the review of the Supervisory Board. All amounts in the unaudited interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the unaudited interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. See Note 3.2 Use of judgement, estimates and assumptions. The unaudited interim consolidated financial statements of the Company have been prepared in compliance with IAS 34 – “Interim Financial Reporting”. As they are unaudited interim condensed financial statements, they do not contain all information required for the consolidated annual financial statements and should therefore be read in conjunction with the consolidated financial statements of the Company for the financial year ended December 31, 2022 as described below. Seasonality of the Company’s activities According to IAS 34 – Interim Financial Reporting, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed financial statements in order to provide a better understanding and comparison of its interim financial statements. As mentioned in Note 15 Revenue and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. Therefore, the following unaudited interim condensed financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34-20. Statement of compliance and basis of presentation The unaudited interim condensed consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of June 30, 2023. The unaudited interim condensed consolidated financial statements are also compliant with IFRS as adopted by the European Union in effect at the date of preparation of these financial statements. The accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2023 are identical to those used for the year ended December 31, 2022 except for the standards listed below that required adoption in 2023. Application of New or Amended Standards and Interpretations The following standards, interpretations and amendments to existing standards applicable for reporting periods beginning on or after January 1, 2023, were applied where necessary to the interim condensed consolidated financial statements for the six months ended June 30, 2023: •Amendments to IAS 8 – Definition of Accounting Estimates •Amendments to IAS 1 and IFRS Practice Statement 2 – Disclosure of Accounting Policies •Amendments to IAS 12 – Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction The application of these standards and these amendments had no impact on the Company’s interim condensed consolidated financial statements. Standards, interpretations and amendments to existing standards available for early adoption in reporting periods beginning on or after January 1, 2023 In first-half 2023, there were no new standards, interpretations or amendments to existing standards applicable to accounting periods starting on or after January 1, 2024 that the Group could have early adopted as from January 1, 2023. Standards, interpretations and amendments to existing standards published but not yet applicable The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable concern: •Amendments to IAS 1 – Classification of Liabilities as Current or Non-current •Amendment to IAS 12 – International Tax Reform – Pillar Two Model Rules The Company is currently evaluating if the adoption of these amendments will have a material impact on our results of operations, financial position, or cash flows. Going Concern The Company experienced net losses of €28.1 million in the six months ended June 30, 2023 and a net decrease in cash and cash equivalents of €19.8 million during the same period. As of June 30, 2023, the Company’s accumulated deficit was €283.0 million with a negative working capital of €22.7 million. the Company expects to continue to incur significant expense related to the development and manufacturing of nanotechnology product candidates such as NBTXR3 and conducting clinical studies. Additionally, the Company may encounter unforeseen difficulties, complications, development delays and other unknown factors that require additional expense. As a result of these expenditures, the company expects to continue to incur significant losses in the near term. Additionally, the Company’s debt instruments contain covenants that require maintenance of minimum cash and cash equivalent balances that limit the availability of cash resources to pursue operational needs: Pursuant to the terms of the finance contract for the EIB loan, for so long as the EIB loan remains outstanding, the Company was required to maintain a minimum cash and cash equivalents balance equal to the outstanding principal owed to EIB which is €25.3 million as of June 30, 2023. The remaining principal of the loan would become payable, together with accrued interest, prepayment fees and other accrued or outstanding amounts, if and when requested by EIB, if the cash balance were to fall below this minimum cash amount requirement. However, in March 2023, the Company has obtained a temporary waiver that reduces the minimum cash balance requirement by €15.0 million: upon the Company’s entry into the global licensing agreement executed with Janssen - condition that has been fulfilled following the “HSR” antitrust clearance announced as of August 15, 2023 - the duration of this temporary waiver was automatically extended until January 31, 2024. Therefore, the Company’s covenant obligations and the ongoing activities entail that the amount of cash and cash equivalents, amounting to €21.6 million as of June 30, 2023 (see section II note 9 cash and cash equivalents) is sufficient to fund its operating expenses into the first quarter of 2024. While the Company has taken and will continue to take actions to obtain additional funding and manage costs, as necessary, the above factors raise substantial doubt about the Company’s ability to continue as a going concern as there is no assurance that the Company will be successful in satisfying its future cash needs. The Executive Board has determined that it is appropriate to prepare its unaudited condensed consolidated financial statements as of and for the period ended June 30, 2023, on a going concern basis, assuming the Company will continue to operate for the foreseeable future, and to address its liquidity challenges by pursuing activities to generate additional cash inflows and by closely monitoring its operating expenditures. As part of the Company’s efforts to address the risk of going concern, management has undertaken the following: •The Company has signed a Global Trial Collaboration Agreement with LianBio which was executed as of June 30, 2023, providing for LianBio to participate in the global registrational Phase 3 trial “HNSCC 312” costs; •On July 7, 2023, the Company entered into the Janssen worldwide co-development and commercialization Agreement, allowing the Company to receive a $30 million upfront payment, which became payable as of August 15, 2023, following the “HSR” antitrust clearance period, and which has been received by the Company from Janssen; •In addition, as of September 13, 2023, the Company has received a gross amount of $5 million in consideration of the initial tranche equity investment by JJDC according to the terms of the JJDC SPA; •Operating Expense Monitoring: the Company continues efforts to control its operating expenses and to focus on its priority programs by enhancing operational efficiencies and optimizing capital allocation for continued investment in priority development pathways. The Company also continuously evaluates additional financing avenues on an opportunistic basis. Such opportunities may include one or more possible new financings from institutional or strategic investors, debt or product financing structures, from the capital markets, business development and licensing, grants or subsidies, or a combination of the above, whether or not in combination with the potential second tranche equity investment of $25.0 million under the JJDC SPA, if the conditions thereto are satisfied. Additionally, the Equity Line (PACEO) executed in May 2022 might provide financing flexibility until its expiration in May 2024. Moreover, the Company is eligible for success-based milestones under its collaboration agreements, including the Janssen Agreement, although the Company cannot guarantee if or when such milestones will be achieved.
Basis of consolidation	BASIS OF CONSOLIDATION Consolidated entities As of June 30, 2023, the consolidation scope is identical to that at December 31, 2022 as Nanobiotix S.A. has five wholly owned subsidiaries: •Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA, •Nanobiotix Germany GmbH, created in October 2017 and located in Germany, •Nanobiotix Spain S.L.U., created in December 2017 and located in Spain, •Curadigm SAS, created on July 3, 2019 and located in France, and •Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Cambridge, Massachusetts. Accordingly, the unaudited interim condensed consolidated financial statements as of June 30, 2023 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation. Foreign currency transactions The unaudited interim condensed consolidated financial statements are presented in thousands of euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate for the statement of financial position, whereas items of the statement of operations, statement of comprehensive loss and statement of cash flow are converted at the average exchange rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar-to-euro exchange rate used in the interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were a closing of $1.0866 as of June 30, 2023 and an average of $1.0811 for the six-month period ended June 30, 2023 compared with $1.0387 and $1.0940 respectively, as of and for the six-month period ended June 30, 2022 (source: Banque de France). The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.
Use of judgement, estimates and assumptions	USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONSThe preparation of interim condensed consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are going concern, share-based payments, deferred tax assets, clinical trials accruals and the measurement of financial instruments (fair value and amortized costs). Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Executive and Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., option vesting terms) and market data (e.g., expected share volatility) (See Note 17 Share-based payments). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. Deferred tax assets are also recognized for unused tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow for sufficiently reliable income projections to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position. Clinical trial accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision is recognized accordingly. (See Note 13.1 Trade and other payables for information regarding the clinical trial accruals as of June 30, 2023 and December 31, 2022.) Revenue recognition In order to determine the amount and timing of revenue under the contract with customers, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to customers Determining the distinctiveness of performance obligations — A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services. Allocation of transaction price to performance obligations — A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. To determine the proper revenue recognition method, the Company evaluates whether the contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment. Some of the Company’s contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Variable consideration — Due to the nature of the work required to be performed on many of the Company’s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch‑up basis. Revenue recognized over time and input method — Some of the Company’s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers. See Note 15 for additional detail regarding the Company’s accounting policies for its additional sources of revenue and other income. Measurement of financial assets and liabilities At the renegotiation date in October 2022, the fair value measurement of the EIB loan required the Company to determine: –the discount rate of the new liability executed in October 2022. The discount rate reflects the company’s credit risk at the Amendment Agreement date as well as a premium to reflect uncertainties associated with the timing and the amount of the royalties’ payment. The Company involved external financial instruments valuation specialists to support in determining the average discount rate; –the amount of additional interest (“royalties”, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing upon commercialization. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to annual sales turnover relating to NBTXR3 through specific Company’s license agreement. For the purpose of measuring the fair value of the EIB loan, the Company forecasts expected sales relating to NBTXR3 during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see Notes 4.3 and 12 for details about this loan and the accounting treatment applied). Subsequently to the estimate of the fair value of the EIB loan performed at the renegotiation date, the debt has been measured at amortized cost based on the revised best estimate of the future cash flows related to the debt at each closing date. Accordingly, the Company determines the amount of additional interest as described above. Any subsequent adjustment of flows indexed to turnover has been discounted at the original effective interest rate and the adjustment is recognised in Profit or loss.
Revenues and other income	The revenue recognition accounting principles used to prepare the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2023 are identical to those used for the year ended December 31, 2022. Application of IFRS 15 to the license and collaboration agreement and clinical supply agreement with LianBio In May 2021, the Company executed a license arrangement with LianBio, pursuant to which LianBio received an exclusive right to develop and commercialize NBTXR3 in China and other east Asian countries. the Company remains responsible for the manufacturing of the licensed products. The Company is not required to transfer manufacturing know-how, unless the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's requirements for licensed products in a given calendar year. Pursuant to the agreement, the parties will collaborate on the development of NBTRX3 and LianBio will participate in global Phase 3 registrational studies, for several indications, by enrolling patients in China. The Company received in June 2021 a non-refundable upfront payment of $20 million. In addition, the Company may receive up to $205 million potential additional payments upon the achievement of certain development and sales milestones, as well as tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The Company is also entitled to receive payments for development and commercial vials ordered by LianBio and supplied by the Company. The license to commercialize a product candidate, ongoing transfer of unspecified know-how related to development and commercialization and the supply services (for commercial products) are in the scope of IFRS 15, as they are an output of the Company’s ordinary activities. For IFRS 15 purpose, it was determined that the license is not distinct from the commercial manufacturing services because the customer cannot benefit from the license without the manufacturing services and such services are not available from third party-contract manufacturers. Accordingly, the license and commercial manufacturing services are treated as one single performance obligation which is recognized as manufacturing services are performed. Milestone payments linked to regulatory marketing approvals will be included in the transaction price only when and if the contingency is resolved and will be recognized as revenue when manufacturing services are provided. Sales-based milestone payments will be recognized when the sales thresholds are achieved. Royalties will be recognized when the underlying sales are made by LianBio. The $20 million upfront payment received in June 2021 has been recognized as a Contract Liability and will be recognized as revenue over the term of the arrangement, as manufacturing services (for commercial products) are provided. The execution of development efforts leading to the regulatory marketing approvals are treated as a collaboration arrangement outside of the scope of IFRS 15. If any R&D cost incurred is eligible for partial reimbursement by Lianbio, the corresponding recharge is recognized as Other Income, as well as the supply of products necessary to conduct the clinical trials. The related income is recognized respectively when the products will be delivered to Lianbio and when the eligible costs are incurred by LianBio. On May 9, 2022, the Company signed the clinical supply agreement with LianBio as defined in the license, development, and commercialization agreement This agreement provides for the supply by the Company to LianBio of vials of NBTXR3 and Cetuximab products for clinical trial development activities. For the period ended June 30, 2023, the Company billed the delivery of NBTXR3 and Cetuximab vials to LianBio amounting to €217 thousand, recorded within Other Income as it relates to the non-IFRS 15 components of the agreement (the development collaboration). As of June 30, 2023, the Company signed a global trial collaboration agreement (or “GTCA”) with LianBio in connection with the License Agreement signed on May 11, 2021. As contemplated by the LianBio License Agreement, LianBio shall participate in the global registrational Phase 3 trial “HNSCC 312” conducted by Nanobiotix, with regards to NANORAY-312 trials conducted within the licensed territories. According to the GTCA, LianBio is responsible for all internal and external costs incurred in connection with the study in the licensee territories as well as all external costs and expenses incurred by or on behalf of the Company for the global study that are generally applicable to both the licensee territories study with respect to the patients enrolled within the enrollment commitment and the portion of the global study conducted outside of the licensee territories. Recharge of related costs to LianBio cumulated since 2021, has started to be invoiced by the Company during the first half of 2023: the recharge invoice billed to LianBio amounting to €1.3 million as of June 30, 2023, has been recorded within Other Income as it relates to the non-IFRS 15 components of the agreement (the development collaboration). Grants and Subsidies Since its creation, the Company has received, because of its innovative approach to nanomedicine, certain grants and subsidies from the French State or French public authorities. These grants and subsidies are intended to finance its general or specified activities. Grants are recognized as income as the related expenses are incurred, provided there is reasonable assurance that the Company will comply with the conditions attaching to them and that the grants will be received. Research tax credit The research tax credit ("CIR") is granted to companies by the French government to encourage them to conduct technical and scientific research. Companies that can prove that they have incurred expenses that meet the required criteria (research expenses located in France or, since January 1, 2005, in the European Community or in another country that is a party to the Agreement on the European Economic Area and that has entered into a tax treaty with France containing an administrative assistance clause) are entitled to a tax credit which, in principle, can be offset against the corporate income tax due for the fiscal year in which the expenses were incurred and for the three following years. Any unused portion of the tax credit is then reimbursed by the Treasury. In the particular case where the Company qualifies as a small and medium-sized enterprise (SME), the Company may request immediate reimbursement of the balance of the tax credit without application of the three-year period. The Company has benefited from the research tax credit since its creation. This financing is recorded under "Other income" in the year in which the corresponding expenses were incurred. The portion of the financing related to capitalized expenses is deducted in the balance sheet from the capitalized expenses and in the income statement from the amortization charges of these expenses.

Non-current financial assets (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure of financial assets [abstract]

Disclosure of Changes in Non-current Financial Assets

The change in non-current financial assets breaks down as follows:


(in thousands of euros)	Liquidity contract - Cash account	Other long- term investments pledged as collateral	Security deposits paid	Total
Net book value as of December 31, 2021	98	—	421	519
Additions	—	—	—	—
Decreases	(97)	—	(133)	(230)
Transfer	—	—	—	—
Currency translation adjustments	—	—	3	3
Net book value as of Net book value as of December 31, 2022	1	—	291	291
Additions	—	—	12	12
Decreases	—	—	(9)	(9)
Transfer	—	—	—	—
Currency translation adjustments	—	—	—	1
Net book value as of June 30, 2023	1	—	293	294

Intangible assets - Additional Information (Details)	6 Months Ended
Intangible assets - Additional Information (Details)	Jun. 30, 2023 EUR (€)
Intangible assets other than goodwill [abstract]
Impairment loss recognised in profit or loss, intangible assets other than goodwill	€ 0

Cash and cash equivalents - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of other provisions
Net decrease in cash and cash equivalents	€ 19,759	€ 20,900
EIB loan
Disclosure of other provisions
Minimum cash balance	€ 10,300

Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure of financial assets
Non-current financial assets at beginning of period	€ 291	€ 519
Additions	12	0
Decreases	(9)	(230)
Transfer	0	0
Currency translation adjustments	1	3
Non-current financial assets at end of period	294	291
Liquidity contract - Cash account \| Financial assets at fair value, class
Disclosure of financial assets
Non-current financial assets at beginning of period	1	98
Additions	0	0
Decreases	0	(97)
Transfer	0	0
Currency translation adjustments	0	0
Non-current financial assets at end of period	1	1
Other long- term investments pledged as collateral \| Financial assets at amortised cost, class
Disclosure of financial assets
Non-current financial assets at beginning of period	0	0
Additions	0	0
Decreases	0	0
Transfer	0	0
Currency translation adjustments	0	0
Non-current financial assets at end of period	0	0
Security deposits paid \| Financial assets at amortised cost, class
Disclosure of financial assets
Non-current financial assets at beginning of period	291	421
Additions	12	0
Decreases	(9)	(133)
Transfer	0	0
Currency translation adjustments	0	3
Non-current financial assets at end of period	€ 293	€ 291

Consolidated principles and methods (Details)	6 Months Ended
Consolidated principles and methods (Details)	Jun. 30, 2023 subsidiary	Jun. 30, 2022
Significant Accounting Policies [Abstract]
Number of subsidiaries	5
Closing foreign exchange rate	1.0866	1.0387
Average foreign exchange rate	1.0811	1.0940

Revenue and other income - Schedule of Revenues and Other Income (Details) - EUR (€) € in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers
Revenues	€ 0	€ 0
Research tax credit	1,604	1,053	€ 1,053
Subsidies	202	111
Other Income	1,487	165
Other income	3,293	1,329
Total revenues and other income	3,293	1,329
Services
Disclosure of disaggregation of revenue from contracts with customers
Revenues	0	0
Other sales
Disclosure of disaggregation of revenue from contracts with customers
Revenues	€ 0	€ 0

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 32
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 33
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 34
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard
-URIDate 2022-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2022-03-24
-Paragraph 33
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2022-03-24

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B12
-Subparagraph b
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 82
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2022-03-24

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard
-URIDate 2022-03-24

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 102
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard
-URIDate 2022-03-24

+ Details

Non-current financial assets

6 Months Ended

Jun. 30, 2023

Disclosure of financial assets [abstract]

Non-current financial assets

The change in non-current financial assets breaks down as follows:


(in thousands of euros)	Liquidity contract - Cash account	Other long- term investments pledged as collateral	Security deposits paid	Total
Net book value as of December 31, 2021	98	—	421	519
Additions	—	—	—	—
Decreases	(97)	—	(133)	(230)
Transfer	—	—	—	—
Currency translation adjustments	—	—	3	3
Net book value as of Net book value as of December 31, 2022	1	—	291	291
Additions	—	—	12	12
Decreases	—	—	(9)	(9)
Transfer	—	—	—	—
Currency translation adjustments	—	—	—	1
Net book value as of June 30, 2023	1	—	293	294

Provisions

6 Months Ended

Jun. 30, 2023

Provisions [abstract]

Provisions

Details of provisions


(in thousands of euros)	As of December 31, 2022	Increases	Decreases(1)	Currency translation adjustments	As of June 30, 2023
Lump-sum retirement benefits	270	38		—	307
Non-current provisions	270	38	—	—	307
Provisions for disputes	177	10	—	(1)	186
Provisions for charges	150	4		—	154
Current provisions	327	14	—	(1)	340
Total provisions	596	52	—	(1)	647

(1)See Note 16.4 Depreciation, amortization and provision expenses for the nature of these decreases

Commitments for retirement benefits


	As of
(in thousands of euros)	June 30, 2023	December 31, 2022
Provision as of beginning of period	270	318
Cost of services	33	75
Discounting costs	5	3
Expense for the period	38	78
Actuarial gains or losses recognized in other comprehensive income	—	(126)
Provision as of the end of period	307	270

The assumptions used to measure lump-sum retirement benefits are as follows:


Measurement date	June 30, 2023	December 31, 2022
Retirement assumptions	Executive: Age 66 Non-Executive: Age 64	Executive: Age 66 Non-Executive: Age 64
Social security contribution rate	44 %	44 %
Discount rate	3.69 %	3.69 %
Mortality tables	Regulatory table INSEE 2016 - 2018	Regulatory table INSEE 2016 -2018
Salary increase rate (including inflation)	Executive: 3% Non-Executive: 2.5%	Executive: 3% Non-Executive: 2.5%
Staff turnover	Constant average rate of 5.86%	Constant average rate of 5.86%
Duration	20 years	20 years

The rights granted to Company employees are defined in the collective agreement for the pharmaceutical industry (manufacturing and sales of pharmaceutical products).The staff turnover rate was determined using a historical average over the 2017-2022 period.

Share Capital - Equity Line Agreement (Details)		1 Months Ended		6 Months Ended
Share Capital - Equity Line Agreement (Details)	May 18, 2022 shares	May 31, 2022	May 18, 2022	Jun. 30, 2023 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Underwriting agreement, maximum number of shares issued (in shares)	5,200,000
Kepler Cheuvreux subscription agreement \| BSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Underwriting agreement, term of exercise			24 months
Underwriting agreement, maximum extension period			6 months
Underwriting agreement, maximum discount		5.00%
Number of warrants (BSAs) exercised (in shares)				0
Kepler Cheuvreux subscription agreement \| BSA \| Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Underwriting agreement, percentage of total number of shares traded			25.00%

Share Capital

6 Months Ended

Jun. 30, 2023

Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]

Share Capital

10.1 CAPITAL ISSUED

Detail of share capital transactions


(in thousands or number of shares)	Nature of transaction	Share Capital	Premiums related to share capital	Number of shares
December 31, 2022		1,046	255,760	34,875,872
April 24, 2023	Capital increase AGA 2021	11	—	354,510
March 31, 2023	Prior period adjustment	—	—	—
June 27, 2023	AGA 2023	—	(26)	—
June 30, 2023		1,057	255,734	35,230,382

As of June 30, 2023, the share capital was €1,057 thousand divided into 35,230,382 fully paid up ordinary shares, each with a par value of €0.03.

10.2 FOUNDER’S WARRANTS, WARRANTS, STOCK OPTIONS AND FREE SHARES

As of June 30, 2023, there are four different types of securities and other valid instruments entitling their holders to a stake in the Company's share capital: warrant (bons de souscription d’actions or BSA), founders’ warrant (bons de souscription de parts de créateur d’entreprise or BSPCE), stock option (options de souscription ou d’achat d’actions or OSA) and free shares (attribution gratuite d’actions or AGA).

Stock options

No stock options were granted in the first half of 2023.

Free Shares

At a meeting on June 27, 2023, the Executive Board, acting pursuant to the authorization granted by Company’s shareholders’ meeting on June 23, 2022, granted 427,110 free shares (AGA 2023 P1), each with a par value of €0.03 to employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on June 27, 2025. Such free shares are governed by the 2023 free share plan adopted by the Executive Board on June 27, 2023.

Furthermore, the definitive acquisition of the free shares granted to members of the Executive Board is conditioned upon the achievement of 3 of the 7 following milestones, including the mandatory achievement of one of the milestones between #1 to #3:

1.Establish a collaboration/development deal with a pharma or industry partner (signed term sheet);

2.Non-dilutive financing to reach interim readout;

3.Double share price as compared to weighted average value of the first 6 months of 2023 or share price to outperform a biotech index over next 12 months starting at attribution date;

4.Launch a new trial IO combo with NBTXR3;

5.2 new trials launched by our partner(s);

6.Complete half of the patients recruitment of 312 (to exceed the number needed for the Futility Analysis);

7.Positive data in phase I pancreatic cancer allowing to consider moving into next clinical phase;

The achievement of these conditions must be acknowledged by the Executive Board, with the prior approval of the Supervisory Board, before a period ending twenty-four months following June 27, 2023.

At a meeting on June 27, 2023, the Executive Board, acting pursuant to the authorization granted by Company’s shareholders’ meeting on June 23, 2022, granted 439,210 free shares (AGA 2023 P2), each with a par value of €0.03 to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on June 27, 2025. Such free shares are governed by the 2023 free share plan adopted by the Executive Board on June 27, 2023.

Furthermore, the definitive acquisition of these free shares granted to members of the Executive Board and all employees is conditioned upon the achievement of the following conditions:

1.Closing a collaboration/development deal;

2.Achievement of one of the two following conditions:

•the dosing the 50th patient in the NANORAY-312 study

•the start by the new partner of a clinical trial in one indication.

The achievement of these conditions must be acknowledged by the Executive Board, with the prior approval of the Supervisory Board, before a period ending twenty-four months following June 27, 2023.

As of June 30, 2023, the assumptions related to the estimated vesting of the founders’ warrants, the warrants and performance stock options have been updated (See Note 17 Share-based payments).

10.3 WARRANTS (BSA) EQUITY LINE KEPLER CHEUVREUX

On May 18, 2022, in accordance with the twenty-first resolution adopted at the April 28, 2021 annual shareholders’ meeting, the Executive Board decided, with the prior approval of the Supervisory Board, to implement an equity line financing with Kepler Cheuvreux for the following twenty-four months and, accordingly, to issue to Kepler Cheuvreux a total of 5,200,000 warrants to subscribe for the same number of the Company’s ordinary shares (bons de souscription d’actions or BSA Kepler). Although Kepler Cheuvreux is acting as the underwriter of the equity line program, Kepler Cheuvreux does not intend to maintain ownership of any shares issued in conjunction with the equity line. Instead, it is expected that Kepler Cheuvreux will sell these shares on the regulated market of Euronext Paris or to investors through block trades.

The main terms and conditions of the BSA Kepler are described in the table below:


			BSA Kepler
Date of the shareholders’ meeting			April 28, 2021
Date of grant by the Executive Board			May 18, 2022
Maximum number of BSAs authorized			5,200,000
Total number of BSAs granted			5,200,000
Number of shares to which the BSA were likely to give right on the date of their grant			5,200,000
Starting date for the exercise of the BSA			(1)
BSA expiry date			(2)
BSA issue price			500 € in the aggregate
Exercise price per new share			(3)
Terms of exercise			(1)(4)
Number of shares subscribed as of the date of the Report			0
Total number of forfeited or cancelled BSAs as of the Report			0
Total number of BSAs outstanding as of the date of the Report			5,200,000
Total number of shares available for subscription as of the date of the Report (considering the conditions of exercise of the BSAs)			5,200,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)			5,200,000

1) Subject to meeting the contractual conditions, Kepler Cheuvreux undertakes to exercise the BSA Kepler within 24 months of their date of issue. These conditions include:

(4) The BSA Kepler may be exercised at any time in whole or in part by Kepler Cheuvreux during their exercise period, subject to a minimum proceeds condition.

Considering that the Company can terminate or suspend the Equity line agreement by buying back the BSAs or increasing the minimum exercise price and that Kepler Cheuvreux is committed to subscribe the shares if the conditions are met, the BSAs granted to Kepler Cheuvreux under the Equity line agreements are off-balance sheet commitments and therefore there is no option or derivative. As structuring commissions are not related to an asset or liability, structuring commissions are expensed at the initiation of the contract.

No BSA has been exercised as of June 30, 2023.

Subsequent events	6 Months Ended
Subsequent events	Jun. 30, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events	Subsequent events Janssen agreement On July 10, 2023, Nanobiotix announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, for the investigational, potential first-in-class radioenhancer NBTXR3. Under the terms of the license agreement, the Company granted Janssen a worldwide license for the development and commercialization of NBTXR3. The license is exclusive, excepting territories previously licensed to Nanobiotix partner LianBio. Nanobiotix will maintain operational control of NANORAY-312 and all other currently ongoing studies, along with NBTXR3 manufacture, clinical supply, and initial commercial supply. Janssen will be fully responsible for an initial Phase 2 study evaluating NBTXR3 for patients with stage three lung cancer and will have the right to assume control of studies currently led by Nanobiotix. Following the Hart-Scott-Rodino Act (“HSR”) antitrust clearance, the Company has received an upfront cash licensing fee of $30 million. The Company is eligible for success-based payments of up to $1.8 billion, in the aggregate, relating to potential development, regulatory, and sales milestones. Moreover, the agreement includes a framework for additional success-based potential development and regulatory milestone payments of up to $650 million, in the aggregate, for five new indications that may be developed by Janssen at its sole discretion; and of up to $220 million, in the aggregate, per indication that may be developed by Nanobiotix in alignment with Janssen. Following commercialization, the Company will also receive tiered double-digit royalties on net sales of NBTXR3. Separately, the Company is eligible to receive up to $30 million in equity investments from Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), including an initial tranche equal to $5 million issued without preferential subscription rights that has already been received as of September 13, 2023. A second tranche of $25 million may be received subject to certain maximum ownership caps and in connection with a future qualified equity raise of at least $25 million (excluding the potential investment by JJDC) which must occur prior to certain long-term development milestones or December 31, 2027, at the latest. Shareholders meeting held on September 1, 2023 A shareholders’ meeting of the Company was held on September 1, 2023 in which shareholders voted on the implementation of the first tranche of $5 million by JJDC in a private placement previously announced on July 10, 2023. All resolutions relating to this operation were approved and, consequently, the Company was cleared to issue the shares in a subscription by JJDC of 959,637 new ordinary shares representing, as of today, 2.65% of the issued share capital of the Company. The proceeds of the first equity investment by JJDC were received on September 13, 2023. Termination agreement with a financial service provider The Company and its financial service provider had entered into an advisory services agreement on November, 28, 2018 to facilitate transactions and act as the Company’s exclusive financial adviser relating to a certain scope of transactions, including a major licensing transaction. As part of the termination agreement executed by and between the Company and this financial service provider as of July 19, 2023, the Company is committed to pay to its financial service provider, in addition to the $1.5 million paid in August 2023: •an amount of $750 thousand on the sooner of a next financing round of a certain minimum amount or when the Company will receive an amount in consideration of the achievement of a clinical development milestone as per the license agreement signed with Janssen. •an additional payment of $750 thousand, upon the achievement of further milestones as per the license agreement signed with Janssen.

Net financial income (loss) (Tables)

6 Months Ended

Jun. 30, 2023

Net Financial Income (Loss) [Abstract]

Summary of Net Financial Income (Loss)


	For the six month period ended June 30,
(in thousands of euros)	2023	2022
Income from cash and cash equivalents	450	6
Foreign exchange gains	370	2,459
Other financial income	—	—
Total financial income	820	2,465
Interest cost	(3,714)	(2,602)
EIB debt catch-up	809	—
IFRS 16 related interests	(103)	(122)
Foreign exchange losses	(537)	(216)
Total financial expenses	(3,545)	(2,940)
Net financial income (loss)	(2,725)	(474)

General information, statement of compliance and basis of presentation (Tables)	6 Months Ended
	Jun. 30, 2023
General Information, Statement of Compliance and Basis of Presentation [Abstract]
Disclosure of New or Amended Standards and Interpretations	tandards, interpretations and amendments to existing standards applicable for reporting periods beginning on or after January 1, 2023, were applied where necessary to the interim condensed consolidated financial statements for the six months ended June 30, 2023: •Amendments to IAS 8 – Definition of Accounting Estimates •Amendments to IAS 1 and IFRS Practice Statement 2 – Disclosure of Accounting Policies •Amendments to IAS 12 – Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction

Share-based payments

6 Months Ended

Jun. 30, 2023

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Share-based payments

Detail of share-based payments

The Company has granted stock options (OSA), founders’ warrants (BSPCE), warrants (BSA), and free shares (AGA) to corporate officers, employees, members of the Executive and Supervisory Board and consultants of the Group. In certain cases, exercise of the stock options, founders’ warrants and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.

The number of stock options, founders’ warrants, warrants and free shares outstanding on June 30, 2023 and their main characteristics, are detailed below:

Founders’ warrants outstanding as at June 30, 2023


	BSPCE 08-2013	BSPCE 09-2014	BSPCE 2015-1	BSPCE 2015-3
Date of the shareholders' meeting	28-Jun-13	18-Jun-14	18-Jun-14	18-Jun-14
Date of grant by the Executive Board	28-Aug-13	16-Sep-14	10-Feb-15	10-Jun-15
Total number of BSPCEs authorized	500,000	450,000	450,000	450,000
Total number of BSPCEs granted	50,000	97,200	71,650	53,050
Total number of shares to which the BSPCE were likely to give right on the date of their grant	50,000	97,200	71,650	53,050
the number of which that may be subscribed by corporate officers:	—	21,000	24,000	—
the number that can be subscribed by Laurent LEVY	—	21,000	24,000	—
Number of beneficiaries who are not corporate officers	1	30	13	42
Starting date for the exercise of the BSPCE	08/28/13	09/16/15	02/10/2016	06/10/2016
BSPCE expiry date	08/28/23	09/16/24	02/10/2025	06/10/2025
BSPCE exercise price	€5.92	€18.68	€18.57	€20.28
Number of shares subscribed as of June 30, 2023	—	—	—	—
Total number of BSPCEs lapsed or cancelled as of June 30, 2023	—	11,250	3,200	23,050
Total number of BSPCEs outstanding as of June 30, 2023	50,000	85,950	68,450	30,000
Total number of shares available for subscription as of June 30, 2023	50,000	85,950	68,450	30,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met)	50,000	85,950	68,450	30,000


	BSPCE 2016 Ordinary	BSPCE 2016 Performance	BSPCE 2017 Ordinary	BSPCE “2017”
Date of the shareholders' meeting	25-Jun-15	25-Jun-15	23-Jun-16	23-Jun-16
Date of grant by the Executive Board	2-Feb-16	2-Feb-16	7-Jan-17	7-Jan-17
Total number of BSPCEs authorized	450,000	450,000	450,000	450,000
Total number of BSPCEs granted	126,400	129,250	117,650	80,000
Total number of shares to which the BSPCE were likely to give right on the date of their grant	126,400	129,250	117,650	80,000
the number of which that may be subscribed by corporate officers:	23,500	23,500	26,400	32,000
the number of which that may be subscribed by Laurent LEVY	23,500	23,500	26,400	32,000
Number of beneficiaries who are not corporate officers	43	50	42	3
Starting date for the exercise of the BSPCE	02/02/2017	02/02/2016	01/07/2017	01/07/2017
BSPCE expiry date	02/02/2026	02/02/2026	01/07/2027	01/07/2027
BSPCE exercise price	€14.46	€14.46	€15.93	€15.93
Number of shares subscribed as of June 30, 2023	333	—	—	—
Total number of BSPCEs lapsed or cancelled as of June 30, 2023	25,850	29,682	18,850	—
Total number of BSPCEs outstanding as of June 30, 2023	100,217	99,568	98,800	80,000
Total number of shares available for subscription as of June 30, 2023	100,217	99,568	98,800	80,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of said BSPCEs are met)	100,217	99,568	98,800	80,000

Warrants outstanding as at June 30, 2023


	BSA 2013	BSA 2014	BSA 2015-1	BSA 2015-2 (a)
Date of the shareholders’ meeting	4-May-12	18-Jun-14	18-Jun-14	18-Jun-14
Date of grant by the Executive Board	10-Apr-13	16-Sep-14	10-Feb-15	25-Jun-15
Maximum number of BSAs authorized	200,000	100,000	100,000	100,000
Total number of BSAs granted	10,000	14,000	26,000	64,000
Number of shares to which the BSA were likely to give right on the date of their grant	10,000	14,000	26,000	64,000
including the total number of shares that may subscribed by the corporate officers of the Company	—	8,000	15,000	—
Relevant officers:
Anne-Marie GRAFFIN	—	—	5,000	—
Enno SPILLNER	—	—	3,000	—
Alain HERRERA	—	4,000	5,000	—
Gary PHILLIPS	—	—	—	—
Christophe DOUAT (observer)	—	4,000	2,000	—
Number of beneficiaries who are not corporate officers	1	1	2	1
Starting date for the exercise of the BSA	04/30/2014	09/16/2014	02/10/2015	06/25/2015
BSA expiry date (6)	04/10/2023	09/16/2024	02/10/2025	06/25/2025
BSA issue price	€2.50	€4.87	€4.87	€5.00
Exercise price per BSA	€6.37	€17.67	€17.67	€19.54
Number of shares subscribed as of June 30, 2023	—	—	—	—
Total number of forfeited or cancelled BSAs as of June 30, 2023	10,000	4,000	5,000	—
Total number of BSAs outstanding as of June 30, 2023	—	10,000	21,000	64,000
Total number of shares available for subscription as of June 30, 2023 (considering the conditions of exercise of the BSAs)	—	—	—	—
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)	—	10,000	21,000	64,000


	BSA 2018	BSA 2018-1	BSA 2018-2	BSA 2019-1	BSA 2020	BSA 2021 (a)	BSA 2021 (b)
Date of the shareholders’ meeting	14-Jun-17	14-Jun-17	23-May-18	23-May-18	11-Apr-19	30-Nov-20	30-Nov-20
Date of grant by the Executive Board	6-Mar-18	6-Mar-18	27-Jul-18	29-Mar-19	17-Mar-20	20-Apr-21	20-Apr-21
Maximum number of BSAs authorized	116,000	116,000	140,000	140,000	500,000	650,000	650,000
Total number of BSAs granted	18,000	10,000	5,820	18,000	18,000	48,103	30,000
Number of shares to which the BSA were likely to give right on the date of their grant	18,000	10,000	5,820	18,000	18,000	48,103	30,000
including the total number of shares that may subscribed by the corporate officers of the Company	12,700	—	—	12,700	14,024	—	—
Relevant officers:
Anne-Marie GRAFFIN	2,900	—	—	2,900	3,843	—	—
Enno SPILLNER	4,000	—	—	4,000	3,829	—	—
Alain HERRERA	2,900	—	—	2,900	3,195	—	—
Gary PHILLIPS	—	—	—				—
Christophe DOUAT (observer)	2,900	—	—	2,900	3,157	—	—
Number of beneficiaries who are not corporate officers	1	1	1	1	1	1	1
Starting date for the exercise of the BSA	03/06/2018	03/06/2018	07/27/18	03/29/19	03/17/20	04/20/21	04/20/21
BSA expiry date (6)	03/06/2023	03/06/2023	07/27/28	03/29/29	03/17/30	04/20/31	04/20/31
BSA issue price	€1.62	€1.62	€2.36	€1.15	€0.29	€2.95	€0.68
Exercise price per BSA	€13.55	€13.55	€16.10	€11.66	€6.59	€13.47	€13.64
Number of shares subscribed as of June 30, 2023	—	—	—	—	—	—	—
Total number of forfeited or cancelled BSAs as of June 30, 2023	18,000	10,000	—	—	—	33,672	30,000
Total number of BSAs outstanding as of June 30, 2023	—	—	5,820	18,000	18,000	14,431	—
Total number of shares available for subscription as of June 30, 2023 (considering the conditions of exercise of the BSAs)	—	—	—	—	—	—	—
Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met)	—	—	5,820	18,000	18,000	14,431	—

Stock options outstanding as at June 30, 2023


	OSA 2016-1 Performance	OSA 2016-2	OSA 2017 Ordinary	OSA 2018	OSA 2019-1	OSA 2019 LLY
Date of the shareholders’ meeting	25-Jun-15	23-Jun-16	23-Jun-16	14-Jun-17	23-May-18	11-Apr-19
Date of grant by the Executive Board	02-Feb-16	03-Nov-16	07-Jan-17	6-Mar-18	29-Mar-19	24-Oct-19
Total number of OSAs authorized	450,000	450,000	450,000	526,800	648,000	500,000
Total number of OSAs granted	6,400	4,000	3,500	62,000	37,500	500,000
Total number of shares to which the OSAs were likely to give right on the date of their grant	6,400	4,000	3,500	62,000	37,500	500,000
including the number that may be subscribed or purchased by corporate officers:	—	—	—	—	—	500,000
the number that can be subscribed by Laurent LEVY	—	—	—	—	—	500,000
the number that can be subscribed by Anne-Juliette HERMANT	—	—	—	—	—	—
the number that can be subscribed by Bart VAN RHIJN	—	—	—	—	—	—
Number of beneficiaries who are not corporate officers	2	1	2	5	12	—
Starting date for the exercise of the OSA	02/02/2017	11/03/2017	01/08/2018	03/07/2019	03/30/2021	10/24/2019
OSA expiry date	02/02/2026	11/03/2026	01/07/2027	03/06/2028	03/29/2029	10/24/2029
Exercise price per OSA	€13.05	€14.26	€14.97	€12.87	€11.08	€6.41
Number of shares subscribed as of June 30, 2023	—	—	—	—	—	—
Total number of lapsed or cancelled OSAs as of June 30, 2023	6,000	—	3,000	10,000	11,750	—
Total number of OSAs outstanding as of June 30, 2023	400	4,000	500	52,000	25,750	500,000
Maximum number of shares available for subscription as of June 30, 2023 (given the vesting conditions of the OSAs)	120	4,000	500	52,000	25,750	—
Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)	400	4,000	500	52,000	25,750	500,000


	OSA 2020	OSA 2021-04 Ordinary	OSA 2021-04 Performance	OSA 2021-06 Performance	OSA 2021-06 Ordinary
Date of the shareholders’ meeting	11-Apr-19	30-Nov-20	30-Nov-20	30-Nov-20	28-Apr-21
Date of grant by the Executive Board	11-Mar-20	20-Apr-21	20-Apr-21	21-Jun-21	21-Jun-21
Total number of OSAs authorized	500,000	850,000	1,000,000	1,000,000	850,000
Total number of OSAs granted	407,972	143,200	428,000	60,000	60,000
Total number of shares to which the OSAs were likely to give right on the date of their grant	407,972	143,200	428,000	60,000	60,000
including the number that may be subscribed or purchased by corporate officers:	180,000	—	240,000	60,000	60,000
the number that can be subscribed by Laurent LEVY	120,000	—	180,000	—	—
the number that can be subscribed by Anne-Juliette HERMANT	60,000	—	60,000	—	—
the number that can be subscribed by Bart VAN RHIJN	—	—	—	60,000	60,000
Number of beneficiaries who are not corporate officers	104	13	14	—	—
Starting date for the exercise of the OSA	03/11/2021	04/20/22	04/20/22	06/21/22	06/21/22
OSA expiry date	03/11/2030	04/20/31	04/20/31	06/21/31	06/21/31
Exercise price per OSA	€6.25	€13.74	€13.74	€12.99	€12.99
Number of shares subscribed as of June 30, 2023	—	—	—	—	—
Total number of lapsed or cancelled OSAs as of June 30, 2023	28,065	103,000	60,000	—	—
Total number of OSAs outstanding as of June 30, 2023	379,907	40,200	368,000	60,000	60,000
Maximum number of shares available for subscription as of June 30, 2023 (given the vesting conditions of the OSAs)	379,907	30,128	—	—	40,000
Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)	379,907	40,200	368,000	60,000	60,000


	OSA 2022-001 Performance	OSA 2022-06 Performance	OSA 2022-06 Ordinaire
Date of the shareholders’ meeting	30-Nov-20	30-Nov-20	28-Apr-21
Date of grant by the Executive Board	22-Jun-22	22-Jun-22	22-Jun-22
Total number of OSAs authorized	1,000,000	1,000,000	850,000
Total number of OSAs granted	20,000	170,400	410,500
Total number of shares to which the OSAs were likely to give right on the date of their grant	20,000	170,400	410,500
including the number that may be subscribed or purchased by corporate officers:	—	—	245,000
the number that can be subscribed by Laurent LEVY	—	—	150,000
the number that can be subscribed by Anne-Juliette HERMANT	—	—	35,000
the number that can be subscribed by Bart VAN RHIJN	—	—	60,000
Number of beneficiaries who are not corporate officers	1	83	49
Starting date for the exercise of the OSA	04/14/23	06/22/23	06/22/23
OSA expiry date	04/14/32	06/22/32	06/22/32
Exercise price per OSA	€6.17	€4.16	€4.16
Number of shares subscribed as of June 30, 2023	—	—	—
Total number of lapsed or cancelled OSAs as of June 30, 2023	20,000	14,400	12,500
Total number of OSAs outstanding as of June 30, 2023	—	156,000	398,000
Maximum number of shares available for subscription as of June 30, 2023 (given the vesting conditions of the OSAs)	—	—	139,333
Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met)	—	156,000	398,000

Free shares outstanding as at June 30, 2023


	AGA 2020	AGA 2021	AGA 2022	AGA 2023 -= P1	AGA 2023 - P2
Date of the shareholders’ meeting	11-Apr-19	30-Nov-20	20-Apr-21	27-Jun-23	27-Jun-23
Date of grant by the Executive Board	11-Mar-20	20-Apr-21	22-Jun-22	27-Jun-23	27-Jun-23
Total number of AGAs authorized	650,000	850,000	850,000	1,200,000	1,200,000
Total number of AGAs granted	50,000	362,515	300,039	427,110	439,210
Total number of shares to which the AGAs were likely to give right on the date of their grant	50,000	362,515	300,039	427,110	439,210
including the number that can be subscribed by corporate officers:	50,000	270,000	245,000	298,860	293,470
the number that can be subscribed by Laurent LEVY	—	180,000	150,000	200,116	200,116
the number that can be subscribed by Anne-Juliette HERMANT	50,000	90,000	35,000	33,354	33,354
the number that can be subscribed by Bart VAN RHIJN	—	—	60,000	65,390	65,390
Number of beneficiaries who are not corporate officers	—	79	79	88	87
Date of acquisition (end of the acquisition period)	03/11/22	04/20/23	06/22/24	06/27/25	06/27/25
Number of shares subscribed as of June 30, 2023	50,000	354,510	—	—	—
Total number of AGAs lapsed or cancelled as of June 30, 2023	—	8,005	1,009	—	—
Total number of AGAs outstanding as of June 30, 2023	—	—	299,030	427,110	439,210
Total number of shares that may be subscribed	—	—	299,030	427,110	439,210
Duration of the holding period	1 year	1 year	1 year	1 year	1 year


	BSPCE	BSA	OSA	AGA	Total
Total number of shares underlying grants outstanding as of June 30, 2023	612,985	151,251	2,044,757	1,165,350	3,974,343

The measurement methods used to estimate the fair value of stock options, warrants and free shares are described below:

•The exercise price is based on the share price at the grant date, except for the BSA 2014 which exercise price was set at €17.67, taking into account both the average share price on the 20 days preceding the grant date and the expected development perspectives of the Company;

•The risk-free rate was determined based on the average life of the instruments; and

•Volatility was determined based on a sample of listed companies in the biotechnology sector at the grant date and for a period equal to the life of the warrant or option.

The performance conditions for all of the plans were assessed as follows:

•Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and

•Market-related performance conditions were directly included in the calculation of the fair value of the instruments.

As of June 30, 2023, the assumptions related to the probability that the performance conditions of the BSPCE, BSA and OSA will be met have been updated:


BSPCE	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
BSPCE 2012-2	6.65	6.63	44.3% - 47.6%		5 / 7.3	0.84% - 1.22%		0.00	%	288	—	—
BSPCE 08-2013	6.30	5.92	256	%	7	0.90	%	0.00	%	152	—	—
BSPCE 09-2014	18.68	18.68	58	%	5.5/6/6.5	0.64	%	0.00	%	932	—	—
BSPCE 2015-2	18.57	18.57	58% - 62% - 61%		5.5/6/6.5	0.39	%	0.00	%	50	—	—
BSPCE 2015-3	20.28	20.28	61% - 62% - 61%		5.5/6/6.5	0.56	%	0.00	%	483	—	—
BSPCE 2016 Ordinary	14.46	14.46	59% - 62% - 60%		5.5/6/6.5	0.32	%	0.00	%	1,080	2	—
BSPCE 2016 Performance	14.46	14.46	59	%	5	0.19	%	0.00	%	1,212	18	27
BSPCE 2017 Ordinary	15.93	15.93	58% - 61% - 59%		5.5/6/6.5	0.23	%	0.00	%	1,000	1	—
BSPCE 2017	15.93	15.93	59	%	5	0.11	%	0.00	%	627	—	—
Total BSPCE	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	25	27


BSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
BSA 04-2012	6.00	6.00	49	%	10	0.96	%	0.00	%	183	—	—
BSA 2013	6.30	6.30	156	%	6	0.90	%	0.00	%	1	—	—
BSA 2014	18.68	17.67	57	%	5	0.41	%	0.00	%	—	—	—
BSA 2015-1	17.67	17.67	58	%	5	0.26% - 0.27%		0.00	%	63	—	—
BSA 2015-2 (a)	17.67	17.67	58%-58%-57%-58%		5/5.1/ 5.3/5.4	0.39	%	0.00	%	16	—	—
BSA 2017	15.76	15.76	33	%	2.4	—	%	0.00	%	—	—	—
BSA 2018	13.55	13.55	38	%	4.8	0.7% - 0.1%		0.00	%	2	—	—
BSA 2018-1	13.55	13.55	38	%	4.8	0.7% - 0.1%		0.00	%	—	—	—
BSA 2018-2	16.10	16.10	38	%	4.8	0.7% - 0.1%		0.00	%	1	—	—
BSA 2019-1	11.66	11.66	37	%	9.8/9.9	0.16% - 0.50%		0.00	%	24	—	—
BSA 2020	13.03	6.59	38	%	10	/ -0.07%		0.00	%	19	—	—
BSA 2021 (a)	13.47	13.47	39.10	%	10	0.27	%	0.00	%	44	—	—
BSA 2021 (b)	n.a.	13.64	n.a.		10	n.a.		0.00	%	—	—	—
Total BSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	—	—


OSA	Share price (in euros)	Exercise price (in euros)	Volatility		Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
OSA 2016 Performance	13.05	13.05	59	%	5	0.19	%	0.00	%	69	—	—
OSA 2016-2	14.26	14.26	58% - 62% - 59%		5.5 / 6 /6.5	0.04	%	0.00	%	27	—	—
OSA 2017 Ordinary	15.93	14.97	58% - 61% - 59%		5.5 / 6 /6.5	0.23	%	0.00	%	31	—	—
OSA 2018	12.87	12.87	35	%	5.5 / 6 /6.5	—	%	0.00	%	252	—	—
OSA 2019-1	11.08	11.08	38.1% / 37.4%		6 /6.5	0.103% / 0.149%		0.00	%	140	—	(1)
OSA 2019-2	6.41	6.41	37	%	10	0.40	%	0.00	%	252	—	—
OSA 2020	6.25	6.25	38.30	%	10	0.31	%	0.00	%	939	13	28
OSA 2021-04 O	13.60	13.74	38.9% - 37.8% - 38.3%		5.5 / 6 /6.5	0.38% / 0.33% / 0.28%		0.00	%	684	25	(49)
OSA 2021-04 P	13.60	13.74	39.10	%	10	0.03	%	0.00	%	1,816	86	76
OSA 2021-06 O	12.20	12.99	39.2% - 37.9% - 38.1%		5.5 / 6 /6.5	0.35% / 0.30% / 0.26%		0.00	%	246	33	72
OSA 2021-06 P	12.20	12.99	39.10	%	10	0.13	%	0.00	%	212	12	12
OSA 2022-001 P	6.06	6.17	40.00	%	10	1.29	%	0.00	%	1	—	—
OSA 2022-06 P	3.68	4.16	40.08	%	10	2.28	%	0.00	%	71	4	—
OSA 2022-06 O	3.68	4.16	42.06% - 41.21% - 40.65%		5.5 / 6 /6.5	1.83% / 1.87% / 1.90%		0.00	%	580	170	8
Total OSA	n.a.	n.a.	n.a.		n.a.	n.a.		n.a.		n.a.	343	147


AGA	Share price (in euros)	Exercise price (in euros)	Volatility	Maturity (in years)	Risk-free rate		Yield		Value of initial plan (in thousands of euros)	Expense for the first half of 2023 (in thousands of euros)	Expense for the first half of 2022 (in thousands of euros)
AGA 2018-1	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	4,951	—	—
AGA 2018-2	12.87	0.00	n.a.	n.a.	0.00	%	0.00	%	75	—	—
AGA 2019-1	10.90	0.00	n.a.	n.a.	0.19% / 0.141%		0.00	%	4,776	—	—
AGA 2020	5.90	0.00	n.a.	n.a.	-0.74%/ -0.69%		0.00	%	287	—	28
AGA 2021	13.60	0.00	n.a.	n.a.	0.63% / 0.59%		0.00	%	4,869	694	1,146
AGA 2022	3.68	0	n.a.	n.a.	0.95% /1.46%		0.00	%	1,092	271	12
AGA 2023 - P1	4.87	0.00	n.a.	n.a.	3% / 3.2%		0.00	%	2,071	9	n.a.
AGA 2023 - P2	4.87	0	n.a.	n.a.	3% /3.2%		0.00	%	2,130	9	n.a.
Total AGA	n.a.	n.a.	n.a.	n.a.	n.a.		n.a.		n.a.	982	1,186


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended June 30, 2023	25	—	343	982	1,349


(in thousands of euros)	BSPCE	BSA	OSA	AGA	Total
Expense for the year ended June 30, 2022	27	—	147	1,186	1,360

Operating expenses - Disclosure of Payroll Costs (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€) employee	Jun. 30, 2022 EUR (€) employee
Analysis of income and expense [abstract]
Wages and salaries	€ (6,814)	€ (6,711)
Payroll taxes	(2,338)	(2,531)
Share-based payments	(1,349)	(1,360)
Retirement benefit obligations	(33)	(38)
Total payroll costs	€ (10,534)	€ (10,640)
Average headcount \| employee	98	99
End-of-period headcount \| employee	101	103

Share-based payments - Disclosure of Warrants Outstanding (Details)											6 Months Ended
	Jun. 30, 2023 shares	Apr. 20, 2021 shares benefeciary € / shares	Mar. 17, 2020 shares benefeciary € / shares	Mar. 29, 2019 shares benefeciary € / shares	Jul. 27, 2018 shares benefeciary € / shares	Mar. 06, 2018 shares benefeciary € / shares	Jun. 25, 2015 shares benefeciary € / shares	Feb. 10, 2015 shares benefeciary € / shares	Sep. 16, 2014 shares benefeciary € / shares	Apr. 10, 2013 shares benefeciary € / shares	Jun. 30, 2023 shares € / shares
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards outstanding (in shares)	3,974,343										3,974,343
BSA 2013
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)										200,000
Number of shares issued (in shares)										10,000
Total number of shares to which the awards were likely to give right (in shares)										10,000
BSA issue price (in euro pere share) \| € / shares										€ 2.50
Exercise price (in euros per share) \| € / shares										€ 6.37
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	10,000
Total number of awards outstanding (in shares)	0										0
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	0										0
BSA 2013 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)										0
BSA 2013 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary										1
BSA 2014
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)									100,000
Number of shares issued (in shares)									14,000
Total number of shares to which the awards were likely to give right (in shares)									14,000
BSA issue price (in euro pere share) \| € / shares									€ 4.87
Exercise price (in euros per share) \| € / shares									€ 17.67		€ 17.67
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	4,000
Total number of awards outstanding (in shares)	10,000										10,000
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	10,000										10,000
BSA 2014 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)									8,000
BSA 2014 \| Alain HERRERA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)									4,000
BSA 2014 \| Christophe DOUAT (observer)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)									4,000
BSA 2014 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary									1
BSA 2015-1
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)								100,000
Number of shares issued (in shares)								26,000
Total number of shares to which the awards were likely to give right (in shares)								26,000
BSA issue price (in euro pere share) \| € / shares								€ 4.87
Exercise price (in euros per share) \| € / shares								€ 17.67
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	5,000
Total number of awards outstanding (in shares)	21,000										21,000
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	21,000										21,000
BSA 2015-1 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)								15,000
BSA 2015-1 \| Anne-Marie GRAFFIN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)								5,000
BSA 2015-1 \| Enno SPILLNER
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)								3,000
BSA 2015-1 \| Alain HERRERA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)								5,000
BSA 2015-1 \| Christophe DOUAT (observer)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)								2,000
BSA 2015-1 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary								2
BSA 2015-2 (a)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)							100,000
Number of shares issued (in shares)							64,000
Total number of shares to which the awards were likely to give right (in shares)							64,000
BSA issue price (in euro pere share) \| € / shares							€ 5.00
Exercise price (in euros per share) \| € / shares							€ 19.54
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	64,000										64,000
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	64,000										64,000
BSA 2015-2 (a) \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)							0
BSA 2015-2 (a) \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary							1
BSA 2018
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)						116,000
Number of shares issued (in shares)						18,000
Total number of shares to which the awards were likely to give right (in shares)						18,000
BSA issue price (in euro pere share) \| € / shares						€ 1.62
Exercise price (in euros per share) \| € / shares						€ 13.55
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	18,000
Total number of awards outstanding (in shares)	0										0
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	0										0
BSA 2018 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)						12,700
BSA 2018 \| Anne-Marie GRAFFIN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)						2,900
BSA 2018 \| Enno SPILLNER
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)						4,000
BSA 2018 \| Alain HERRERA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)						2,900
BSA 2018 \| Christophe DOUAT (observer)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)						2,900
BSA 2018 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary						1
BSA 2018-1
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)						116,000
Number of shares issued (in shares)						10,000
Total number of shares to which the awards were likely to give right (in shares)						10,000
BSA issue price (in euro pere share) \| € / shares						€ 1.62
Exercise price (in euros per share) \| € / shares						€ 13.55
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	10,000
Total number of awards outstanding (in shares)	0										0
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	0										0
BSA 2018-1 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)						0
BSA 2018-1 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary						1
BSA 2018-2
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)					140,000
Number of shares issued (in shares)					5,820
Total number of shares to which the awards were likely to give right (in shares)					5,820
BSA issue price (in euro pere share) \| € / shares					€ 2.36
Exercise price (in euros per share) \| € / shares					€ 16.10
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	5,820										5,820
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	5,820										5,820
BSA 2018-2 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)					0
BSA 2018-2 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary					1
BSA 2019-1
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)				140,000
Number of shares issued (in shares)				18,000
Total number of shares to which the awards were likely to give right (in shares)				18,000
BSA issue price (in euro pere share) \| € / shares				€ 1.15
Exercise price (in euros per share) \| € / shares				€ 11.66
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	18,000										18,000
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	18,000										18,000
BSA 2019-1 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)				12,700
BSA 2019-1 \| Anne-Marie GRAFFIN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)				2,900
BSA 2019-1 \| Enno SPILLNER
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)				4,000
BSA 2019-1 \| Alain HERRERA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)				2,900
BSA 2019-1 \| Christophe DOUAT (observer)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)				2,900
BSA 2019-1 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary				1
BSA 2020
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)			500,000
Number of shares issued (in shares)			18,000
Total number of shares to which the awards were likely to give right (in shares)			18,000
BSA issue price (in euro pere share) \| € / shares			€ 0.29
Exercise price (in euros per share) \| € / shares			€ 6.59
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	18,000										18,000
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	18,000										18,000
BSA 2020 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)			14,024
BSA 2020 \| Anne-Marie GRAFFIN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)			3,843
BSA 2020 \| Enno SPILLNER
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)			3,829
BSA 2020 \| Alain HERRERA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)			3,195
BSA 2020 \| Christophe DOUAT (observer)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)			3,157
BSA 2020 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary			1
BSA 2021 (a)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)		650,000
Number of shares issued (in shares)		48,103
Total number of shares to which the awards were likely to give right (in shares)		48,103
BSA issue price (in euro pere share) \| € / shares		€ 2.95
Exercise price (in euros per share) \| € / shares		€ 13.47
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	33,672
Total number of awards outstanding (in shares)	14,431										14,431
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	14,431										14,431
BSA 2021 (a) \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)		0
BSA 2021 (a) \| Anne-Marie GRAFFIN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)		0
BSA 2021 (a) \| Enno SPILLNER
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)		0
BSA 2021 (a) \| Alain HERRERA
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)		0
BSA 2021 (a) \| Christophe DOUAT (observer)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)		0
BSA 2021 (a) \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary		1
BSA 2021 (b)
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of awards authorised (in shares)		650,000
Number of shares issued (in shares)		30,000
Total number of shares to which the awards were likely to give right (in shares)		30,000
BSA issue price (in euro pere share) \| € / shares		€ 0.68
Exercise price (in euros per share) \| € / shares		€ 13.64
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	30,000
Total number of awards outstanding (in shares)	0										0
Total number of awards available for subscription (in shares)	0										0
Maximum total number of awards that may be subscribed (in shares)	0										0
BSA 2021 (b) \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the awards were likely to give right (in shares)		0
BSA 2021 (b) \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary		1

Share-based payments - Disclosure of Changes in Share Options (Details)	Jun. 30, 2023 shares	Jun. 30, 2022 shares	Jun. 22, 2022 shares benefeciary € / shares	Jun. 21, 2021 shares benefeciary € / shares	Apr. 20, 2021 shares benefeciary € / shares	Mar. 11, 2020 shares benefeciary € / shares	Oct. 24, 2019 shares benefeciary € / shares	Mar. 29, 2019 shares benefeciary € / shares	Mar. 06, 2018 shares benefeciary € / shares	Jan. 07, 2017 shares benefeciary € / shares	Nov. 03, 2016 shares benefeciary € / shares	Feb. 02, 2016 shares benefeciary € / shares
OSA 2016-1 Performance
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)												450,000
Total number of share options granted (in shares)												6,400
Total number of shares to which the share options were likely to give right (in shares)												6,400
Exercise price (in euros per share) \| € / shares												€ 13.05
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	6,000
Total number of share options outstanding (in shares)	400
Maximum number of shares available for subscription (in shares)	120
Maximum total number of shares that may be subscribed (in shares)	400
OSA 2016-1 Performance \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)												0
OSA 2016-1 Performance \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary												2
OSA 2016-2
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)											450,000
Total number of share options granted (in shares)											4,000
Total number of shares to which the share options were likely to give right (in shares)											4,000
Exercise price (in euros per share) \| € / shares											€ 14.26
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	4,000
Maximum number of shares available for subscription (in shares)	4,000
Maximum total number of shares that may be subscribed (in shares)	4,000
OSA 2016-2 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)											0
OSA 2016-2 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary											1
OSA 2017 Ordinary
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)										450,000
Total number of share options granted (in shares)										3,500
Total number of shares to which the share options were likely to give right (in shares)										3,500
Exercise price (in euros per share) \| € / shares										€ 14.97
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	3,000
Total number of share options outstanding (in shares)	500
Maximum number of shares available for subscription (in shares)	500
Maximum total number of shares that may be subscribed (in shares)	500
OSA 2017 Ordinary \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)										0
OSA 2017 Ordinary \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary										2
OSA 2018
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)									526,800
Total number of share options granted (in shares)									62,000
Total number of shares to which the share options were likely to give right (in shares)									62,000
Exercise price (in euros per share) \| € / shares									€ 12.87
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	10,000
Total number of share options outstanding (in shares)	52,000
Maximum number of shares available for subscription (in shares)	52,000
Maximum total number of shares that may be subscribed (in shares)	52,000
OSA 2018 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)									0
OSA 2018 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary									5
OSA 2019-1
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)								648,000
Total number of share options granted (in shares)								37,500
Total number of shares to which the share options were likely to give right (in shares)								37,500
Exercise price (in euros per share) \| € / shares								€ 11.08
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	11,750
Total number of share options outstanding (in shares)	25,750
Maximum number of shares available for subscription (in shares)	25,750
Maximum total number of shares that may be subscribed (in shares)	25,750
OSA 2019-1 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)								0
OSA 2019-1 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary								12
OSA 2019 LLY
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)							500,000
Total number of share options granted (in shares)							500,000
Total number of shares to which the share options were likely to give right (in shares)							500,000
Exercise price (in euros per share) \| € / shares							€ 6.41
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	500,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	500,000
OSA 2019 LLY \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)							500,000
OSA 2019 LLY \| Laurent LEVY
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)							500,000
OSA 2019 LLY \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary							0
OSA 2020
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)						500,000
Total number of share options granted (in shares)						407,972
Total number of shares to which the share options were likely to give right (in shares)						407,972
Exercise price (in euros per share) \| € / shares						€ 6.25
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	28,065
Total number of share options outstanding (in shares)	379,907
Maximum number of shares available for subscription (in shares)	379,907
Maximum total number of shares that may be subscribed (in shares)	379,907
OSA 2020 \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)						180,000
OSA 2020 \| Laurent LEVY
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)						120,000
OSA 2020 \| Anne-Juliette HERMANT
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)						60,000
OSA 2020 \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary						104
OSA 2021-04 Ordinary
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)					850,000
Total number of share options granted (in shares)					143,200
Total number of shares to which the share options were likely to give right (in shares)					143,200
Exercise price (in euros per share) \| € / shares					€ 13.74
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	103,000
Total number of share options outstanding (in shares)	40,200
Maximum number of shares available for subscription (in shares)	30,128
Maximum total number of shares that may be subscribed (in shares)	40,200
OSA 2021-04 Ordinary \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)					0
OSA 2021-04 Ordinary \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary					13
OSA 2021-04 Performance
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)					1,000,000
Total number of share options granted (in shares)					428,000
Total number of shares to which the share options were likely to give right (in shares)					428,000
Exercise price (in euros per share) \| € / shares					€ 13.74
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	60,000
Total number of share options outstanding (in shares)	368,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	368,000
OSA 2021-04 Performance \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)					240,000
OSA 2021-04 Performance \| Laurent LEVY
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)					180,000
OSA 2021-04 Performance \| Anne-Juliette HERMANT
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)					60,000
OSA 2021-04 Performance \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary					14
OSA 2021-06 Performance
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)				1,000,000
Total number of share options granted (in shares)				60,000
Total number of shares to which the share options were likely to give right (in shares)				60,000
Exercise price (in euros per share) \| € / shares				€ 12.99
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	60,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	60,000
OSA 2021-06 Performance \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)				60,000
OSA 2021-06 Performance \| Bart VAN RHIJN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)				60,000
OSA 2021-06 Performance \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary				0
OSA 2021-06 Ordinary
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)				850,000
Total number of share options granted (in shares)				60,000
Total number of shares to which the share options were likely to give right (in shares)				60,000
Exercise price (in euros per share) \| € / shares				€ 12.99
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	60,000
Maximum number of shares available for subscription (in shares)	40,000
Maximum total number of shares that may be subscribed (in shares)	60,000
OSA 2021-06 Ordinary \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)				60,000
OSA 2021-06 Ordinary \| Bart VAN RHIJN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)				60,000
OSA 2021-06 Ordinary \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary				0
OSA 2022-001 Performance
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)			1,000,000
Total number of share options granted (in shares)			20,000
Total number of shares to which the share options were likely to give right (in shares)			20,000
Exercise price (in euros per share) \| € / shares			€ 6.17	€ 6.17
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	20,000
Total number of share options outstanding (in shares)	0
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	0
OSA 2022-001 Performance \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			0
OSA 2022-001 Performance \| Laurent LEVY
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			0
OSA 2022-001 Performance \| Anne-Juliette HERMANT
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			0
OSA 2022-001 Performance \| Bart VAN RHIJN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			0
OSA 2022-001 Performance \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary			1
OSA 2022-06 Performance
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)			1,000,000
Total number of share options granted (in shares)			170,400
Total number of shares to which the share options were likely to give right (in shares)			170,400
Exercise price (in euros per share) \| € / shares			€ 4.16
Number of shares subscribed (in shares)		0
Total number of share options lapsed or cancelled (in shares)		14,400
Total number of share options outstanding (in shares)	156,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	156,000
OSA 2022-06 Performance \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			0
OSA 2022-06 Performance \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary			83
OSA 2022-06 Ordinaire
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of share options authorised (in shares)			850,000
Total number of share options granted (in shares)			410,500
Total number of shares to which the share options were likely to give right (in shares)			410,500
Exercise price (in euros per share) \| € / shares			€ 4.16
Number of shares subscribed (in shares)		0
Total number of share options lapsed or cancelled (in shares)		12,500
Total number of share options outstanding (in shares)	398,000
Maximum number of shares available for subscription (in shares)	139,333
Maximum total number of shares that may be subscribed (in shares)	398,000
OSA 2022-06 Ordinaire \| Corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			245,000
OSA 2022-06 Ordinaire \| Laurent LEVY
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			150,000
OSA 2022-06 Ordinaire \| Anne-Juliette HERMANT
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			35,000
OSA 2022-06 Ordinaire \| Bart VAN RHIJN
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Total number of shares to which the share options were likely to give right (in shares)			60,000
OSA 2022-06 Ordinaire \| Beneficiaries other than corporate officers
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of beneficiaries who are not corporate officers \| benefeciary			49